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A b st r a c t
Cardiovascular disease is the principal cause of death in the Western world. 
Atherosclerosis is a major contributor to the progression of cardiovascular disease. 
Increased proliferation of vascular smooth muscle cells plays an important role in the 
development of atherosclerotic plaques and, as increased glucose transport is an early 
response common to all mitogens, it is reasonable to presume that increased proliferation 
of VSMCs in atherosclerotic plaques is accompanied by an increase in glucose transport 
in these cells. To date, however, very little is known about the regulation of glucose 
transport in VSMCs. The work presented in this thesis examines the regulation of glucose 
transport in VSMCs.
Firstly the glucose transporters expressed in VSMCs were studied. It was determined that 
in VSMC freshly isolated from aorta GLUT-4 was present, however, as the cells were 
passaged in culture GLUT-4 was lost and GLUT-3 levels increased. GLUT -1 was present 
in both freshly isolated VSMCs and in cells that had been passaged in cell culture. The 
effects of PDGF, a growth factor believed to play an important role in mediating 
increased VSMC proliferation in atherosclerotic plaque development, on glucose 
transport was examined. PDGF could stimulate a 2- to 5-fold increase in glucose 
transport in cultured VSMCs, and this was dependent on both MAP kinase (p38 and 
p42/44) and PI3’ kinase activity, as determined by the use of specific inliibitors of these 
kinases.
Both cAMP and cGMP are known to be important regulators of VSMC function and as 
such the ability of cyclic nucleotides to regulate glucose transport was studied. Analogues 
of cAMP were capable of stimulating a 2-fold in crease in glucose transport, and like 
PDGF-stimulated transport it was dependent on PI3’ kinase and p38 MAP kinase activity, 
however there was no role for p42/44 MAP kinase. Agonists that stimulated adenyl 
cyclase activity in VSMCs were unable to stimulate an increase in glucose transport, but 
inhibitors of PDE 3 activity did stimulate a.two-fold increase in glucose transport in
VSMCs. The cGMP analogue (8-Br cGMP) had no effect on basai glucose transport 
rates, but was inhibitory with regard to PDGF-stimulated glucose transport.
Finally, the mechanisms by which glucose transport is increased in response to mitogens 
were studied. To determine if translocation of GLUT-1 may be responsible for increased 
glucose transport, chimeras of GLUT-1 and green fluorescent protein were made to allow 
the movement of GLUT-1 within the cell to be followed. As well as translocation of 
GLUTs it is possible that altered GLUT activity, perhaps mediated by phosphorylation of 
the transporters, may be responsible for increased glucose transport. To address this 
possibility the phosphorylation state of both GLUT-1 and GLUT-3 from VSMCs wwas 
investigated under different conditions. The results from this work indicated that 
phosphorylation of the GLUTs is unlikely to be responsible for increased glucose 
transport in VSMCs.
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1.1 G e n e r a l  I n t r o d u c t io n
Cardiovascular disease is the principal cause of death in the USA, Europe and much 
of Asia. Atherosclerosis is an inflammatoiy disease of the vasculature and is a major 
contributor to the progression of cardiovascular disease (Ross, 1999, Ross, 1993). It 
can lead to myocardial and cerebral infarction, which can result in heart attack, stroke, 
gangrene and loss of function of the extremities. The process of atherosclerosis is, in 
normal circumstances, a protective response to the insults that the endothelium and 
smooth muscle cells of the artery are exposed to. Several factors can be important in 
atherosclerotic plaque development, including increased serum cholesterol, which is 
considered to be the most important factor in the development of atherosclerotic 
lesions. Hypertension appears to accelerate plaque formation, and patients with 
diabetes mellitus are more likely to develop severe lesions (Ross, 1999). Vascular 
smooth muscle cell (VSMC) proliferation and migration is fundamental to the 
development of atherosclerotic plaques. Since growing cells have an increased energy 
requirement, one of the early events which follows re-entry into the cell cycle is the 
stimulation of glucose uptake, an effect which is common to all mitogens. In the work 
described below, the mechanisms involved in regulating glucose uptake in vascular 
smooth muscle cells were investigated.
1 .1 .1  P a t h o p h y s io l o g y  o f  A t h e r o s c l e r o s is
The lesions of atherosclerosis occur principally in the large and medium-sized elastic 
and muscular arteries. Atherosclerotic plaques are likely to be present throughout a 
person’s lifetime, and the earliest form of lesion, the so-called fatty streak, is common 
in infants and young children (Napoli et al, 1997). The fatty streak is a pure 
inflammatoiy lesion and consists of an aggregation of lipid-rich macrophages and 
VSMCs, known as foam cells, and T lymphocytes within the inner-most layer of the 
artery wall, the intima (Stary et al, 1994). In people with hypercholesterolaemia, the 
influx of these cells into the intima is preceded by the extracellular deposition of 
amorphous and membranous lipids. The development of the fatty streak precedes the 
formation of intermediate lesions which are composed of layers of macrophages and
smooth muscle cells, which in turn develop into the more advanced, complex, 
occlusive lesions called fibrous plaques. The fibrous plaques increase in size, and by 
projecting into the lumen of the artery may impede blood flow. Lesions consist of a 
fibrous cap of comiective tissue, beneath which there is a cell-rich layer consisting of 
lipid loaded smooth muscle cells, macrophages and activated T-cells. The cell-rich 
region usually overlays a core of lipid and necrotic debris, containing cholesterol 
crystals and insoluble calcium salt. Most sudden deaths from myocardial infarcts aie 
due to the rupturing or fissures in the plaque resulting in haemoiThage, thrombosis and 
occlusion of the artery (Ross, 1993, Ross, 1999).
A number of observations gave rise to the “response to injuiy” hypothesis for the 
formation of plaques, which initially proposed the denudation of the endothelium as 
the first step in atherosclerosis (Ross & Glomset 1973, Ross & Glomset 1976). The 
most recent version of this hypothesis is that endothelial dysfunction rather than 
denudation is the initiating factor for progression of atherosclerosis (Ross, 1993, Ross, 
1999). The endothelial dysfunction that occurs in response to the injury leads to 
compensatoiy responses that alter the normal homeostatic properties of the 
endothelium. The formation of fibrous lesions in response to injuiy is in itself not 
remarkable; wound healing, for example follows such a course. But the response to 
arterial injury differs from that of injuiy to most other organs in that the sources of 
injuiy (hypercholesterolaemia, hypertension, cigarette smoking, diabetes, obesity etc.) 
are likely to be chi'onic, so that progression of fatty streak to fibrous plaque is unlikely 
to be interrupted.
An overview of plaque development is shown in Figure 1.1. The injury to the 
endothelium increases its adhesiveness with regard to leukocytes or platelets, as well 
as its permeability. The injury also induces the endothelium to have procoagulant 
instead of anticoagulant properties and to produce and secrete vasoactive molecules, 
cytokines and growth factors (Resnick et al, 1993, Lin et al, 1997, Nakashima et al, 
1998). If the inflammatoiy response does not immediately remove or neutralise the 
offending agent then the response can continue indefinitely. The monocytes and T- 
lymphocytes migrate between the endothelial cells under the influence of growth 
factors and chemoattractants released by the altered endothelium, activated platelets
1and adherent leukocytes. The major chemoattractant is lipoprotein that has been 
oxidised by the endothelium, smooth muscle cells or early-arriving monocytes or 
macrophages (Quinn et al, 1987). Migrating cells reach further beneath the arterial 
surface, where the monocytes become macrophages, accumulate lipids and become 
foam cells and, together with the accompanying lymphocytes, form a fatty streak. If 
the inflammatoiy response continues there is stimulation of proliferation and 
migration of vascular smooth muscle to form an intermediate lesion. If these 
responses continue unabated, they can thicken the arteiy wall, resulting in a 
compensatoiy dilation of the blood vessel to maintain a constant lumen volume. 
Continued inflammation results in increased numbers of macrophages and 
lymphocytes, which both migrate from the blood stream and multiply within the 
lesion. Activation of these cells leads to the release of hydrolytic enzymes, cytokines, 
chemokines and growth factors, which can induce further damage and eventually lead 
to focal necrosis. Thus, cycles of accumulation of mononuclear cells, migration and 
proliferation of smooth muscle cells, and formation of fibrous tissue lead to further 
enlargement and restructuring of the lesion, so that it becomes covered by a fibrous 
cap that overlies a necrotic core. At some point the artery can no longer compensate 
by dilation and the lesion may alter blood flow (see Ross 1993, Ross 1999 for 
reviews).
1 .1 .2  R e g u l a t io n  o f  V a s c u l a r  S m o o t h  M u s c l e  C e l l s  in  P l a q u e  
F o r m a t io n
Any concept of atherogenesis must account for the stimulation of vascular smooth 
muscle cell proliferation, which is fundamental to the development of the plaque. 
Vascular smooth muscle cells are subject to regulation by a huge number of growth 
factors, cytokines and small molecules (such as nitric oxide, NO) in normal blood 
vessels as well as in atherosclerotic lesions. It is the alteration in equilibrium between 
factors secreted from the endothelium and smooth muscle cells that is probably crucial 
to migration and hyperproliferation of VSMCs. Some of the most important growth 
factors and cytokines, in terms of VSMC proliferation are platelet derived growth 
factor (PDGF), basic fibroblast growth factor (bFGF), insulin-like growth factor 1 
(lGF-1), interleukin-1 (lL-1), tumour necrosis factor a  (TNFa) and transforming
growth factor |3 (TGFp) (Bobik & Campbell, 1993). All of these can induce VSMC 
proliferation and are up regulated in the lesions of atherosclerosis. Many of the growth 
factors that contribute to these often dramatic changes in arteiy vessel wall structure 
are vessel wall derived. Activated platelets adhering to the endothelium will release 
their granules and the growth factors contained within. The adherent macrophages and 
T-lymphocytes will secrete growth factors and cytokines such as IL-1, TNFa and 
TGFp. The dysfunctional endothelial cells in lesions secrete growth factors and small 
signalling molecules such as NO. Other important growth factors are produced from 
the VSMC themselves and act in an autocrine manner (see Ross, 1993 and Bobik & 
Campbell, 1993 for reviews).
It is unlikely that any of these growth factors work alone in the process of 
atherogenesis. Through a network of cellular interactions, the release of one factor 
will stimulate the expression of a second factor in a target cell that can then stimulate 
cells in a paracrine or autocrine manner. One example of this is the secretion of 
cytokines and growth factors by macrophages. Activated macrophages in the lesions 
will secrete PDGF, which can act directly on the VSMC. As well as PDGF secretion, 
they release lL-1, TNFa and TGFp. These cytokines can act on both endothelial cells 
and VSMC to induce production of PDGF, which can further stimulate the 
proliferation of VSMCs. Interestingly, when there are high levels of lL-1, TNFa and 
TGFp an inhibition of the proliferative effect of the secreted PDGF occurs, by 
downregulating the PDGF receptor (Battegay et al, 1990).
There may be great diversity in the smooth muscle cells in the lesions of 
atherosclerosis, as smooth muscle cells are derived from individual organ parenchyma 
during embryogenesis, whereas the endothelium appears to be derived from the 
embryonic vasculature that invades the organ (Schwartz et al, 1990). Therefore the 
smooth muscle cells in different arteries have different origins. As well as differences 
in VSMC in different arteries there also appears to be heterogeneity of VSMCs within 
a single area of the vessel (Benzakour et al, 1996). Different sub-populations of 
VSMCs may give rise to smooth muscle cells that can respond very differently to the 
same stimuli.
VSMCs are also able to display at least two phenotypes, contractile and synthetic 
(Mosse et ai, 1985, Campbell and Campbell 1985). These phenotypes can be 
differentiated based on the distribution of myosin filaments and the amounts of 
secretoiy protein apparatus, such as rough endoplasmic reticulum and Golgi 
(Chamley-Campbell et al, 1979, Gonzales-Crussi 1971). It is likely that these 
phenotypes are the extremes of a spectrum of phenotypes that may coexist in the 
vessel wall. When the cells are in the contractile phenotype they respond to agents that 
induce either vasoconstriction or vasodilation. In contrast, in the synthetic state the 
cells are capable of expressing genes for a number of growth regulatory molecules and 
cytokines (Libby et al, 1988, Slôjund et al, 1988). Several observations have 
suggested that smooth muscle cells in lesions are of the synthetic phenotype and are 
therefore more susceptible to proliferative stimuli than contractile VSMCs.
1 .2  R e g u l a t i o n  o f  G l u c o s e  U p t a k e
Increased glucose transport is an early response to growth factors in all cells 
(Thomson & Gould, 1997). Despite the importance of smooth muscle cell 
proliferation in the development of atherosclerotic plaques, little is loiown about the 
mechanism and regulation of glucose transport in VSMCs.
1 .2 .1  T h e  f a c il it iv e  g l u c o s e  t r a n s p o r t e r  f a m il y  (G L U T S )
A summary of the tissue distribution of the facilitative glucose transporters is shown 
in Table 1.1.
The transport of glucose across the plasma membrane and into the cytosol is arguably 
the most important function a cell performs, as D-glucose is required for cellular 
growth, homeostasis, and metabolism. The existence of a protein moiety responsible 
for glucose transport was first demonstrated by Jung, 1971, who showed that the 
transport capacity of erythrocytes was retained by eiythrocyte ghosts but not by 
erythrocyte lipids alone. In 1982 Lienhard and his colleagues purified and partially 
sequenced the first member of the family, now known as the facilitative glucose
transporters or GLUTs (Baldwin et al, 1982). These transporters allow the movement 
of glucose across the plasma membrane down its concentration gradient, either into or 
out of the cell. Furthermore, this family of proteins are specific for the D-enantiomer 
of glucose and are not coupled to any energy-requiring components, such as ATP 
hydrolysis or a gradient. GLUT-1 was purified from eiythrocytes and antibodies 
were raised against the polypeptide. Using the partial sequence obtained from the 
purified protein a cDNA clone was isolated in 1985 (Meukler et al, 1985) and 
subsequently the isolation of the gene coding for GLUT-1 (Fukomoto et al, 1988). 
GLUT-1 protein and mRNA is present in many tissues and cells. In humans GLUT-1 
is expressed at highest levels in brain and erythrocytes, but is also enriched in tissues 
of the blood-tissue barriers, such as the blood-brain barrier and the placenta (Gould & 
Holman, 1993). GLUT-1 is located on the plasma membrane and in the recycling 
endosomes. It is widely regarded as the “house-keeping” glucose transporter (Flier et 
al, 1987).
Subsequent to the isolation of the GLUT-1 cDNA, more members of the glucose 
transporter family were isolated by screening of cDNA libraries of several tissues with 
the GLUT-1 cDNA under low stringency conditions. Using this method, a cDNA 
encoding GLUT-2 was isolated from hepatocytes (Fukomoto et al, 1988; Thorens et 
al, 1988). Analysis of the properties of this transporter revealed that it is a high- 
capacity, high Km transporter for glucose. These properties are ideally suited to allow 
the liver to function as one of the key tissues involved in glucose homeostasis; the 
high Km and transport capacity endows GLUT-2 with properties enabling the rapid 
influx of glucose into the liver after eating, and rapid efflux of glucose from the liver 
following gluconeogenesis and glycogenolysis.
GLUT-3 was identified by Nagamatsu et al, 1992, and was found to be the prominent 
isoforra expressed in brain and neural tissue. GLUT-3 is expressed in human foetal 
muscle, but Northern blot analysis of the adult skeletal muscle revealed no trace of 
GLUT-3 mRNA. High levels of GLUT-3 mRNA are present in a range of other adult 
tissues such as the placenta, liver, heart and kidney. The mRNA for GLUT-3 has been 
found at high levels in these tissues, but the sites of protein expression are more
restricted, indicating that perhaps GLUT-3 may undergo negative post-translational 
regulation (Gould & Holman, 1993).
The GLUT-4 isoform is the insulin-responsive glucose transporter. Adipose and 
skeletal muscle are unique with respect to glucose transport, in that they exhibit acute 
insulin-stimulated increases in transport, up to 30-fold (fat) and 10-fold (muscle) 
(Gould, 1997). These tissues have a large pool of the GLUT-4 glucose transporter 
sequestered inside the cells which is not normally available for glucose transport. 
Upon exposure of the cells to insulin the GLUT-4 is rapidly translocated to the cell 
surface (Cushman et al, 1980; Suzuki & Kono, 1980). This means that the cells have 
a low resting rate of glucose transport, but ai e able to achieve a rapid and large 
increase in glucose transport in response to insulin.
cDNA library screening also identified GLUT-5, the major facilitative glucose 
transporter of the small intestine (Kayano et al, 1988). GLUT-5 is localised to the 
apical brush border on the luminal side of the absorptive epithelial cells (Davidson et 
al, 1992). This transporter has a high affinity for fructose and a low affinity for 
glucose, therefore it seems reasonable to assume that it plays a major role in the 
uptake of dietary fructose (Burant et al, 1992). GLUT-5 is also found in several other 
human tissues, including muscle, brain, adipose tissue, kidney and testis (Shepherd et 
al, 1992).
In 1990 Kayono et al identified a further transporter-like transcript by homology 
screening. This transcript has a ubiquitous tissue distribution and is 79.6% identical to 
GLUT-3. However, sequence analysis of the cDNA revealed that it contained several 
stop codons and frame shifts, and is therefore unlikely to encode a functional glucose 
transporter and most likely a pseudo gene.
1 ,2 .2  S t r u c t u r e  a n d  m e m b r a n e  t o p o l o g y  o f  t h e  G L U T s
After cloning of the GLUTs analysis of the predicted amino acid sequences revealed a 
high degree of homology between the mammalian glucose transporters and those of 
other species including bacteria, yeast, algae and protozoa (Walmsley et al, 1998,
Barrett et al.,1999). This degree of similarity probably relates to a common 
mechanism of transport catalysis, a common type of substrate and is suggestive of a 
common evolution from a single gene. The common features revealed by sequence 
alignment and analysis of the transporters include 12 predicted amphipathic helices 
arranged so that both the N- and C-termini are at the cytoplasmic surface (Gould, 
1997). Also predicted are large loops between helices 1 and 2 and between helices 6 
and 7 (Figure 1.2). The loop between helices 6 and 7 divides the structure into two 
halves, usually referred to as the N-terminal domain and the C-terminal domain. The 
loops between the remainder of the helices are very short and the length of these loops 
is a conserved feature of the entire family. The short loops place severe constraints on 
the possible tertiaiy structure of the protein, and suggest very close packing of the 
helices at the inner surface of the membrane, in each half of the protein. The length 
and sequence identity of the loops at the extracellular surface of these proteins is very 
varied but is generally longer than the loops on the cytoplasmic surface. This may 
potentially result in a less compact helical packing at the external surface. The general 
features of this model including the membrane-spanning topology have been 
confirmed by extensive experimental analysis using a range of approaches (Barrett et 
al, 1999).
1 .2 .3  S ig n a l l in g  P a t h w a y s  M e d ia t in g  G l u c o s e  T r a n s p o r t
1 .2 ,3 .1  G ro w th  fa c to r -m ed ia ted  g lu co se  tr a n sp o r t
Exposure of quiescent cells to mitogens results in the stimulation of numerous 
intracellular signalling cascades, culminating in cell growth and division several hours 
later. Due to the increased energy requirements of growing cells, one of the early 
responses of cells common to all mitogens is an increase in the rate of glucose uptake. 
GLUT-1 is thought to be the glucose transporter responsible for growth factor- 
stimulated increases in glucose transport (Thomson & Gould, 1997).
Time-courses of growth-factor induced glucose transport reveal a biphasic pattern, 
consisting of an acute phase response occurring within minutes and a chronic phase 
after about 4-12 hours. The acute phase of transport is thought to occur by a
movement of GLUT-1 from the recycling endosomal system to the plasma membrane, 
therefore increasing the number of functional transporters at the plasma-membrane, 
and also possibly via an increase in the intrinsic activity of the transporters (Gould & 
Holman, 1993, Czech et al, 1992). However the molecular mechanisms underlying 
these effects are poorly understood.
The chronic effect of mitogens on glucose transport is inhibited by cycloheximide, 
suggesting that it is dependent on new protein synthesis. Several studies have shown 
that GLUT-1 mRNA is increased during the late phase of growth-factor stimulated 
uptake (Kitagawa 1989, Rollins e/a/., 1988, Hiraki n/., 1988).
Different classes of growth factors exist which work at structurally distinct receptors 
and mediate intracellular signals via distinct mechanisms. There are two classes of 
mitogen receptor, the protein tyrosine kinase receptors, which transduce their signals 
via intrinsic tyrosine kinase activities in their cytoplasmic domain, and the seven- 
transmembrane domain receptor family, which transduce their signals by coupling 
with heterotrimeric G-proteins. Despite their distinct receptors and the differences in 
the initial signal transduction mechanisms, activation of both receptor types leads to a 
similar biphasic profile of glucose transport, suggesting that the signal transduction 
pathways activated by these distinct classes of receptor converge (Thomson & Gould, 
1997).
Receptor tyrosine kinase signalling
Receptor tyrosine kinase signalling is probably the best understood mechanism of 
growth factor signal transduction. Following growth-factor binding to receptor, the 
receptors undergo a conformational change, which activates the intrinsic tyrosine 
kinase activity of the receptor, resulting in autophosphorylation of the specific 
tyrosine residues within the cytoplasmic domain of the receptor and receptor 
dimérisation (Fantl et al, 1993). These specific phosphotyrosine residues can act as 
“docking sites” for intracellular signalling proteins. The phosphotyrosine residues aie 
contained within specific amino acid sequences, which result in highly selective 
binding sites for SH2 domains (Pawson & Gish, 1995). Many proteins contain such
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SH2 domains and are able to bind the phosphotyrosines on active receptors, including 
PI3-K, PLC y, Ras GTPase activating protein (Ras GAP), growth factor residue 
binding protein-2 (Grb-2), SHPTP-2 (the phosphotyrosine phosphatase) and the Src 
family of non-receptor tyrosine kinases. Upon binding to the receptors these signalling 
proteins are thought to undergo tyrosine phosphorylation, and those with a catalytic 
domain are subsequently activated, thus propagating the signal. Not all proteins that 
bind to the receptors have catalytic activity, but instead act as adaptor proteins which 
couple the activated receptor to intracellular signalling molecules i.e. Grb 2 (Egan ei 
al, 1993). It should be noted that the insulin receptor and IGF-1 receptor, both 
tyrosine kinases receptors, transduce their signals via a distinct mechanism, utilising 
the adaptor proteins, insulin receptor substrate (IRS-1, 2, 3), described below.
G-protein coupled receptor signalling
G-protein coupled receptors transduce their signals by activating heterotrimeric G- 
proteins. Heterotrimeric G-proteins consist of a , p and y subunits. When an agonist 
binds to receptor it results in the exchange of GTP for GDP on the a  subunit of the G- 
protein. This causes the a  subunit to separate from the Py subunits. Both the GTP- 
bound a  subunit and the py dimer are important activators for a number of signalling 
molecules (for review see Milligan, 1993, Sternweis, 1994). It is clear that G-protein 
coupled receptors can stimulate many of the same intracellular signalling molecules 
that the protein tyrosine kinase receptors activate. It is probable, therefore, that 
stimulation of glucose transport by protein tyrosine kinase receptors and G-protein 
coupled receptors utilise common signal transduction pathways (see Figure 1.3 for 
overview).
Phospholipid hydrolysis and PKC
Both receptor tyrosine kinases and G-protein Py subunits can stimulate phospholipase 
C (PLC) activity (Ronnstrand et al, 1992, Milligan, 1993, Sternweis, 1994). This 
results in the hydrolysis of PI(4,5)P2 to Ins(l,4,5)P3 and diacylglycerol (DAG). 
Ins(l,4,5,)P3 can mobilise Ca^ "^  from intracellular pools and DAG can stimulate the
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protein kinase C (PKC) family of serine/threonine kinases. Both Ca^ "*" and PKC have 
been implicated in a number of physiological functions and as such a role for these in 
glucose transport has been sought.
It has been shown that purified PKC can phosphorylate GLUT-1 in vitro (Witters et 
al., 1985), but as yet there has been no demonstration of a functional consequence of 
this event. Pharmacological activators of PKC, such as phorbol esters, have been 
shown to stimulate glucose uptake in Swiss 3T3 fibroblasts (Farese et al., 1986, 
Kitagawa et al, 1986), further implying a role for PKC in glucose transport. However, 
although PLC, DAG and PKC can all stimulate glucose transport, subsequent studies 
have all but ruled out a role for PKC in glucose transport in response to many 
mitogens. For example down-regulation of PKC by prolonged incubation with 
phorbol esters has no effect on PDGF or IGF-1 stimulated glucose transport in 
fibroblasts (Merrall et al, 1993). In addition, IGF-1 and PDGF do not stimulate PKC 
activity in fibroblasts, but can stimulate glucose transport (Merrall et al, 1993).
Recently it has been shown that [Ca^^] may be important with regard to glucose 
transport. Quinn et al, 1998, have shown that angiotensin II stimulated glucose 
transport in rat aortic VSMC is dependant on the levels of extracellular [Ca^^j. When 
the cells were incubated in growth media without calcium, angiotensin failed to 
stimulate glucose transport, as compared to cells grown in media with normal calcium 
levels. It was also shown that the inliibitors of calmodulin, W-7 and caimidazolium 
could inhibit angiotensin II stimulation of glucose transport in these cells. These 
results point to a role for calcium in regulating glucose transport.
Mitogen Activated Protein Kinase
A  wide variety of grov/th factors stimulate the mitogen activated protein kinase 
(MAPK) family, an event that is believed to play a major role in the transduction of 
mitogenic signals into intracellular responses. Both tyrosine kinase receptors and 
GPCR stimulate the activation of p42/44 MAP kinase via a similar mechanism, by the 
activation of a sequential phosphorylation cascade (see Figure 1.3). The MAP kinase 
family consists of the p42/44 MAPK, p38 MAPK and JNK (reviews Canos et al,
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1995, Davis, 1994). This family of proteins are stimulated by distinct but parallel 
phosphoiylation cascades in response to mitogens, stress and cytokines respectively 
(Canos e/a/., 1995).
There is now good evidence supporting a role for MAPK involvement in mitogen- 
stimulated glucose transport. By using specific inhibitors of p42/44 MAPK (PD 
98059) it is possible to inhibit IGF-1 stimulated glucose uptake in KB cells (Gould ei 
al, 1995). Therefore it seems likely that p42/44 is involved in the growth factor- 
stimulated signal transduction transport from protein tyrosine kinase receptors leading 
to glucose uptake. In contrast, the p42/44 inhibitor had no effect on IL-1 stimulated 
transport in these cells, instead this uptake was completely inliibited by the p38 
specific inhibitor, SB 203580, indicating that p38 MAPK is involved in mediating 
cytokine stimulated glucose transport.
The mechanism by which MAPKs regulate glucose uptake is poorly understood. Two 
known downstream targets of MAPK, MAPKAP and insulin-sensitive protein kinase, 
were without effect on glucose transport when injected into oocytes (Merrall et al,
1993), suggesting that the effect of MAPK on glucose transport is direct, or via some 
as yet unidentified downstream target. Previous work has shown, however, that direct 
phosphorylation of the glucose transporter does not occur in response to PDGF, EGF 
and insulin in 3T3-L1 fibroblasts (GWG unpublished data). Furthermore the GLUTl 
transporter is not phosphorylated in vitro by either MAPK or MAPKK, so it would 
seem unlikely that MAPK stimulates glucose transport by modulating phosphorylation 
of the GLUT-1 protein itself (FJT & GWG unpublished results).
Phosphatidyl 3 ' Kinase (PIS 'kinase)
The widespread activation of PI3’ kinase by growth factors points to a common 
fundamental role for this enzyme in growth factor signalling, and thus PI3 ’ kinase has 
been investigated as a possible mediator of glucose uptake. PI3 ’ kinase catalyses the 
phosphorylation of phosphoinositides at the 3 position of the inositol ring, to generate 
PI(3)P, PI(3,4)P2 and PI(3,4,5)P] (Leevers et al, 1999).
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There are three classes of PI3’ kinase; class I PI3’ kinases are stimulated by both 
receptor tyrosine kinases and G-protein-coupled receptors and can generate all 3 
phosphoinositide forms. Class II PI3’ kinases generate PI(3)P and PI(3,4)P2 and class 
III PI3’ kinases generate PI(3)P only (Leevers et al, 1999). These phosphoinositide 
products of PI3 ’ kinase act as second messengers for signal transduction by interacting 
'with proteins containing specific phosphoinositide binding domains. Examples of 
such domains include: FYVE domains, which are cysteine-rich zinc-finger-like motif 
(Stemnark et al, 1996), which bind PI(3)P specifically (Patki et al, 1998) and 
pleckstrin homology domains (PH domains) which are modules of -100 amino acids 
which bind PI(3,4,)P2 and PI(3,4,5)P] (Lemmon et al, 1997).
Many groups have studied the role of PI3 ’ kinase in glucose transport. It has been 
shown that gro'wth factor stimulated glucose transport can be inhibited by using PI3 ’ 
kinase inhibitors, such as wortmannin and LY 294002, in a variety of cell types 
(Gould et al, 1994, Clarke et al, 1994, Barros et al, 1995).
The exact role of PI3’ kinase in growth factor stimulated glucose transport remains to 
be elucidated. PI3 ’ kinase activation of c-AKT in insulin-stimulated glucose transport 
is known to be vital (see section 1.2.3.2) and perhaps PI3’ kinase plays a similar 
important second messenger role in mitogen-stimulated glucose transport. It has been 
difficult to elucidate a signalling role for PÏ3 ’ kinase in mitogen-stimulated glucose 
transport, as the downstream effectors of PI3’ kinase are as yet poorly defined. PI3’ 
kinase activation is also involved in regulating a variety of vesicular trafficking events 
(Corvera & Czech, 1998, Wusmer et al, 1999) and may therefore be important in 
recruiting GLUT-1 to the plasma membrane. However demonstrating a role for PI3’ 
kinase in regulating specifically signalling events or specifically trafficking events 
involved in glucose transport would be technically veiy difficult. It may be that PI3 ’ 
kinase is important in mediating mitogen-stimulated glucose transport via its both its 
roles as a signalling protein and in trafficking, however as yet this is speculation.
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1.2.3.2 Insulin-stimulated glucose transport
Insulin can activate a number of cellular intracellular signalling pathways, however its 
primaiy function is to regulate metabolism of sugars, amino acids and fats in its 
peripheral target tissues, adipocytes, heart and skeletal muscle as well as in the liver. 
Insulin acts at the insulin receptor, which is a receptor tyrosine kinase. Insulin- 
stimulated increases in glucose transport results from a redistribution of GLUT4 from 
an intracellular pool to the cell surface, thus increasing the total number of 
transporters at the cell surface available for transport (Cushman et al, 1980, Suzuki & 
Kono, 1980).
IRS-l and -2
Insulin receptor substrate 1 and 2 (IRS-1 & 2) have been identified as major substrates 
of the insulin receptor (Sun et al, 1991, Sun et al, 1995). IRS-1 and 2 will bind to the 
insulin receptor upon receptor stimulation, via an SH2 domain (see above for 
description of receptor tyrosine kinase activation). Upon binding to the insulin 
receptor these proteins become phosphorylated on specific tyrosine residues and can 
then act as an adaptor for proteins containing SH2 domains. IRS-1 and 2 bind many of 
the same proteins that will be bound by classical tyrosine kinase receptors such as 
Grb-2, SHPTP2 and PI3'K (Skolnik et al, 1993, Kuline et al, 1993, Myers et al,
1992, Backer et al, 1993). These proteins can then mediate insulin’s myriad of 
actions in the cell.
P I S ’ K
Insulin, as well as many other growth factors (see above) rapidly stimulates the 
activation of PI3’ kinase. PI3’ kinase stimulates the accumulation of 3’ 
phosphoinositides. These molecules can then act as second messengers by interacting 
with proteins containing specific phosphoinositide binding domains (see above). 
Phosphorylation of 1RS-1 and 2 by the insulin receptor results in binding sites for the 
p85 subunit of PI-3’ K, and upon binding to IRS-1 or 2 the enzyme is activated 
(Myers et al, 1992, Carpenter et al, 1993).
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Insulin stimulated hexose transport and GLUT-4 translocation in 3T3-L1 adipocytes 
BndXenopus oocytes can be inhibited by the use of specific inhibitors of P13’K, 
wortmannin and LY 294002 (Clarke et al, 1994, Evans et al, 1995, Gould et al, 
1994). Therefore it is clear that PBTC activity is very important in mediating insulin- 
stimulated glucose transport. However, the ability of PI3’K alone to stimulate glucose 
transport is controversial. Both insulin and PDGF stimulate PI3’K activity to the same 
extent in 3T3-L1 adipocytes, but only insulin significantly stimulates glucose transport 
in these cells (Wiese et al, 1995).
Since discovering that PI3’K is involved in mediating insulin-stimulated glucose 
transport, efforts have been made to identify possible down-stream effectors. Recently 
a serine/threonine kinase, protein kinase B (PKB), has been shown to be down-stream 
of PI3’K (Bos, 1995, Coffer et al, 1998). PKB is also laiown as c-AKT, and as yet the 
nomenclature for this kinase has not been resolved. Currently thiee isoforms of PKB 
are known, a , p and y. PKB is able to act as a down-stream target for PI3’K by virtue 
of its pleckstrin homology domain, which mediates binding to PI(3,4)P2 and 
PI(3,4,5)P3. Upon binding to phosphoinositides PKB is itself phosphoiylated and 
activated (Coffer et al, 1998).
A role for PKB in insulin-stimulated glucose transport has been sought. Work has 
shown that if a constitutively active form of PKB is transfected in to 3T3-L1 
preadipocytes spontaneous differentiation of these cells into mature adipocytes occurs 
(Magun et al, 1996). Expression of the constitutively active PKB stimulated glucose 
uptake and GLUT-4 translocation levels similar to those seen upon insulin treatment 
in 3T3-L1 adipocytes (Kohn et al, 1996). It is interesting to note here that PDGF can 
stimulate PI3’K activity in these cells but is unable to stimulate phosphorylation of 
PKB (Nave et al, 1996). This demonstrates a parallel between an agonist’s ability to 
stimulate GLUT-4 translocation and PKB activation. These results suggest an 
important role for PKB in insulin-mediated glucose transport. The mechanism by 
which PKB mediates insulin-stimulated glucose transport is as yet unclear.
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MAP Kinase Cascade
The insulin receptor can stimulate the MAP kinase cascade via activation of the small 
molecular weight G-protein p2P^^ Insulin activates p2P‘*^ via two different 
mechanisms, one requiring IRS-1 and the other independent of 1RS-1 (Myers et al, 
1994). The activation of ras requires the exchange of GDP for GTP. This exchange is 
catalysed by the guanine-nucleotide exchange factor SOS (Sakaue et al, 1995). Upon 
binding of insulin to its receptor, Grb2/S0S is recruited to the membrane via 
interaction with IRS-1 or She, an insulin receptor adapter protein (Skolnik et al.,
1993, Myers et al, 1994). Once at the membrane the Grb/SOS complex can catalyse 
the nucleotide exchange on ras, and ultimately the activation of the MAP kinase 
cascade (see Figure 1.4).
However, the use of an inhibitor of p42/44 MAP kinase activation, PD98059, fails to 
inliibit insulin stimulated glucose transport in 3T3-L1 adipocytes (Lazar et al, 1995). 
These results indicate that the MAP kinase pathway is not responsible for mediating 
insulin-stimulated glucose transport.
1.2.3.3 Cyclic nucleotide regulation of glucose transport
To date very little is known about the role of cyclic nucleotides in regulating glucose 
transport. Depending on the tissue studied cAMP can be either stimulatory, inliibitory 
or without effect on glucose transport. In 3T3-L1 preadipocytes the cAMP analogue, 
8-Br cAMP, was found to be stimulatoiy with regard to glucose transport (Cornelius 
et al, 1991). In fat cells cAMP is without effect on basal glucose transport rates but is 
inhibitoiy with regard to insulin-stimulated transport in these cells (Lonnroth et al, 
1987). In cultured rat thyroid cells glucose transport is increased by thyroid- 
stimulating hormone in a cAMP-dependent manner (Hosaka et al, 1992). In these 
cells it was seen that cAMP analogues stimulated an increase in GLUT -1 mRNA 
levels but caused a decrease in GLUT-4 mRNA levels. This, along with the effect of 
cAMP in fat cells and preadipocytes, seems to suggest that cAMP may be stimulatory 
with regard to GLUT-1 mediated glucose transport, but inhibitoiy with regard to 
GLUT-4 mediated transport. In pancreatic (3 cells phosphorylation of the glucose
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transporter GLUT-2 by protein kinase A (PKA) results in a decrease in glucose 7
transport (Thorens et al., 1996). In cardiomyocytes agents altering intracellular levels 
of cAMP had no effect on glucose transport (Fischer et al., 1996). j
Less is known about the ability of cGMP to regulate glucose transport. In ?
cardiomyocytes, there are early reports of cGMP being able to stimulate glucose
'.3
transport in these cells (Shanahan & Edwards, 1989), but later publications report that 
cGMP is without effect on glucose transport in cardiomyocytes (Fischer et al., 1996).
‘‘Ï
1 .2 .4  G l u c o s e  T r a n s p o r t  in  V a s c u l a r  S m o o t h  M u s c l e  C e l l s
■|
As stated earlier, VSMC proliferation is an important factor in the development of 
atherosclerotic plaques. Glucose transport is an early response common to all 
mitogens, however veiy little is known about the regulation of glucose transport in 
VSMC.
Most studies of glucose transport in vascular smooth muscle cells have concentrated 
on the effects of insulin and IGF-1. In these studies it has been shown that both insulin 
and IGF-1 are capable of eliciting a two- to tliree-fold increase in glucose transport in 
these cells (Sowers, 1996, Fujiwara & Nakai, 1996). In both studies it was shown that 
IGF-1 is a more potent stimulator of glucose transport than insulin in VSMCs. It has 
been suggested that the effects of insulin on VSMC are mediated via the IGF-1 
receptor. Both insulin and IGF-1 stimulated glucose transport are inhibited by the 
PI3’K inhibitor, wortmannin (Fujiwara & Nakai, 1996), therefore insulin and IGF-1 
both mediate glucose transport via a PI3’kinase-dependent mechanism.
Angiotensin II, an endogenous vasoconstrictor that acts at a G-protein-coupled 
receptor, has also been shown to be able to increase glucose transport in VSMCs 
(Quinn & McCumbee, 1998). This agonist also elicits an approximately two-fold 
increase in glucose transport. Inhibition of PKC did not affect the ability of 
angiotensin II to stimulate glucose transport in VSMC. However it was shown that 
extracellular calcium and calmodulin are important in mediating angiotensin II- 
stimulated glucose uptake. Reducing the extracellular calcium concentration or
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inhibiting calmodulin, with W-7 or caimidazolium, reduces angiotensin Il-stimulated 
uptake by approximately 50%, but had no effect on basal rates of transport.
As well as various agonists being able to modulate glucose transport in VSMCs, it has 
been shown that the concentration of glucose that the cells are exposed to is also very 
important. In cells grown in media with high concentrations of glucose (25 niM) both 
basal and stimulated rates of uptake are lower than in cells grown in 0, 2.5 or 5 mM 
glucose. This is true in response to both insulin and angiotensin II (Fujiwara et al., 
1996, Quinn & McCumbee, 1998). The fold stimulation of glucose transport is much 
greater in cells grown in high glucose concentrations, due to the very low basal levels 
of uptake, than in cells grown in low glucose concentrations. The mechanisms 
underlying the regulation of transport by the concentration of glucose in the growth 
medium are poorly understood.
There is some controversy as to which glucose transporter(s) are responsible for 
increased glucose uptake in VSMC. Sowers’ work indicates that the insulin 
responsive glucose transporter GLUT-4 is present in the cells and may be involved in 
mediating the insulin/IGF-1 increase in uptake (Sowers, 1996). Flowever other groups 
investigating glucose transport in VSMC found GLUT-1 mRNA but failed to find 
mRNA for GLUT-4 in these cells (Kihara et al, 1998), implying that it is GLUT-1, 
and not GLUT-4, which is responsible for mediating the increases in glucose 
transport. This point is returned to later in this thesis.
1.3 C y c l ic  3 ’5%Ad e n o s in e  M o n o p h o s p h a t e
Cyclic 3’5’-adenosine monophosphate (cAMP) is an important second messenger 
involved in mediating a wide range of cellular functions. cAMP can regulate many 
cellular processes including cell grovrth and differentiation (Kronemann et al, 1999, 
Yarwood 1995, Schmidt et al, 1990), relaxation of smooth muscle (Murray, 1990, 
Murthy & Makhlouf, 1995), glucose transport (Piper et al, 1993, Cornelius et al, 
1991), secretory processes (Katsura et al, 1997, Muniz et al, 1996) and ion channel 
conductance (Briiggermann et al, 1993, Jureviçius et al, 1996) and many others.
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The intracellular concentration of cAMP is determined by both its rate of synthesis, by 
a family of adenylyl cyclases (Tesmer & Sprang, 1998), and its rate of degradation, by 
the multi-enzyme family of phosphodiesterases (PDEs) (Manganiello et al, 1995, 
Houslay & Milligan, 1997).
1.3.1 Generation of cAMP
cAMP is synthesised by adenylyl cyclase which catalyses the conversion of ATP to 
cAMP. Mammalian cells express up to nine adenylyl cyclase isoforms. Adenylyl 
cyclases are integral membrane glycoproteins with twelve transmembrane spamiing 
helices (Tesmer & Sprang, 1998). Both the N- and C- terminal are intracellular, and 
the active site of the enzyme is formed by the intracellular loop between helices 6 and 
7 (Cl domain) and the C-terminal tail (Cz domain) (Tesmer & Sprang, 1998), which 
forms a wreath-like structure (Tesmer & Sprang, 1998). The activity of the enzyme 
requires the presence of the divalent cation Mg^^ (Smit & Iyengar, 1998) and can be 
regulated by a number of mechanisms within the cell depending on the isoform 
(Iyengar, 1993, Smit & Iyengar 1998). An overview of the adenylyl cyclase isoforms 
and how they are regulated is shown in Table 1.2.
The best understood means of regulating adenylyl cyclase activity is by the action of 
heterotrimeric G-proteins. Heterotrimeric G-proteins consist of an a, |3 and y subunit. 
Stimulation of a G-protein coupled receptor leads to the exchange of GDP for GTP on 
the a  subunit of the receptor-associated G-protein. This results in the activation of the 
G-protein and dissociation of the a  subunit from the Py subunits. Both the a  subunit 
and the Py subunits are capable of transducing signals. There are a number of a  
subunits in cells and these can be stimulatory, inhibitoiy or without effect on adenylyl 
cyclase activity (for review see Milligan, 1993). The Gs a  subunits are stimulatory 
with regard to all nine adenylyl cyclase isoforms, whereas the Gi a  subunits inhibit 
adenylyl cyclase I, V, VI and VIII (Houslay & Milligan, 1997, Smit & Iyengar, 1998). 
The Py subunits can also regulate the activity of adenylyl cyclase (Sternweis, 1994, 
Smit & Iyengar, 1998). The effects of the Py subunits can be either stimulatory or
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inhibitory, depending on the isoform of adenylyl cyclase. Gpy inhibits type I and VIII 
adenylyl cyclase, whereas it is stimulatory with regard to types II, IV and VII. The 
effects of the Gpy are most efficacious in the presence of an activating agent (such as 
Gs a). Thus Gpy acts primarily to enhance or dampen the activity of the stimulated 
enzyme.
As well as regulation by the heterotrimeric G-proteins adenylyl cyclase activity can be 
modulated by several other mechanisms, including protein kinase C and intracellular 
calcium (Smit and Iyengar, 1998, Iyengar, 1993), see table 1.2. Many growth factors 
and hormones signal via receptor tyrosine kinases. This can result in the stimulation of 
protein kinase C and an increase in the levels of intracellular calcium (see figure 1.3). 
The ability of certain adenylyl cyclase isoforms to be regulated by Ca^^ and PKC 
allows a mechanism for crosstalk between signals from receptor tyrosine kinases and 
those from G-protein coupled receptors.
Protein kinase A can phosphorylate and inhibit the activity of type V and VI adenylyl 
cyclases. This is thought to provide means of desensitisation of cAMP signalling. As 
cAMP accumulates, the activity of PKA increases. PKA, as well as mediating 
intracellular signals, phosphoiylates and inliibits adenylyl cyclase activity, therefore 
inhibiting further production of cAMP and further stimulation of PKA (Smit &
Iyengar, 1998).
1.3.2 Degradation of cAMP
As stated above the intracellular levels of cAMP is determined both by its rate of 
synthesis and its rate of degradation. The breakdown of cAMP is catalysed by a large 
multi-gene family of phosphodiesterases (Bolger, 1994, Manganiello, 1995).
CuiTently ten families of PDE have been identified which are differentiated between 
based on their biochemical and pharmacological characteristics (see table 1.3 for an 
overview of the properties of PDEs). Some PDE isoforms degrade cGMP specifically, 
such as PDE VI and IX, some degrade cAMP specifically, such as III, IV, VII and VIII 
whereas PDEs I, II and X ai'e promiscuous and catalyse the degradation of both cAMP 
and cGMP (Manganiello et al, 1995, Soderling et al, 1998, Fisher et al, 1998,
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Soderling et al, 1998, Soderling et al, 1999). Seven families of PDE are Icnown to 
hydrolyse cAMP: I, II, III, IV, VII, VIII and X (Manganiello et al, 1995).
The PDE isoforms ail have a central core region of about 330 amino acids, which 
contains the active site. Outside this core region the PDE isoforms are distinct. 
Alternative mRNA splicing leads to a huge number of isoforms within each PDE 
family, and this gives rise to a sophisticated system for generating PDE isoforms 
targeted to distinct intracellular structures. This is exemplified in the PDE IV family 
(Bolger, 1994). Four genes encode the mammalian types IV PDEs. Analysis of 
cDNAs from human PDE4A, 4B and 4D revealed that each locus produces clones 
with regions of variant sequence consistent with alternative mRNA splicing (reviewed 
Bolger, 1994). This takes the form of 5’-domain swapping, leading to a family of over 
16 different active isoforms being produced, each of which has a distinct amino- 
terminal region. Analyses of the PDE 4A isoforms has shown that amino-terminal 
truncation produces a highly active core region, which is localised entirely in the 
cytosol. This is in contrast to the full-length isoforms, which show diminished 
catalytic activity and are found associated at specific subcellular sites (Bolger et al, 
1996, McPhee et al, 1995, O’Connell et al, 1996).
Due to the large number of PDE families and the ability of the cells to produce many 
splice variants within each PDE family, the cell has a wide range of ways to terminate 
cAMP signalling. The specific subcellular localisation and activity of PDEs may play 
a very important role in the compartmentalisation of cAMP signalling (Houslay & 
Milligan, 1997). It is believed that the compartmentalisation of cAMP signals could 
be vital in leading to the specific downstream effects of this very ubiquitous second 
messenger.
1.3.3 cAMP signalling
As has been discussed above there are a large number of receptors, G-proteins, 
adenylyl cyclases and PDEs responsible for generating and terminating cAMP signals.
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Protein kinase A (PKA) is the most common and best understood mechanism for 
cAMP to mediate its signal. The PKA holoenzyme is a heterotetramer composed of a 
regulatory subunit dimer (R2), which maintains two catalytic subunits (C) in a 
dormant state (Rubin, 1994 for review). When intracellular levels of cAMP rise each 
regulatoiy subunit binds to two cAMP molecules and the inactive holoenzyme 
dissociates into an R2-CAMP4 complex and active C monomers. To date there are 
three C subunits (ct, p and y) and four R subunits (RIa, Rip, R lla and RIip) known in 
mammals (Gamm et al, 1996, Beebe et al, 1990, Taylor et al, 1990). Dissociated C 
subunits catalyse the phosphoiylation of substrate molecules on serine/threonine 
residues presented in the sequences RRXS/T or RXS/T or KRXXS/T (reviewed by 
Kemp & Pearson, 1990) thereby regulating their functional and/or structural 
properties.
As PKA phosphorylation sequences are abundant in the cell there are various 
regulatory mechanisms in place to ensure that indiscriminate phosphorylation does not 
occur. Firstly, the levels of cAMP present in the cell are tightly regulated by its rate of 
synthesis and degradation by adenylyl cyclases and PDEs, and the subcellular 
localisation of PDEs leads to further localised reduction of cAMP (discussed above). 
Access to cAMP is the primary requirement for PKA activation, but there are 
additional factors responsible for returning the enzyme to its inactive state. The R 
subunit is expressed in excess over the C subunit, favouring reformation of the 
holoenzyme when cAMP levels return to the basal state. The subcellular localisation 
of the PKA isoforms is also believed to play a regulatory role. The type I PKA 
holoenzymes, containing RIa or (3, are predominantly cytoplasmic whereas the type 11 
holoenzymes are targetted to certain intracellular locations (reviewed Rubin, 1994). 
RII isoforms are by means of A Protein Anchoring Proteins, or AKAPs (reviewed in 
Colledge & Scott, 1999, Faux & Scott, 1996). This targetting of type II PKA to 
subcellular compartment may allow a mechanism for the cell to selectively activate 
PKA II depending on the availability of cAMP at this subcellular site (reviewed in 
DelP Acqua & Scott, 1997).
PKA is known to be involved in regulating a large number of cellular activities 
including natriuretic peptide-dependent cGMP accumulation (Ledoux et al, 1997),
23
stimulation and inhibition of MAPKs by altering Raf activity (Yarwood et al, 1996, 
Yao e ta l ,  1998), exocytosis (Muniz a/., 1996, Katsura c/a/., 1997) and relaxation 
of smooth muscle cells (Murthy & Makhlouf, 1995),
As well as signalling via PKA, cAMP is also capable of mediating some of its effects 
directly. cAMP can directly activate cardiac pacemaker chamiels and a voltage-gated 
K^ and Ca^^ channel, independent of any phosphorylation of the chamiel (DiFrancesco 
& Tortora, 1991, Brtiggemann et al, 1993). This is thought to occur by direct cAMP 
binding to the channel. As well as direct activation of ion channels, cAMP can bind 
and activate specific guanine nucleotide exchange factors, GEFS (de Rooij et al, 
1998). It also appears that cAMP can inhibit glucose transport by a mechanism that is 
not dependent on PKA phosphorylation (Piper et al, 1993).
These mechanisms of signal transduction via cAMP allow a whole array of possible 
downstream effectors and countless opportunities for crosstalk with many different 
signalling pathways.
1 .4  C y c l i c  G u a n o s i n e  3  ’5 ’- M o n o p h o s p h a t e
Like cAMP, intracellular levels of cGMP are controlled both by its rate of synthesis 
by guanylyl cyclases and its rate of degradation by PDEs. cGMP has been implicated 
in regulating many cellular processes including inhibition of the MAPK pathway 
(Suhassini et al, 1998), regulation of proliferation in VSMC (Ciche et al, 1998, 
Ki’onemaim et al, 1999), inhibition of protein kinase C activation in VSMC (Kumar 
e ta l,  1997), smooth muscle relaxation and vasodilation (Landgraf rz/., 1992, 
Murthy & Makhlouf, 1995) and stimulation of glucose transport (Shanahan & 
Edwards, 1989).
1.4.1 Guanylyl Cyclase
cGMP is generated by conversion of GTP to cGMP by guanylyl cyclases , by a 
mechanism that is stereochemically analogous to that of adenylyl cyclases (Eturley, 
1998 for review). Guanylyl cyclases occur in both transmembrane and soluble forms.
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Both soluble and transmembrane guanylyl cyclases function as dimers, with the 
soluble guanylyl cyclases forming a|3 heterodimers and transmembrane guanylyl 
cyclases forming homodimers. Both the soluble and transmembrane guanylyl cyclase 
require Mg^^ for activity (Hurley, 1998). The catalytic domains of both the soluble 
and transmembrane guanylyl cyclases are homologous to the C, and C2 domains of 
mammalian adenylyl cyclases (Tesmer & Sprang, 1998). These C domains form the 
wreath-like active site analogous to that of adenylyl cyclase when dimerised (Tesmer 
& Sprang, 1998).
To date four members of the transmembrane guanylyl cyclase receptors have been 
identified: GC-A, GC-B, GC-C and RetGC (the retinal isoform) (Garbers & Lowe, 
1994). The transmembrane forms consist of a single transmembrane domain and a 
single intracellular catalytic domain and an intracellular protein kinase homology 
domain. The transmembrane isoforms appear to function as homodimers, but it is 
possible that heterodimers may also exist based on work canied out on cells 
overexpressing GC-A and -B (Chinkers & Wilson, 1992). The extracellular domain of 
transmembrane guanylyl cyclases acts as a ligand-binding site. The known peptide 
ligands for these guanylyl cyclases fall into two families: the natriuretic peptides 
(ANP, BNP, and CNP) or the heat stable enterotoxins/guanylylins (Garbers & Lowe,
1994). Upon binding of the appropriate ligand the enzyme activity is stimulated, and 
GTP is converted to cGMP. As well as being regulated by ligand binding, the activity 
of transmembrane guanylyl cyclases can be regulated by PKC and Ca^^ (Garbers & 
Lowe, 1994). This allows a mechanism for cross talk between cGMP signalling 
pathways and those which utilise PKC and Ca^ "*", such as PDGF (see section 1.2.3).
Soluble guanylylate cyclase (sGC) is a haem-containing protein found in the cytostolic 
fraction of virtually all mammalian cells. The haem group in soluble guanylylate 
cyclase confers the NO-sensitivity of the protein. Upon NO binding to the haem group 
the guanylyl cyclase activity is stimulated (Garbers & Lowe, 1994). To date three a  
and three p subunits of soluble guanylylate cyclase are known, and these function as 
heterodimers of a  and p subunits (Hobbs, 1997). The ai and Pi subunits are found 
ubiquitously expressed in mammalian tissues and the subunit is found in kidney,
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vascular tissue, chemosensory cells and dorsal root ganglion. The expression of the P2 , 
Œ3 and P3 subunits is much more restricted with the P2 isoform being expressed only 
in liver and the a 3 and P3 isoforms only expressed in vascular smooth muscle and 
endothelial cells (Hobbs, 1997). Soluble guanylyl cyclases can be divided, arbitrarily, 
into three domains: haem-binding domain, a catalytic domain and a domain that 
mediates the dimérisation of monomers (Hobbs, 1997). As yet it is unclear how the 
activity of soluble guanylyl cyclase is regulated beyond the role of NO. It is believed 
that sGC activity may be regulated at the transcriptional level. It has been shown that 
agents which cause an increase in the intracellular levels of cAMP can decrease p 1 
mRNA, resulting in a diminished ability of the cell to generate cGMP in response to 
NO (Hobbs, 1997). sGC activity could also be regulated by the actions of an 
endogenous inhibitor which has been partially purified from bovine lung (Hobbs, 
1997).
1.4.2 Degradation of cGMP
Like cAMP, the large multi-gene family of phosphodiesterases degrades cGMP. Of 
these PDEs, types I, II, III, V and VI will degrade cGMP. Types I, II and III can 
degrade both cAMP and cGMP, whereas types V and VI are cGMP specific. These 
PDEs are regulated by a number of different mechanisms. PDEs are discussed in more 
detail in section 1.3.2, and a table of properties of PDEs is shown in table 1.3.
1.4.3 Signalling via cGMP
Many of cGMPs downstream effects are mediated by the cGMP regulated protein 
kinase PKG. PKG is a serine/threonine kinase and currently there are two types of 
PKG known, types I and II.
Two isoforms of type I PKG exist, cGK la  and cGK Ip (Wolfe et al., 1989). These 
isoforms differ only in their amino termini and both function as homo dimers. It is 
thought that the isoforms dimerise by means of a conserved, amino-terminal leucine 
zipper motif (Francis et al, 1994, Jarchau et al, 1994). Each subunit contains a
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catalytic and a regulatory, cyclic nucleotide binding domain (reviewed in Walter, 
1989, Edelmami et al, 1987) and can bind two molecules of cGMP. The for PKG 
activation is -20-100 iiM cGMP (Heil et al, 1987).
The type II PKG isoform was first identified from microvilli as a monomer associated 
with the membrane fractions (de Jonge, 1981). Type II PKG from mouse brain shows 
66% homology with the cGMP binding domain and the catalytic domain of cGK I. 
Initially type II PKG was thought to function as a monomer, but it also contains an 
amino-terminal leucine zipper (like type I PKGs), and recent work has revealed that 
the type II PKG does, in fact, function as a homodimer (Gamm et al, 1995).
PKG is involved in regulating a large number of cellular processes including 
inliibition of the Ras/MAPK pathway (Suhasini et al, 1998), VSMC proliferation 
(Chiche et al, 1998), inhibition of PKC (Kumar et al, 1997), relaxation of smooth 
muscle (Murthy & Makhlouf, 1995) and many more.
As well as signalling via PKG, cGMP is capable of eliciting some of its responses by 
direct interaction with effector proteins. Like cAMP, cGMP is capable of regulating 
cyclic nucleotide-gated channels. The best characterised of these is probably the cyclic 
nucleotide-gated chamiels in the olfactory and phototransduction systems (Nakamura 
& Gold, 1987, Molokanova et al, 1999). The activity of PDEs can also be altered by 
direct interaction with cGMP (see table 1.3 for details). Depending on the isoform, 
interaction of PDEs with cGMP can be stimulatory, inhibitory or without effect on 
PDE activity (Manganiello et al, 1995). This allows a mechanism for cross talk 
between the cAMP and the cGMP signalling cascades.
By using a large number of mechanisms to generate, terminate and mediate cGMP 
signals the cell is capable of tailoring veiy specific signals via an ubiquitous second 
messenger.
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1.5 C y c l i c  N u c l e o t i d e  S i g n a l l i n g  i n  VSMC
cAMP and cGMP signalling are responsible for a wide range of cellular effects in 
many cell types (as discussed above). One of the most important role for these 
nucleotides in VSMCs is controlling relaxation of these cells (Landgraf et ai, 1992, 
Murthy & Makliiouf, 1995,Toyoshima et al, 1998). The contraction of smooth 
muscle occurs when intracellular levels of Ca^ "^  rise and Ca ^^-calmodulin activates 
myosin light chain kinase. Myosin light chain kinase then phosphorylates and 
activates myosin light chain and the cell contracts (reviewed in Horowitz et al, 1996). 
The relaxation of smooth muscle is associated with a decrease in cytostolic calcium 
and an increase in cAMP or cGMP concentration. In VSMC stimulation of PLCp 
results in the production of IP3 and DAG, IP3 will then bind IP3 receptors on the 
sarcoplasmic reticulum, which results in the release of Ca^^ from this store thereby 
increasing intracellular [Ca^^] (see section 1.2.3). cAMP and cGMP have been shown 
to be able to reduce intracellular [Ca^’*’] and therefore cause relaxation of smooth 
muscle cells. PKG and PKA can phosphoiylate PLCp and inhibit its activity, thereby 
inhibiting IP3 production and release of Ca^ "^  from the sarcoplasmic reticulum (Murthy 
et al, 1993). PKA and PKG can also phosphorylate the IP3 receptor itself, although 
the functional consequences of this phosphoiylation are as yet not clear (Komalavilas 
& Lincoln, 1994, Komalavilas & Lincoln, 1996). It is clear that PKG and PKA can act 
alone or in concert to regulate the relaxation of smooth muscle (Murthy & Makhlouf,
1995).
As well as being able to regulate relaxation of vascular smooth muscle cells, cGMP 
and cAMP appear to be able to inhibit proliferation of these cells (Kronemami et at., 
1999, Chiche et al, 1998). It appears that the growth inhibitory effects of these cyclic 
nucleotides are mediated by an inhibition of the expression of certain cyelins 
necessary for cell cycle progression (Kionemann et al, 1999). cAMP appears to be 
more potent in inhibiting proliferation in VSMC, but this may in part be due to the 
decreased levels of expression of PKG in VSMC which have been passaged in 
culture. In studies where PKG expression and activity has been augmented by
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transfection of PKG into VSMC, the cells show enhanced sensitivity to the 
antiproliferative effects of NO/cGMP (Chiche et al, 1998).
It is interesting to note here that two of the principle effects of cyclic nucleotides in 
VSMC are relaxation and inhibition of proliferation of these cells. It is therefore 
tempting to speculate here that perhaps aberrant cyclic nucleotide signalling is 
involved, at some level, in the progression of plaque formation and ultimately 
atherosclerosis (see section 1.1.1 and 1.1.2).
1 .6  A i m s  o f  t h e  s t u d y
An increase in VSMC proliferation is a major contributor to the development of 
atherosclerotic plaques. As glucose transport is an early response to all mitogens it is 
of interest, therefore, to better characterise mitogen-stimulated glucose transport in rat 
aortic vascular smooth muscle cells. The stimulation of glucose transport in response 
to the mitogen PDGF will be characterised and the signalling mechanisms mediating 
this investigated.
Currently there is controversy as to which glucose transporters mediate transport in 
these cells, some studies report the presence of GLUT-4 whereas others find only 
GLUT-1. The GLUT content of rat aortic vascular smooth muscle cells used will be 
studied.
As cyclic nucleotide signalling is veiy important in causing relaxation and inhibiting 
proliferation of VSMC, it is tempting to speculate that aberrant cyclic nucleotide 
signalling may be involved in the development of atherosclerosis. The role of the 
cyclic nucleotides, cAMP and cGMP, in regulating glucose transport will, therefore, 
be assessed in these cells. The signalling mechanisms mediating cyclic nucleotide 
regulation of glucose transport will also be studied.
Finally, it is cunently unclear whether increases in glucose transport mediated by 
GLUT-1 result from an increase of transporter activity, an increase in the number of
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functional GLUT-1 transporters at the plasma membrane, or a combination of both. 
To address this question, GLUT-1 - green fluorescent protein (GFP) chimeras will be 
utilised to try to visualise movement of GLUT-1 within the cell. The phosphorylation 
of the GLUTs in the cell will also be studied.
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T a b l e  1.1
M a j o r  s i t e s  o f  e x p r e s s i o n  o f  t h e  d i f f e r e n t  g l u c o s e  
t r a n s p o r t e r s  i n  h u m a n  a n d  r o d e n t  t i s s u e s .
ISO F O R M
GLUT-1
T i s s u e
Placenta; brain; blood-tissue barrier; adipose and 
muscle tissue (low levels); tissue culture cells; 
transformed cells.
g l u t -2 Liver; pancreatic (3-cell; kidney proximal tubules and 
small intestine (basolateral membranes).
GLUT-3 Brain and nerve cells in rodents.
Brain, nerve; low levels in placenta, liver and heart 
(humans).
GLUT-4 Muscle; heart; adipose.
GLUT-5 Small intestine (apical membranes); kidney, testis, 
brain, muscle and adipose at low levels (humans). 
Small intestine (apical membranes); kidney (rat).
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T a b l e  1.2 R e g u l a t io n  o f  A d e n y l y l  C y c l a se  Iso fo r m s
R e g u l a t o r s
I s o f o r m  Ca^* c p y  G ,-a  P K C  P K A
AC-I t  i  .1. t  ?
AC-II nc t  (+Gs-a) nc t  ?
AC-III t  (+G,-a) nc ? t  ?
AC- IV nc t  (+Gs-a) nc nc/4- ?
AC-V i  nc 4- nc/t 4-
AC-VI i  nc 4- nc/t 4-
AC-VII nc ( t)  ? (t)? ?
AC-VIII t  ( t)  ( i)  ? ?
AC-IX t  nc ? ? ?
Shown are various regulators of adenylyl cyclase isoforms, t  indicates an increase in 
adenylyl cyclase activity, 4- represents a decrease in adenylylcyclase activity and nc
indicates that the agent elicits no change in adenylyl cyclase activity. ? indicates that 
the effect of the agent on adenylyl cycalse activity is unlaiown.
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Figure 1.1 An overview of atherosclerotic plaque development
The initial trigger for plaque development is poorly understood. It is believed that some 
form of endothelial cell dysfunction or injury can result in an inflammatory response. 
Leukocytes and platelets then adhere to the “injured” area, and induce the endothelium to 
produce and secrete vasoactive molecules, cytokines and growth factors. Monocytes and 
T lymphocytes then migrate between the endothelial cells where the monocytes become 
macrophages. These macrophages, along with VSMCs, accumulate lipids and become 
foam cells forming a fatty streak. If the inflammatory response continues there is 
stimulation of migration and proliferation of VSMCs to form an intermediate lesion. 
Continued inflammation results in increased numbers of macrophages and lymphocytes in 
the plaque, and activation of these leads to the release of hydrolytic enzymes, cytokines, 
chemokines and growth factors, which can induce further damage and eventually lead to 
focal necrosis.
Cells are represented as defined below:
Blue VSMCs
Red Endothelial cells
Purple Macrophages
Pink T lymphocytes
Green Platelets
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•’INJURY"Ox LDL, (mechanical, homocysteine, immunologic, toxins, viruses, etc.)
Figure 1.2 The twelve membrane spanning helix model of the GLUTs.
Shown is a schematic representation of the twelve-membrane spanning domain structure 
of the GLUT family members. Residues indicated by single letter codes are conserved 
between GLUTs 1 to 5. The site for N-linked glycosylation in the large extracellular loop 
is also indicated.
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Figure 1.3 A proposed scheme of cellular signalling pathways involved 
in growth factor control of glucose transport
The pathways that are activated by tyrosine kinase and G-protein-coupled receptors, 
leading to changes in glucose transport, are illustrated schematically. Both tyrosine kinase 
receptor and G-protein-coupled receptor mediated glucose transport are dependant on 
PI3’ kinase.
Both receptor tyrosine kinases and G-protein-coupled receptors also stimulate the 
ras/raf/MAPK pathways, which can also be involved in regulating glucose transport.
The acute phase of mitogen-stimulated glucose transport is accounted for by translocation 
of GLUT-1 containing vesicles to the cell surface, and also possibly by an increase in the 
intrinsic activity of the transporter. The chronic phase of glucose transport is mediated by 
an increase in GLUT-1 gene transcription and ultimately an increase in the number of 
glucose transporters in the cell.
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Figure 1.4 The signal transduction mechanisms activated by tyrosine 
kinase receptors and G-protein-coupled growth factor receptors
This schematic diagram illustrates a summary of the major signal transduction pathways 
that are activated following growth factor stimulation of the two distinct classes of 
receptor.
Many of the same pathways are regulated by the two distinct receptor classes i.e. 
phospholipase C (PLC), PI3’ kinase, ras/raf/MAPK.
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2 .1  M a t e r i a l s
All reagents used in the course of the project were of a high quality and were obtained 
from the following suppliers:
2.1.1 General reagents
All general chemicals were purchased from Fisher Scientific, Loughborough, UK or 
BDH, Merck Ltd, Lutterworth, Leicestershire, UK, unless otherwise stated.
Anachem, Luton, Beds, UK 
Aciylamide/ bis acrylamide mix
Boehringer Mannheim, Lewes, UK 
Tris base
Complete protease inhibitor cocktaiF'^
Kodak Ltd, Hemel Hempstead, Hertfordshire, UK
RP X-Omat liquid fixer/replenisher 
RP X-Omat Liquid developer/replenisher 
X-Omat AR film 
X-Omat S film
Fisons Chemicals, Loughborough, UK
Optiflow Safe 1 liquid scintillation cocktail
Pierce, Rockford, Illinois, USA
BCA protein estimation kit
Premier Brands UK, Knighton Adbaston, Staffordshire, UK 
Marvel powdered milk
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Schleicher andSchuell, Dassel, Germany
Nitrocellulose membrane (0.45fim)
Sigma Chemical Company Ltd, Poole, Dorset, UK
Adenosine triphosphate
Alumina
Ampicillin
Bromophenoi blue
BSA Fraction V
Collagenase
Cyclic adenosine monophosphate 
Cytochalasin B
2-deoxy-D-glucose 
DL-dithiothreitol (DTT)
Dowex
Elastase
Ethidium bromide 
3 -isobutyl-1 -methlxanthine (IBMX)
3-O-methyl glucose
N,N,N’,N’-tetramethylethylenediamine (TEMED) 
Okadaic acid 
Ponceau S
Protein Kinase A, catalytic subunit 
Soybean trypsin inhibitor 
Triton X -100 
Xylene cyanol
Whatman International Ltd, Maidstone, UK
Whatman 3mm filter paper
Branded filters, FPD-200 Whatman GF/C
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2.1.2 Antibodies
Chemicon International, Harrow, UK
Rabbit anti-GLUT-1
New England Biolabs, Hitchin, Herts, UK 
Rabbit anti-phospho p42/44 antibody 
Rabbit anti-p42/44 antibody 
Rabbit anti-phospho p38 antibody 
Rabbit anti-phospho INK antibody
Sigma, Poole, Dorset, UK
Horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG antibody
Antibodies to GLUT-3 and -4 were prepared in house as described in Gould et ai, 
1992 and Brant et al, 1992 respectively.
2.1.3 Cells
American Type Culture Collection, Rockville, USA 
3T3-L1 Fibroblasts
Rat aortic vascular smooth muscle cells (VSMC) were prepared from Wistar-Kyoto 
rat aorta as described in methods section 2.3.1
2.1.4 Cell culture media and reagents 
Gibco BRL, Paisley, Lanarkshire, UK
Dulbecco’s modified Eagle’s media (without sodium pyruvate, with 4500 mg/L 
glucose) (DMEM)
10000 U/ml penicillin,
10000 U/ml streptomycin,
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L-glutamine 200 mM (lOOx)
Foetal calf serum 
New born calf serum
Sigma, Poole, Dorset, UK 
1 X Trypsin
2.1.5 Cell culture plastics
Bibby Sterilin Ltd, Stone, Staffordshire, UK 
Sterile Pipettes
13.5 ml centrifuge tubes
Costar, Corning Incorporated, Corning, NY, USA 
75 cm^ culture flasks 
6-well cell culture plates 
12-well cell culture plates
AS Nunc, DK Rokslide, Denmark
50 ml centrifuge tubes
2.1.6 Radioactive reagents
Amers ham Life Science, Bucks, UK 
[^¥y] -ATP
1-[propyl-2,3-^H] Dihydroalprenolol, Code TRK 551 (DHA) 
2,8-[^H] adenine
[^H] Thymidine
NENDupont (UK) Ltd, Stevenage, Hertfordshire, UK
2-deoxy-D-[2,6-^H] glucose 
[^H] methyl 3-0-methyl glucose
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[^^P] inorganic phosphate
2.1.7 Agonists and inhibitors
Alexis, Bingham, Nottingham, UK 
8-Bromo cAMP 
8-Bromo cGMP
Calbiochem, Boston, Nottingham, UK
Dibutyryl cAMP
Dipyridamole
Milrinone
Rat recombinant PDGF-BB
Rat IGF-1
SB203580
Zaprinast
New England Biolabs, Hite him, Herts, UK
PD98059
Novo Nordisk, Copenhagen, Denmark 
Insulin
Sellering Health Care, Burgess Hill, West Sussex, UK
Iloprost
Sigma, Poole, Dorset, UK
IBMX
Isoprenaline
Dihydroalprenolol
PGE,
Ro 20-1724
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Vent Polymerase,
2.1.8 Molecular biology reagents
Boehriger Mannheim, Lewes, East Sussex, UK 
T4 DNA ligase
Genosys Biotechnologies Ltd, Pampisford, Cambs, UK 
Oligonucleotide primers, as described in the results chapters
Gibco Life Technologies, Paisley, UK
DNA size markers, 1 kilobase ladder
Invitrogen, Leek, The Netherlands
pcDNA3 vector
New England Biolabs, Hite ham, Herts, UK
-A
Oxoid, Basingstoke, Hamps, UK 
Bacto tryptone 
Yeast extract 
Agar
Promega
Restriction enzymes, Bgl II, Bam HI, Eco RI, Kpn I, Xho I 
Wizard"^  ^mini-prep kits
Qiagen, Crawley, West Sussex, UK
Qia spin prep kits 
Qiagen maxi prep kits 
Qiagen Superfect transfection kit
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Stratagem, La Jolla, California, USA
Escherichia coli XL 1-Blue 
Pfu I DNA polymerase
2.1.9 Protein A
Sigma, Poole, Dorset, UK 
Protein A sepherose 
HRP-linked protein A
2.1.10 Transferrin texas red 
Molecular probes, Leiden, The Netherlands
2.2 B u f fe r s  and  m e d ia
2.2.1 Cell culture media 
Serum-free DMEM
100 U/ml penicillin, 100 U/ml streptomycin, 2 mM glutamine in DMEM 
10% NCS/DMEM
100 U/ml penicillin, 100 U/ml streptomycin, 2 mM glutamine, 10% (v/v) NCS in 
DMEM
10% FCS/DMEM
100 U/ml penicillin, 100 U/ml streptomycin, 2 mM glutamine, 10% (v/v) FCS in 
DMEM
VSMC digestion media
800 pg/ml collagenase, 250 pg/ml elastase, 500 pg/ml soybean trypsin inhibitor in 
serum-free DMEM (see above)
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HEPES buffered DMEM
Serum free DMEM (see above) with 20 mM HEPES
2.2.2 General Buffers
Phosphate buffered saline (PBS)
150 mM NaCl, 10 mM NaH2P0 4 .2 H2 0 , (pH 7.4)
Krebs Ringer Phosphate Buffer (KRP)
64 mM Na Cl, 2.5 mM KCl, 2.5 mM NaH2P0 4 .2 H2 0 , 0.6 mM MgS0 4 -7 H2 0 , 0.6 mM 
CaCl2, (pH 7.4)
Lysis Buffer
0.05% SDS (w/v), 20 mM Hepes (pH7.4), 1 mM EDTA, Complete protease iiiliibitor 
cocktail™, 1 pM NaV 0 4 , 1 pMNaF, 1% Triton X-100 (v/v)
Tris EDTA (TE)
10 mM Tris, ImM EDTA (pH7.4)
PKA in vitro phosphorylation buffer
50 mM Tris HCl (pH 7.5), 6 mM MgCh, 1 mM DTT, 50 pM EGTA, 150 pM ATP
A deny I cyclase assay stop solution 
5% TCA, 1 mM cAMP, 1 mM ATP
2.2.3 SDS-PAGE Buffers 
Running Buffer
25 mM Tris-base, 192 mM glycine, 0.1% (w/v) SDS
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Sample buffer
93 mM Tris hydrochloride pH6.8, 20 mM dithiothreitoi, 1 mM sodium EDTA, 10% 
glycerol (w/v), 2% SDS (w/v), 0.002% bromophenoi blue (w/v).
The dithiothi'eitol was added immediately before use.
Urea sample buffer
As normal sample buffer with the addition of 40 mM urea
2.2.4 Western Blot Buffers 
Transfer Buffer
25 mM NaH2P0 4 .2 H2 0 , (pH 6.5)
TBS-T
150 mM NaCl, 150 mM Tris, 0.02% Tween 20 (v/v), (pH 7.4)
Stripping Buffer
100 mM p-Mercaptoethanol, 2% SDS (w/v), 62.5 mM Tris (pH 6.7)
2.2.5 Molecular Biology Buffers 
DNA Loading Buffer
0.25% Bromophenoi blue (w/v), 0.25% xylene cyanol FF (w/v), 30% glycerol inH20 
(v/v)
Ethidium bromide
Stock of 10 mg/ml in H2O made, use at final concentration of 0.5 pg/ml 
L-Agar
As L-Broth plus 1.5% agar (w/v)
47
L-Broth
1% Bacto tryptone (w/v), 0.5% yeast extract (w/v), 1% NaCl (w/v)
TAE
40 mM Tris-acetate, 10 mM EDTA 
Competent bacteria buffer 1
30 mM potassium acetate, 100 mM RJBCl, 10 mM CaCE, 50 mM MnCE, 15% 
glycerol (v/v)
Competent bacteria buffer 2
10 mM MOPS (pH6.5), 75 mM CaCE, 100 mM RbCI, 15% glycerol (v/v)
2 .3  R a t  A o r t ic  V a s c u l a r  S m o o t h  M u s c l e  C e l l  C u l t u r e
2.3.1 Preparation and growth of vascular smooth muscle cells from rat aorta
Rat aortic vascular smooth muscle cells were kindly prepared and supplied by Alison 
Devlin from Anna Dominiczak’s group, Department of Medicne and Therapeutics, 
University of Glasgow, Western Infirmary, Glasgow. Vascular smooth muscle cells 
were isolated from the thoracic aorta of Wistar-Kyoto (WKY) rats by enzymic 
digestion (as described Stanley et al, 1993). All utensils and media used were sterile. 
Thoracic aorta were dissected from the rat and placed into a sterile universal 
containing 20 ml of serum free DMEM (2.2.1) on ice. Fatty tissue was removed by 
blunt dissection and the aorta was washed clean of blood. The intercostal branches 
and arch were removed from the aorta. The aorta was transferred into a small sterile 
cell culture dish and 2.5 ml of digestion media was added (section 2.2.1) and 
incubated at 37 °C in a humidified atmosphere of 5% CO2 for 30 minutes. The 
adventitia was then stripped from the aorta, which comes off like a “sleeve”. The aorta 
was cut longitudinally with small scissors and placed in a further 2.5 ml of fresh 
digestion media to digest endothelium and was incubated for 15 minutes at 37 °C in a 
humidified atmosphere of 5% CO2 . Subsequently the aorta was chopped very finely
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with small scissors and then transferred to a clean dish where 2.5 ml of a 1:8 (v/v) 
dilution of the digestion media added and incubated overnight at 37 °C in a 
humidified atmosphere of 5% CO2 . The following morning 1.05 ml of 2.5 mg/ml 
collagenase in serum free DMEM (section 2.2.1) was added to the aorta digestion 
(final concentration of 1.5mg/ml collagenase, ~ 3 mg per aorta) and was incubated at 
37°C in a humidified atmosphere of 5% CO2 for 30-60 minutes. The cells were 
triturated with a fine-bore pasteur pipette to disaggregate the tissue into a single cell 
suspension. The cells were removed to a sterile universal on ice. 10 ml of 20% 
FCS/DMEM (section 2.2.1) was added to the cells and centrifuged at 1000 x g for 10 
minutes at 4 °C. The supernatent was aspirated from the cells and the cell pellet was 
resuspended in 20% FCS/DMEM.
Cells prepared as described above were positively identified as vascular smooth 
muscle cells by immunofiuorescent staining for smooth muscle-specific a-actin and 
skeletal muscle/smooth muscle myosin (as described in Stanley et al, 1993).
When the cells were approaching 100% confluent they were removed from flasks 
using tiypsin. The media was aspirated from the flasks and the cells rinsed in 5ml of 
sterile PBS. The PBS was aspirated and replaced with 5 ml of a 1:5 dilution of trypsin 
in PBS. The flask was then placed in the incubator for 5 minutes, allowing the cells to 
float before stopping trypsination by addition of an appropriate volume of 10% 
FCS/DMEM (section 2.2.1). The diluted cells were subsequently seeded on to new 
cell culture dishes. VSMC were not diluted more than 1:7.
%
Cells, once positively identified as VSMC, were maintained in 10% FCS/DMEM 
(section 2.2.1), and grown in a humidified incubator at 37 °C in an atmosphere of 5% 
CO2 . The media was replaced every two days.
2.3.2 Trypsination of VSMC
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2.3.3 Storage of rat aortic VSMC in liquid nitrogen
Cells were grown to confluency on 75 cm^ flasks and trypsinised as described 2.3.2. 
The cells were resuspended in 5 ml of 10% FCS/DMEM (section2.2.1). The cell 
suspension was centrifuged at 1000 x g at room temperature for 2 minutes, the 
supernatent was aspirated and the cells resuspended in 1 ml of 10% FCS/DMEM with 
10% DMSO (v/v) previously equilibrated in 5% CO2 for 1 hour at 37 ‘^ C. The cell 
suspension was aliquoted into cryotubes, packed in cotton wool and frozen overnight 
at -80 °C. The tubes were then transferred to liquid nitrogen for long-term storage.
2.3.4 Resurrection of frozen cell stocks from liquid nitrogen
Cell aliquots were removed from liquid nitrogen and placed in a 37 °C water bath. The 
tube was transferred to the cell culture sterile flow hood where the cells were 
triturated gently with a sterile pipette to disperse any large aggregates of cells. The 
cells were then seeded onto 25 cm^ flasks containing 10% FCS/DMEM and 
maintained in an incubator at 37 °C in a humidified atmosphere of 5% CO2 .
2.4 3T3-L1 F i b r o b la s t  C u l t u r e
2.4.1 Growth of 3T3-L1 fibroblasts
3T3-L1 fibroblasts were grown on cell culture flasks and plates in 10% NCS/DMEM 
(section 2.2.1). The medium was replaced every 2 days, the cells being kept in an 
incubator at 37 ^C in a humidified atmosphere at 10% CO2 .
2.4.2 Trypsination of 3T3-L1 fibroblasts
When the cells were 70-80% confluent they were removed from flasks using tiypsin. 
The media was aspirated from the flasks and the cells rinsed in 5 ml of sterile PBS. 
The PBS was aspirated and replaced with 2 ml of trypsin. The flask was then placed in 
the incubator for 5 minutes, allowing the cells to float before stopping trypsination by
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addition of an appropriate volume of 10% NCS/DMEM. The diluted cells were 
subsequently seeded on to new cell culture dishes. 3T3-L1 cells were not diluted more 
than 1:10.
2.4.3 Storage of 3T3-L1 fibroblasts in liquid nitrogen
Cells were grown to confluency on 75 cm^ flasks and trypsinised as described 2.4.2. 
The cells were resuspended in 5 ml of 10% (v/v) NCS/DMEM. The cell suspension 
was centrifuged at 1000 x g at room temperature for 2 minutes. The supernatent was 
aspirated and the cells resuspended in 1 ml of 10% NCS/DMEM with 10% DMSO 
(v/v) equilibrated in 10% CO2 for 1 hour. The cell suspension was aliquoted into 
cryotubes, packed in cotton wool and frozen overnight at -80 °C. The tubes were then 
transferred to liquid nitrogen for long-term storage.
2.4.4 Resurrection of frozen cell stocks from liquid nitrogen
Cell aliquots were removed from liquid nitrogen and placed in a 37 °C water bath. The 
tube was transferred to the cell culture sterile flow hood where the cells were 
triturated gently with a sterile pipette to disperse any large aggregates of cells. The 
cells were then seeded onto 25 cm^ flasks containing 10% NCS/DMEM and 
maintained in an incubator at 37 °C in an atmosphere of 10% CO2 .
2.5 2 - d e o x y - D - g l u c o s e  U p t a k e  in  R a t  A o r t i c  VSMC
Uptake of 2-deoxy-D-glucose was measured using the method of Gibbs et al. (1988) 
and Frost and Lane (1985).
In all experiments cells were used at passages 5-16. For transport assays cells were 
grown to confluency on 6-well plates. Prior to use cells were quiesced in serum-free 
DMEM for 36-48 hours. The cell monolayer was washed in 2 ml KRP (section 2.2.2) 
at 37 °C, then incubated in 950 pi of KRP, 0.25% BSA. Drugs/agonists were added at 
the appropriate concentration and cells were incubated for the appropriate period of 
time in humidified 37 ^C incubator, as noted in the figure legends/text.
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5 minutes prior to the end of incubation time the cells were transferred on to a hot 
plate at 37 "C. The uptake of sugar was initiated by the addition of 50 pi of [^H] 2- 
deoxy-D-glucose to a final concentration of 50 pM and 0.5 pCi/ml. The reaction was 
terminated 5mins after addition of deoxy glucose by rapidly decanting the KRP buffer 
(containing [^H] 2-deoxy-D-glucose) and immediately immersing the 6-well plate in a 
large volume of ice-cold PBS. After air-drying the plates 1 ml of 1% Triton X-100 
(v/v) in water was added to each well and plates shaken for 1 hour. The cell- 
associated radioactivity was measured by scintillation counting. To determine the non­
specific glucose uptake of 2-deoxy-D-glucose, the inhibitor cytochalasin B, was added 
to three of the 6 well of each plate, at a final concentration of 10 pM, just before the 
addition of the radioactive deoxy glucose. The radioactivity in the wells treated with 
cytochalasin B is a measure of non-specific deoxy-glucose associated with the 
monolayer. This value was subtracted from the counts obtained in the absence of 
cytochalasin B to provide specific transport rates.
2 .6  3 -O -M e t h y l  G l u c o s e  T r a n s p o r t  in  V sm c
The uptake of 3-D-methyl glucose transport is measured exactly as described for 2- 
deoxy-D-glucose (section 2.5) except that cold 3-D-methyl glucose and [^H] 3-0- 
methyl glucose replace labelled and unlabelled for 2-deoxy-D-glucose at the same 
concentrations, and the times of incubation with cells was adjusted as shown in the 
figure legends.
2 .7  S D S /P o l y a c r y l a m id e  G e l  E l e c t r o p h o r e s is
SDS/PAGE was carried out using Bio-Rad mini-PROTEAN II or Hoefer large gel 
apparatus.
The Bio-Rad Mini-PROTEAN gels had a stacking gel of 2 cm and the Hoefer 
stacking gel was 5 cm. The stacking gel was composed of 5% aciylamide (w/v),
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0.136% bisacrylamide (w/v) in 125 mM Tris-HCl (pH 6.8), 0.1% SDS (w/v), 
polymerised with 0.1% ammonium persulphate (w/v) and 0.05% N, N, N', N ’- 
tetramethylethylenediamine (TEMED) (v/v).
The seperating gel consisted of an appropriate pereentage of acrylamide in 0.383 mM 
Tris-HCl (pH 8.8), 0.1% SDS (w/v), and polymerised with 0.1% ammonium 
persulphate (w/v) and 0.019% N, N, N% N ’-tetramethylethylenediamine (TEMED) 
(v/v).
The protein samples were solubilised in sample buffer (see 2.2.3) and loaded into the 
wells of the stacking gel. The gel was then immersed in rumiing buffer (section 2.2.3) 
and electrophoresed until the tracking dye had run to the bottom of the gel.
2 .8  W e s t e r n  B l o t t in g  o f  P r o t e in s
After separation of proteins by SDS/PAGE, as described 2.5, gels were removed from 
the apparatus. Each gel was then placed on a nitrocellulose sheet (pore size 0.45 pm) 
pre-soaked in transfer buffer. This was then sandwiched between two layers of 
Whatman 3MM filter paper, also presoaked in transfer buffer. The sandwich was 
placed in a cassette and transfer of the proteins onto the nitrocellulose was performed 
using either a Bio-Rad trans-blot tank for large gels or Bio-Rad mini trans-blot tank 
for the mini-gels. Transfer was achieved at a constant current of 250 mA for 2 hours at 
room temperature. The nitrocellulose membranes were then removed and the 
efficiency of transfer was determined by staining the nitrocellulose with Ponceau S 
solution prior to blocking (section 2.8.1).
2.8.1 Detection of proteins on nitrocellulose with Ponceau S
To detect proteins transferred onto nitrocellulose sheets, the nitrocellulose was soaked 
in a 1:5 dilution (in distilled water) of ponceau S solution for 1-2 minutes. When 
bands could be seen the excess ponceau S solution was rinsed from the nitrocellulose
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in distilled water. The nitrocellulose was then used for immunodetection of proteins 
(section 2.8.2).
2.8.2 Immunodetection of proteins on nitrocellulose membranes
To block non-specific binding sites on the nitrocellulose, the membrane was incubated 
in 5% milk powder (w/v) in TBS-T (section 2.2.4) overnight at 4“C. The membrane 
was then incubated in 1% milk powder in TBS-T containing the appropriate antibody 
at the concentration specified, for 1 hour at room temperature on a shaking platform. 
After incubation with primary antibody the membrane was washed in TBS-T (two 
rinses, two 5 minute washes and two 15 minute washes, wash with large volume). The 
membrane was then incubated with appropriate HRP-linked secondary antibody or 
HRP-linlced protein A (HRP-linlced donlcey anti-rabbit at 1:2000 dilution or HRP- 
linlced protein A at 1:500 dilution) in 1% milk powder in TBS-T for 1 hour at room 
temperature on a platform shaker. Membranes were washed as described above. The 
blot was developed using ECL reagent from Amer sham, according to the 
manufacturers directions. ECL generates light when horseradish peroxidase (linlced to 
the secondary antibody or protein A) along with H2O2 (in the ECL reagent mix) 
catalyse the oxidation of luminol (also in the ECL mix). Immediately after oxidation 
the luminol is in an excited state which then decays to the ground state via a light- 
emitting pathway. The membrane was therefore exposed to Kodak X-Omat S film and 
developed in an X-Omat processor.
2.9 Pr e p a r a t io n  o f  W h o l e  C ell  L ysa te s
Cells were grown to confluency in 75 cm^ flasks. Media was aspirated from the cells 
and the cells washed in 2 x 5 ml of ice-cold PBS per flask. The cells were scraped into 
5 ml of ice-cold PBS per flask and the cells from 4-5 flasks pooled. Cells were 
pelleted by centrifuging the cells at 1000 x g at 4 ^C for 10 minutes, the supernatent 
was aspirated and the cell pellet was resuspended in 1ml of lysis buffer (section 2.2.2). 
The cells were then incubated on ice for 30 minutes. The cells were passed through a 
gauge 25 needle several times to ensure thorough lysis of cells. The lysate was then
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measured for protein content using BCA protein estimation kit (section 2.1.1), from 
Pierce, according to manufacturer’s instructions.
For 6-weIl plates, each well was rinsed twice in 1 ml ice-cold PBS before the addition 
of 200 pi of SDS-PAGE loading buffer (section 2.2.3). Cells were left at room 
temperature with the SDS-PAGE loading buffer for 30 minutes and then scraped into 
eppendorfs. To ensure that the cells were properly lysed they were passed through a 
gauge 25 needle several times.
2.10 P r e p a r a t io n  o f  T o t a l  C e l l  M e m b r a n e s
Cells were grown to confluency in 75 cn f flasks. The media was aspirated from the 
cells and the cells were washed in 2 x 5 ml of ice-cold PBS per flask. The cells were 
scraped into 5 ml of ice-cold PBS per flask and the cells from 4-5 flasks pooled. Cells 
were pelleted by centrifugation at 1000 x g at 4 °C for 10 minutes and the cell pellet 
resuspended in 1ml TE (section 2.2.1). Cells were passed through a gauge 25 needle 
five times and then dounce homogenised with -30 twisting strokes. The homogenate 
was centrifuged for 7 minutes at -500 x g, 4 °C in a microfuge to pellet the nuclei. 
The supernatent was centrifuged at 40 000 x g at 4 *^C for 30 minutes and the pellets 
were resuspended in 200-500 pi TE depending on pellet size. The membrane 
preparations were measured for protein content using BCA protein estimation kit, 
from Pierce, according to manufacturers instructions (2.11).
2.11 T h y m id in e  In c o r p o r a t io n
VSMC were grown to -  40% confluency on 6-well plates. The media was aspirated 
from the cells and 1 ml of serum free DMEM (section 2.2.1) added per well. The 
appropriate drugs were added to the wells and the cells were incubated for at 37 °C in 
a humidified atmosphere of 5% CO2 for 24 hours. For the last 6 hours of the 24 hour 
stimulation 0.5 pCi of [^H] thymidine was added to each well. The reactions were
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terminated by washing each well twice with 2 ml ice-cold PBS. Proteins were 
precipitated by washing each well three times with 2 ml of ice-cold 5% TCA (w/v) 
and twice with 2 ml ice-cold ethanol. The plates were left to air dry for 15 minutes, 
and the precipitate was dissolved in 1 ml of 0.3M NaOH. The plates were shaken 
overnight to ensure the precipitate was thoroughly dissolved. The radioactivity 
associated with each well was determined by scintillation counting.
2.12 IMMUNOPRECIPITATION OF GLUTS FROM VSMC
30 pi of protein A sepharose was washed three times with 1 ml lysis buffer 
(section2.2.2). 6 pi of the appropriate antibody was added to the protein A sepherose 
and -15 pi of lysis buffer (2.2.2) to give a final volume of -  50 pi. The mixture was 
then shaken on vibramax at setting 18 for 4 hours at 4 °C. 500 pg - 1 mg of VSMC 
whole cell lysate (see section 2.9) was added to the antibody, protein A sepharose mix 
and incubated with end over end rotation overnight at 4 °C. Samples were centrifued 
at 1500 X g in microfrige to pellet the protein A sepherose beads along with any 
immunoprecipitated protein. The beads were washed in twice with 1 ml lysis buffer 
and then once with 1 ml lysis buffer containing 0.1% Triton X-100. The beads with 
protein bound were then used in assays or resuspended in urea sample buffer (section 
2.2.3) for western blotting.
2 .1 3 /TV V itr o  P h o s p h o r y la t io n  o f  GLUTS W ith  P r o t e in  K in a se  
A
The reactions were set up as follows:
20 units of PKA catalytic subunit was mixed with substrate prepared by 
immunoprécipitation (section 2.12) and made to a total volume of 47 pi with assay 
buffer (section 2.2.2). To start the phosphorylation 3 pi of [y^^P] ATP, 1 pCi/pl, was 
added to each reaction and incubated at 30 °C for 30 minutes. Adding an appropriate 
volume of SDS-PAGE urea buffer stopped reactions. Samples were then run on SDS-
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PAGE (section 2.7) and the gels were fixed in 14% acetic acid, 7% methanol, dried 
and exposed to X-ray film to identify proteins that had been phosphorylated.
Immimoprecipitates could also be dephosphorylated prior to in vilro phosphorylation 
as described below:
To each immunoprecipitate 250 U of protein phosphatase 2 A (gift from Professor H. 
Nimmo, Bower Building, IBLS, University of Glasgow) was added and buffer (50 
mM Tris pH 7.5, 1 mM DTT, 50 pM EGTA) added to a final volume of 50 pi. This 
mix was incubated for 30 minutes at 30 °C on a vibramax shaker. The phosphatase 
was inactivated by the addition of okadaic acid (200 nM) and phosphorylation carried 
out as described above.
2.14 /TV Vivo  P h o s p h o r y la t io n  o f  GLUTs
VSMCs were grown to confluency on 6-well plates and quiesced in serum-free
DMEM (section 2.2.1) for 36-48 hours. The cells were washed twice with 2 ml of 
phosphate-free DMEM per well and 0.75 ml of phosphate-free DMEM with 0.2 
mCi/ml [^^P] orthophosphoric acid added per well, and the cells incubated for 90 
minutes at 37“C in a humidified atmosphere of 5% €0%. This allows the intracellular 
pool of ATP to become ^^P labelled. After the 90-minute labelling, appropriate 
agonists/drugs were added to the cells (as indicated in the text) and cells incubated at 
37”C in a humidified atmosphere of 5% CO2 . To stop the reactions the cells were 
plaeed on ice, the media was aspirated off and the cells were washed twice with 3 ml 
ice-eold PBS (section 2.2.2). The cells were scraped into 500 pi of lysis bufer per well 
(section 2.2.2), transferred into eppendorfs, then incubated on ice for 30 minutes to 
lyse cells. The lysates were then used for immunoprécipitation, as described in section 
2.12. After immunoprécipitation the samples were resuspended in -40 pi of urea 
sample buffer (section 2.2.3) and run on a 10% SDS-PAGE (section 2.7). Gels were 
then dried and exposed to X-ray film to identify proteins that had been 
phosphorylated.
' i
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2 .1 5  (32 B in d in g  A s s a y s
Assays were carried out as described in MacEwan et al. (1996)
Briefly, total eell membranes were prepared as described in section 2.10. Reactions 
were assembled as follows:
To determine total DHA binding, an appropriate amount of membrane protein (-10 
pg) and 2 nM [^H] DHA were mixed in a total volume of 250pl TE (section 2.2.2). To 
determine non-specific binding reactions were set up as for total binding but in the 
presence of ImM unlabelled DHA to compete for specific binding sites. The reactions 
were ineubated at 30°C for 30 minutes. Reactions were terminated by rapid filtration 
tlu'ough Branded apparatus with a Whatman GF/C filter fitted and washed three times 
in ~5 ml of ice-cold TE buffer. The [^H] DHA associated with each filter was 
determined by scintillation counting.
To determine the amount of specific binding sites in each sample, the dpm obtained 
for non-specific binding is subtracted from that of total binding to get specific dpm. 
Using the specific activity of the [^H] DHA the amount of DHA binding sites can be 
determined using the calculation below.
Specific dpm  X 1000 = fmoles/mg
Specific activity pg protein
2 .1 6  A d e n y l  C y c la s e  A ss a y  in  V sm c
Determination of adenyl cyclase catalytic activity was carried out as described by 
Wong et al (1994) Cells were grown on 12-well plates to confluency and then 
quiesced by incubation in serum free DMEM for 36-48 hours. 24 hours prior to assay 
the cells were labelled with [^H] adenine at 1 pCi/ml. Cells were washed in 2 ml of 
HEPES buffered DMEM (section 2.2.1) and then 0.5 ml of HEPES buffered DMEM 
with ImM IBMX was added to each well with the appropriate drugs or agonists. Cells
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were then incubated on a hot plate at 37°C for 30 minutes. To terminate the reactions, 
the media was aspirated from cells and 1 ml of ice-cold stop solution (section 2.2.2) 
was added to each well and incubated on ice for 30 minutes to lyse cells. Separation of 
radiolabelled cAMP from ATP was achieved using the double-column method 
described by Wong et al (1994).
2 .17  M o l e c u l a r  B io l o g y  M et h o d s
2.17.1 PCR reactions
PGR reactions were carried out with the following basic components
20 ng template DNA 
40 pmol primer 1 
40 pmol primer 2
200 pM dNTPs (200pM of each A, C, G, T)
2.5 units Pfu I polymerase
10 pi Pfu 1 polymerase buffer (lOx)
X pi sterile HgO to final volume of 1 OOpl
All components were mixed except for Pfu I. The reactions were incubated for 10 
minutes at 95"C then Pfu 1 was added (“hot start” PCR). After addition of Pfu 1 the 
cycles were as follows:
3 cycles of 95°C 1 minute 
40°C 5 minutes 
72°C 5 minutes
Followed by
27 cycles of 95°C 1 minute 
75°C 2minutes 
12^C 5 minutes
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PCR products were then analysed by agarose gel electrophoresis.
2.17.2 Agarose gel electrophoresis of DNA
DNA was analysed by agarose gel elctrophoresis. All gels used were 0.7% agarose in 
1 X TAB, containing 0.5 pg/ml ethidium bromide. DNA was visualised under UV 
light. The size of DNA fragments was determined with the use of DNA 1 kB ladder.
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2.17.3 Preparation of competent bacteria
E.coli (strain XL 1-Blue) were grown in L-broth (section 2.2.4) to an optical density of 
0.4 at. The cells were chilled on ice, and then centrifuged at 1000 x g for 10 minutes 
at 4°C. The L-broth was aspirated from cells and the cells were resuspended in 40ml 
buffer 1 (section 2.2.5). The cells were chilled on ice for 5 minutes and then 
centrifuged at 1000 x g. The cell pellet was resuspended in 4 ml buffer 2 (section 
2.2.5) and aliquoted in 220 pi aliquots and stored at -80°C prior to use.
2.17.4 Transformation of competent bacteria
An aliquot of competent bacteria (prepared as described 2.17.1) was thawed and 50pl 
of the cells were added to a sterile tube. Add an appropriate amount of DNA was 
added to the cells (about l-50ng) and incubated on ice for 15 minutes. The cells were 
heat shocked by incubation at 42°C for 90 seconds, then returned to ice for 2 minutes. 
450p 1 of L-broth was added and the cells incubated at 37^C for 45 minutes with 
shaking. 1 OOpl of each transformation reaction was plated on to L-agar plates with the 
appropriate antibiotic mix. The plates were incubated overnight at 37°C to allow 
growth of colonies.
2.17.5 Preparation of DNA
Both large and small scale DNA preparations were made using QIAGEN DNA prep 
kits according to manufacturers instructions. Small scale preps were made using the
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QIA spin prep kit, and large seale preps were made using the QIAGEN maxi prep kit. 
Both kits follow a basic alkaline lysis method. Cells were lysed under alkaline 
conditions in the presence of RNase A and the lysate subsequently neutralised and 
adjusted to high salt binding conditions. The lysate was passed over the QIAGEN 
silica-gel membrane, which ensures only DNA is absorbed but all other components 
are not retained on the membrane. DNA was washed on the membrane and eluted in 
the appropriate buffer.
2.17.6 Gel Extraction of DNA
Gel extractions were carried out using Promega Wizard"^  ^prep kits according to 
manufacturers instructions. Briefly, to purify DNA from agarose gel the band of 
interest was excised from the gel and 1 ml of resin (from kit) was added. The gel slice 
was melted in the resin at 65°C for 10-15 minutes. The melted gel slice is passed over 
a Wizard'’’'^  mini prep column, to bind DNA and resin. DNA was washed on column 
and eluted in TE.
2.17.7 Restriction of DNA
Restriction of double stranded DNA was carried out using restriction enzymes from 
Promega according to manufacturers instructions. In general reactions were as 
follows:
1-5 pg DNA
5 pi restriction enzyme(s)
5 pi Buffer
X pi H2O to 50 pi final volume
Reactions were incubated for 1-2 hours at 37°C. Products of restriction were 
visualised by agarose gel eleetrophoresis.
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2.17.8 Ligation of DNA
DNA was restricted with the appropriate enzymes as described 2.16.7 ready for 
ligation. Ligations were carried using T4 DNA ligase from Boehringer Mannheim 
according to manufacturers directions. Generally twice as much insert DNA as vector 
DNA was used in each ligation, as quantified by gel electrophoresis. Reaction were 
typically carried out in a final volume of 10-15 pi.
2.17.9 Phenol/Cloroform extraction of DNA
To stop enzyme reactions and extract DNA from these reactions a phenol/chloroform 
extraction was carried out. This involved washing the reaction in an equal volume of 
phenol twice, then washing in an equal volume of chloroform once. DNA was then 
concentrated by ethanol precipitation (section 2.17.10).
2.17.10 Ethanol precipitation of DNA
To concentrate DNA samples ethanol precipitation was carried out. Samples were 
mixed with 2 x volume of ethanol and 0.1 x volume of 5 M Na Acetate. The mixture 
was incubated for 1 hour at -20^C then centrifuged at 15 000 x g  for 10 minutes to 
pellet precipitated DNA. The pellet was then washed in 1 ml of 70% ethanol, and 
centrifuged at 10 000 x g to re-pellet DNA, The 70% ethanol was aspirated from the 
pellet,the pellet air-dried and resuspended in a small volume of TE. DNA was 
quantified by agarose gel electrophoresis.
2.17.11 Sequencing of DNA
Samples sequenced by the University of Glasgow Molecular Biology Support Unit 
(MBSU) using the Big Dyes kit from Perkin Elmer and analysed using the ABI Prism 
377 sequencer.
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2.17.12 RT-PCR
mRNA was made using the Rneasy kit from QIAGEN. Two 75 cm^ flasks of VSMCs 
were grown to confluency and cells scraped from flasks into 2 ml of ice-cold sterile 
PBS, and RNA prepared aecording to manufaeturers instructions. Reverse 
transcription and PCR carried out using Wizard RT-PCR kit from Promega. Reverse 
transcription reactions were as follows:
3 pg VSMC RNA
3 pi dT primer (use 0.5 pg primer/ pg of RNA)
X pi RNase free H2 O to a final volume of 10 pi
Reactions incubated at 70 °C for five minutes to allow primer/RNA annealing. Then 
to each reaction the following reagents are added:
5 pi MgCC (25 mM)
5 pi 5 X AMV/tfl buffer
2.5 pi dNTPs (200pM of each A, C, G, T)
0.5 pi RNaisin 
2 pi AMV
X pi RNase free H2O to final volume of 25 pi
The reaction is then incubated at 42 ‘^ C for 60 minutes to allow extension.
PCR reactions were then set up as below:
5 pi Reverse transcription 
5 pi Tag Mg free buffer 
5  nl M g c r (25 mM)
1 nl dNTPs (to a final of 200 |_iM)
25 pmol primer 1 ) Primers are defined in main text
25 pmol primer 2 )
1 pi Taq
X pi Sterile PI2O to a final volume of 50 pi
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PCR cycles were as follows:
1 X 95°C 5 minutes
5 X 95°C 45 seconds
55°C 1 minute
72^C 1.5 minutes
25 X 95°C 45 seconds
55°C 1 minute
72°C 1.5 minutes
1 X 72°C 10 minutes
PCR products were analysed by agarose gel electrophoresis (section 2.17.2).
2.14 CONFOCAL M ic r o s c o p y
Cells were visualised using a Zeiss 4 laser scanning confocal microscope using either 
40X, 63X or lOOX Plan-APOCHROMAT 1.4 NA oil-immersion objectives, with 
samples on a heated stage to provide a bathing medium 37°C. Images were collected 
using either (or both) a 488 mn or a 543 mn laser with the appropriate filter sets for 
collection of the GPP signal (band-pass 505-520 nm) or red signals (long-pass 590 
nm). Data files were saved in .TIP format and analysed using Metamorph software 
(Universal Imaging, CA).
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C h a p t e r  3
C h a r a c t e r is a t io n  o f  G l u c o s e  T r a n s p o r t  in  R a t  
A o r t ic  V a s c u l a r  S m o o t h  M u s c l e  C e l l s  in  R e s p o n s e  
TO P l a t e l e t -D e r iv e d  G r o w t h  F a c t o r
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3.1 A im s
The aims of this chapter are:
1. To determine which glucose transporters are expressed in the aortic vascular 
smooth muscle cells (VSMC).
2. To determine the effect of platelet-derived growth factor (PDGF-BB) on the rate 
of glucose transport in VSMC.
3. To determine which signalling pathways are involved in mediating the effects of 
PDGF-BB on glucose transport in VSMC.
I
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3.2 In t r o d u c t io n
An increase in vascular smooth muscle cell proliferation is fundamental to the 
progression of atherosclerotic plaques (Ross, 1993). Many growth factors are secreted 
from the cells involved in plaque formation, which can stimulate VSMC proliferation 
(Bobik & Campbell, 1993). Platelet derived growth factor (PDGF) is considered to be 
a principle regulator of VSMC proliferation in plaque development, and is secreted 
from the endothelial cells, platelets, activated macrophages and the smooth muscle 
cells themselves during plaque development (see section 1.1.2) (Ross, 1993, Bobik & 
Campbell, 1993).
A common early response of cells to all growth factors is an increase in the rate of 
glucose transport, to provide the cells with the extra energy required for cell growth 
and differentiation (Thomson & Gould, 1997). As an increase in proliferation of 
VSMC is an important step in atherosclerotic plaque development, it is reasonable to 
hypothesize that this is accompanied by an increase in glucose transport in these cells. 
However, very little is known about the regulation of glucose transport in these cells. 
Most studies on glucose transport in VSMC, to date, have concentrated on the effects 
of insulin and lGF-1. Both insulin and lGF-1 have been reported to induce a 1.2 to 3- 
fold stimulation of glucose transport in VSMCs (Sowers, 1996, Fujiwara & Nakai, 
1996). In both of these studies, lGF-1 stimulates a greater increase in glucose 
transport than insulin. This suggests that the effect of insulin in these cells may be 
mediated by its interaction with the lGF-1 receptor, rather than via the insulin receptor 
itself. To date, no published studies have described the effect of PDGF on the rates of 
glucose transport in these cells.
Currently there is controversy as to which glucose transporters are expressed in 
VSMC. Sower’s group have reported that the insulin-responsive glucose transporter 
GLUT-4 is present in VSMC (Sowers, 1996), whereas others have been unable to 
detect GLUT-4 mRNA and demonstrated the presence of GLUT-1 mRNA only (e.g. 
Kihara et ai, 1998). As insulin stimulates a relatively low fold increase in glucose 
transport in these cells, it is unlikely that this is mediated by GLUT-4.
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Very little is known about the signalling mechanisms mediating glucose transport in 
response to growth factors (discussed fully in Chapter 1). To date, it is clear that there 
is a role for PI3’ kinase (Gould, ei ai, 1994, Clarke et ai, 1994, Barros et ai, 1995), 
and MAP kinase (Gould et ai, 1995) in mediating growth factor-stimulated glucose 
transport. Apart from the involvement of these two signalling pathways, the 
mechanisms by which growth factors increase glucose transport are largely unclear.
In VSMC, P13’ kinase has been shown to be involved in mediating insulin and lGF-1 
stimulated transport (Fujiwara & Nakai, 1996). Both woitmannin and LY294002 
inhibited insulin- and IGF-1-stimulated glucose transport. As well as the involvement 
of P13 ’ kinase, studies have shown a role for Ca^ "*" in regulating glucose transport in 
VSMC. Angiotensin 11 stimulated transport was inhibited by growing VSMC in media 
with low levels of Ca^  ^(Quinn et ai, 1998). Apart from the role of P13’ kinase and 
calcium, very little is known about the regulation of glucose transport in VSMC.
Here, the level of the glucose transporters GLUT-1, GLUT-3 and GLUT-4 in the rat 
aortic vascular smooth muscle cell line was determined by immunoblotting. The 
levels of different GLUT isoforms in cultured VSMCs and VSMCs freshly isolated 
from aorta was determined. The ability of platelet-derived growth factor to regulate 
glucose transport in these cells was also determined. PDGF-BB was found to be 
stimulatoiy with regard to glucose transport in VSMC, and the role of the signalling 
molecules P13’ kinase and the MAP kinases, p38, p42/44 and JNK, in regulating 
PDGF-BB-stimulated glueose transport was determined.
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3.3  R e su l t s
3.3.1 Analysis of glucose transporter expression in rat aortic vascular smooth 
muscle cells
The presence of glucose transporters in VSMCs was examined. GLUT-1 and GLUT-4 
have been reported in VSMC, and GLUT-3, the brain-type glucose transporter, is 
expressed in various non-neuronal tissues, so I sought to determine whether these 
isoforms were expressed in VSMCs.
To analyse which of the glucose transporters were present in VSMCs, samples of 
whole cell lysates from cultured VSMCs (paasage 12) were subjected to 
immunoblotting. Both GLUT-1 and GLUT-3 were expressed in VSMC as determined 
by the detection of a band of -49 kDa with antibodies to the C-terminal regions of 
GLUT-1 and GLUT-3 respectively (Figure 3.1). However there was no detectable 
GLUT-4, as determined by immunoblotting, in the VSMC lysates (Figure 3.1). This 
contradicts some previous publications which had demonstrated the expression of 
GLUT-4 (Sowers, 1996) in freshly isolated aortic VSMCs. Our inability to detect 
GLUT-4 could be because GLUT-4 expression was decreased during passage. We 
therefore sought to determine if GLUT-4 was present in freshly isolated cells. VSMCs 
were isolated from fresh aorta and whole cell lysates were prepared and subjected to 
immunoblotting. A band of -49 kDA, corresponding to GLUT-4 was indeed detected 
by immunoblotting, as was GLUT-1 (Figure 3.2). There was, however, no detectable 
GLUT-3 protein in fresh vascular smooth muscle cells (Figure 3.2). To determine at 
what stage of cell culture the changes in the levels of the glucose transporters occurs, 
samples of cells from passages 2, 6 and 16 were analysed. By immunoblotting it was 
determined that GLUT-4 protein was not present at detectable levels as early as 
passage 2, whereas GLUT-1 and GLUT-3 proteins were detected in all passages 
analysed (data not shown).
Therefore, freshly isolated aortic vascular smooth muscle cells do express GLUT-1 
and GLUT-4. However, as these cells are passaged in culture GLUT-4 expression is
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lost immediately and expression of GLUT-3, the brain-type glucose transporter, is 
increased. Glucose transport in cultured rat aortic VSMC is therefore mediated by 
GLUT-1 and also possibly GLUT-3.
3.3.2 Characterisation of PDGF-BB-stimulated glucose transport in rat aortic 
vascular smooth muscle cells
We next set out to characterize the effects of PDGF-BB on glucose transport in VSMC. 
Firstly we wished to determine if PDGF-BB-stimulated glucose transport in these cells 
followed the biphasic pattern typically seen in response to mitogens (see section
1.2.3.1). Cell were treated with PDGF-BB (10 ng/ml) for different lengths of time prior 
to assay of 2-deoxyglucose uptake (section 2.5). The results are shown in figure 3.3. 
There was an initial increase in glucose transport, peaking after about 1 hour (Figure 
3.3), with an 5.57 ± 0.52-fold stimulation over basal rates of transport (n=3 
experiments). This acute phase of transport plateaued after 1 hour, but after 2 hours a 
chronic increase in glucose transport became apparent (Figure 3.3). The chronic 
increase in glucose transport plateaued after about 6 hours and the maximum rate of 
transport was 10.13 ± 0.27-fold over basal rates (n=3 experiments). This biphasic 
pattern is consistent with previous studies on mitogen-stimulated glucose transport in a 
range of cells (Thomson & Gould, 1997).
To determine if the increase in transport was dependent on new protein synthesis, cells 
were treated with 10 ng/ml PDGF-BB in the presence or absence of cycloheximide (50 
pM), an inhibitor of protein synthesis. 2-deoxyglucose transport was then measur ed, as 
above. In cells that were treated with PDGF-BB for 2 hours the addition of 
cycloheximide had no effect on rates of glucose transport (Figure 3.4). However after 3 
hour and 4 hour treatments of cells with PDGF-BB, cycloheximide inhibited glucose 
transport as compared to cells treated with PDGF-BB alone. This indicates that the 
acute phase of PDGF-BB-stimulated glucose transport in VSMC is not dependant on 
new protein synthesis (up to 2 hours), however the chronic phase of glucose transport 
obseiwed (greater than 3 hours) is dependent upon synthesis of new proteins. This is
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consistent with previous work on mitogen-stimulated glucose transport. All further 
work in this thesis studies the acute phase of glucose transport in VSMC.
Next, the EC50 of the acute phase of PDGF-BB-stimulated 2-deoxy glucose transport in 
VSMC was determined. Cells were treated with PDGF-BB (0-500 ng/ml) for one hour 
and then subjected to 2-deoxyglucose transport assay (Figure 3.5). The EC50 for the 
acute phase of PDGF-BB-stimulated glucose transport in VSMC was -10 ng/ml. The 
rate o f 2-deoxyglucose transport in VSMC in response to a 1 hour treatment of 10 
ng/ml PDGF-BB was 381 ±34 pmol/niin/mg protein, representing a ~7 fold increase 
over basal (n=3 experiments). This figure is high, as compared with that seen using 
other mitogens, this will be returned to in the discussion.
Glucose can be transported across the plasma membrane in both directions (Walmsley 
et ai, 1998). To prevent this happening glucose is immediately phosphorylated once it 
enters the cell. Glucose-6-phosphate is not a substrate for glucose transporters, so 
cannot be transported back across the plasma membrane. To ensure that the increase in 
the rate of 2-deoxglucose transport in response to PDGF-BB is not limited by the rate 
of its phosphorylation, analogues of glucose that camiot be phosphorylated can be used. 
3-0-methyl glucose is an analogue of glucose that camiot be phosphoiylated, therefore 
by using 3-O-methyl glucose the rate of glucose flux can be measured. The ability of 
PDGF-BB to stimulate 3-G-methyl glucose transport was measured. Cells were treated 
with or without 10 ng/ml PDGF-BB for 1 hour, and 3-0-methyl glucose transport was 
measured over different times (as outlined in section 2.6). Cells treated with PDGF-BB 
showed a higher rate of 3-0-methyl glucose transport at all time points measured 
(Figure 3.6). The rates of transport were converted to give a straight line using the 
equation:
-In [(Cm-Ct)/Cm]
where Cm is the maximum cpm/well, and Ct is the cpm/well at the time point, t (Figure 
3.6). The gradient of each line represents the rate constant, k, for glucose transport in
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these cells. The k of basal and PDGF-BB-stimulated 3-0-methyl glucose transport were 
0.36 min‘* and 0.54 min'^ respectively. Therefore the rate of PDGF-BB-stimulated 3-0- 
methyl glucose transport in VSMCs is -1.5-fold that of basal. This is not a 7-fold 
increase in transport, as is seen when measuring 2-deoxyglucose transport (see above). 
When 2-deoxyglucose is transported onto the cell it is immediately phosphorylated by 
hexokinase and is no longer a substrate for glucose transporters. 3-0-methyl glucose, 
on the other hand, does not undergo phosphorylation when it enters the cell and so is 
still a substrate for glucose transport. Therefore, rates of 3-0-methyl glucose transport 
will be lower than rates of 2-deoxyglucose transport, measured under the same 
conditions as there will be a degree a back flux of 3-0-methyl glucose out of the cell.
The ability of PDGF-BB to stimulate growth of VSMCs was then assessed by 
measuring [^H] thymidine incorporation into the cells. Cells were treated with varying 
doses of PDGF-BB (0-40 ng/ml) for 24 hours and [^ FI] thymidine incorporated was 
measured. PDGF-BB elicited a 2.81 ±0.15 fold increase in [^H] thymidine 
incorporation in VSMC at doses of 10 ng/ml (n=3 experiments) (Figure 3.7). The levels 
of thymidine incorporation increased in a dose dependent manner with a 4.65 ± 0.2 fold 
increase seen at the maximum dose used, 40 ng/ml (n=3 experiments) (Figure 3.7).
Therefore, PDGF-BB can stimulate a biphasic increase in 2-deoxyglucose transport. A 
7-fold increase in 2-deoxyglucose at doses of 10 ng/ml PDGF-BB occurs within 1 hour, 
with a rate of -380 pmol/min/mg protein, and this is not dependent on the synthesis of 
new protein. After ~2 hours a chronic increase in 2-deoxyglucose transport becomes 
apparent, with a ~10-fold increase in transport after 6 hours. The chronic phase of 
transport is dependent on new protein synthesis. The 2-deoxyglucose transport is not 
dependent on the rate of phosphorylation of 2-deoxyglucose as 3-O-methyl glucose 
transport, an analogue of glucose that is not a substrate for phosphorylation, is also 
stimulated by 10 ng/ml PDGF-BB. 10 ng/ml PDGF-BB stimulates an approximately 
two-fold increase VSMC growth, as determined by thymidine incorporation.
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3.3.3 Cell signalling pathways involved in mediating PDGF-BB-stimulated 
glucose transport in rat aortic vascular smooth muscle cells.
As described in the introduction (see section 1.2.3.1), the only cell signalling 
mechanisms known to be involved in mediating growth-factor stimulated glucose 
transport, to date, are PI3’ kinase, MAP kinases and Ca^ .^ The role of these signalling 
molecules in mediating PDGF-BB-stimulated glucose transport in VSMC was 
examined.
PI3 ’ kinase
Firstly, to determine which regulatory subunits of PI3’ kinase are present, p85 and/or 
p55, in VSMCs, immunoblotting was carried out on whole cell lysates. p85 PI3’ kinase 
was present in VSMC as determined by the presence of a band of ~85 kDa, however 
there was no detectable p55 in VSMCs (Figure 3.8). The role of P13’ kinase in 
mediating PDGF-BB-stimulated glucose transport was assessed by using specific 
inhibitors of PI3’ kinase, wortmannin and LY 294002. Cells were treated with 
inliibitors for 30 minutes followed by a 1 hour treatment with PDGF-BB (10 ng/ml) 
prior to 2-deoxyglucose transport assay. Both LY 294002 and wortmannin inhibited 
PDGF-BB-stimulated glucose transport (Figure 3.9). Wortmannin inhibited PDGF-BB- 
stimulated transport with an IC50 o f -10-20 nM, with 100% inhibition at -100 nM. LY 
294002 also inhibited PDGF-BB-stimulated glucose uptake, although higher 
concentrations of LY 294002 were required, with the IC50 being -1.3 pM. These figures 
for inhibition of glucose transport by inhibitors of P13’ kinase are consistent with those 
previously reported for a specific inhibition of P13’ kinase (Thomson et al, 1996). This 
data suggests that PI3’ kinase does indeed play a role in mediating PDGF-BB- 
stimulated glucose transport in VSMCs.
MAP kinase
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As described in the introduction (see section 1.2.3.1), there are three families of MAP 
kinase, p42/44, p38 and JNK. To determine which, if any of these MAP kinases might 
be involved in PDGF-BB-stimulated glucose transport, we assessed which of these 
undergo phosphorylation, and therefore activation (Canos et al, 1995), in response to 
PDGF-BB in VSMC. The phosphorylation and activation of each MAP kinase can be 
determined by immunoblotting using phospho-specific antibodies to each protein. 10 
ng/ml PDGF-BB was capable of stimulating p42/44 phosphorylation, as determined by 
the presence of immunoreactive bands at 42 and 44 kDa, within 5 minutes (Figure 
3.10). This intensity of this band, therefore the phosphorylation and activation of 
p42/44, began to decline after 15 minutes stimulation with PDGF-BB, and by 60 
minutes the phosphorylation had returned to basal levels. Phosphorylation of p38 was 
also stimulated by PDGF-BB (10 ng/ml), as determined by the presence of an 
immunoreactive band o f -38 kDa (Figure 3.10). As with p42/44, phosphorylation and 
activation of p38 was highest after a 5 minute stimulation with PDGF-BB and was 
declining after 15 minutes. After 60 minutes the phosphorylation of p38 had returned to 
basal levels. JNK did not appear to be phosphorylated and activated in response to 
PDGF-BB (Figure 3.10), however the cross-reactivity of the antibody with phospho- 
p42/44 did not allow accurate analysis of this.
As both p38 and p42/44 are phosphorylated and activated by PDGF-BB in VSMC, the 
role of these in mediating PDGF-BB-stimulated glucose transport was assessed by 
using the specific inhibitors of p38, SB 203580, and of p42/44 activation, PD 98059 
(Gould et al, 1995). Cells were pretreated for one hour with the appropriate inhibitor 
then treated for a further one hour with 10 ng/ml PDGF-BB prior to 2-deoxyglucose 
transport assay (section 2.5). Both SB 203580 and PD 98059 were capable of inhibiting 
PDGF-BB-stimulated glucose transport in VSMC (Figure 3.11). SB 203580 inhibited 
PDGF-BB-stimulated glucose transport with an IC50 of-lO pM , whereas PD 98059 
inhibited transport with an IC50 of -50pM. These IC50 values were consistent with 
those previously reported to inhibit glucose transport in other cells (Gould et al, 1995). 
To ensure specificity of the MAP kinase inhibitors, immunobloting of cell lysates, 
treated as above, was carTied out to determine the relative levels of phosphorylation,
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and therefore activation of the MAP kinases in the presence of SB 203580 and PD 
98059. Figure 3.12 shows that PD 98059 only inhibited p42/44 phosphorylation and 
had little effect on p38 levels of phosphorylation and that SB 203580 had little effect on 
the phosphorylation of p42/44.
These results show that PDGF-BB is capable of stimulating both p38 and p42/44 in 
VSMC, however it has no apparent effect on JNK. The activation of both p38 and 
p42/44 is necessary for PDGF-BB-stimulated 2-deoxyglucose transport in VSMCs as 
determined by the use of the specific inhibitors SB 203580 and PD 98059.
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3.4  D isc u ssio n
Increased glucose transport is an early response of all cells to mitogens (Thomson & 
Gould, 1997). Increased vascular smooth muscle cell proliferation, and presumably 
therefore glucose transport, is fundamental to atherosclerotic plaque development 
(Ross, 1993, Ross, 1999). However very little is known about glucose transport in 
vascular smooth muscle cells. It is as yet unclear which glucose transporters are present 
in VSMC, with some groups reporting the presence of the insulin-responsive glucose 
transporter, GLUT-4, and GLUT-1 in VSMCs, whereas others have failed to find 
GLUT-4 mRNA (Sowers, 1996, Kihara et ah, 1998). It is therefore important to 
establish which glucose transporters are expressed in the cultured VSMC used in this 
study. As well as little being known about which glucose transporters are expressed, 
very little is known about what regulates glucose transport in these cells. Most studies 
to date have concentrated on the effects of insulin and IGF-1 to regulate glucose 
transport (Sowers, 1996, Fujiwam & Nalcai, 1996), but there has been no work on the 
growth factors suspected of being major regulators of VSMC proliferation in plaque 
development. PDGF is thought to be the principle regulator of VSMC proliferation in 
atherosclerotic plaques (Bobik & Campbell, 1993), and as such it is of interest to study 
the effects of PDGF on glucose transport in cultured rat aortic vascular smooth muscle 
cells. The cell signalling mechanisms involved in mediating mitogen-stimulated 
glucose transport in any cell system are poorly defined. To date only PI3’ kinase and 
MAP kinases are known to be involved (Thomsen & Gould 1997), and hence we 
wished to determine what role, if any, these play in mediating PDGF-BB-stimulated 
glucose transport.
3.4.1 Glucose transporter content of rat aortic vascular smooth muscle cells
We found that GLUT-1 and GLUT-3 were present in the cultured VSMC used, but 
there was no detectable GLUT-4 (Figure 3.1). As the reports of GLUT-4 expression 
were from freshly isolated VSMC, and not cultured VSMCs, the levels of GLUT-1, -3 
and -4  were investigated in fresh VSMC. In fresh vascular smooth muscle cells GLUT-
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4 was indeed present (Figure 3.2). GLUT-1 was also present in fresh aortic smooth 
muscle cells, however there was no detectable GLUT-3 (Figure 3.2). When the levels of 
GLUTs in cells from a number of different passages was studied, GLUT-4 expression 
was only observed in vascular* smooth muscle cells freshly extracted from aorta, and 
GLUT-3 protein was only detected when the cells were cultured (data not shown). The 
level of GLUT-1 was similar* in freshly isolated vascular smooth muscle cells and in all 
passages of cultured smooth muscle cells looked at.
Therefore, fresh rat aortic smooth muscle cells express GLUT-4 and GLUT-1, however 
the expression of GLUT-4 is lost immediately after the cells are isolated for culture, and 
the cells start to express GLUT-3. This loss of expression of a protein with the culturing 
of cells is not unusual. In vascular smooth muscle cells, for example, it is Imown that 
expression of protein kinase G is lost with increasing passage (Cornwell et al, 1994). It 
is possible that as GLUT-4 is lost that the cell compensates for this by increasing the 
levels of GLUT-3. However GLUT-3 and GLUT-4 have quite different properties. Both 
GLUT-3 and GLUT-4 have a relatively low Km for glucose transport (Gould, 1997), but 
GLUT-4 is localised predominantly in specialized intracellular vesicles in the absence 
of insulin. Upon exposui'e to insulin GLUT-4 is mobilised to the plasma membrane 
(Cushman et al, 1980, Suzuki & Kono, 1980), this is believed to be the case for 
GLUT-3. There are, however, reports of GLUT-3 being recruited to the plasma 
membrane in response to appropriate signals. When platelets are activated they have a 
vastly increased demand for energy in the form of glucose. It has been reported that in 
platelets activated by tln ombin, the amount of GLUT-3 at the plasma membrane can be 
increased by 2.7-fold with a T 1/2 of 1-2 minutes (Sorbara et al, 1997). So, perhaps the 
cultured VSMCs are compensating for the lack of GLUT-4 expression by increasing 
levels of GLUT-3. Unfortunately, it is difficult to perform sub-cellular fractionation on 
VSMCs. This means that the subcellular localisation of GLUT-3 could not be readily 
determined. It is therefore unclear if GLUT-3 is stored in an intracellular compartment 
and is capable of being mobilised in response to an appropriate signal, and therefore 
capable of replacing the role of GLUT-4 in these cells.
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The mechanisms regulating the altered expression of these proteins in this system are 
unclear. The expression of GLUT-4 is regulated by a number of factors in vivo, 
including diet and exposure of cells to insulin (Gould, et al 1997). The most plausible 
explanation for such a rapid loss of GLUT-4 expression is that there is some factor that 
the VSMCs are exposed to in intact aorta, perhaps from the endothelium, which 
normally maintains the expression of GLUT-4. When the VSMCs are isolated away 
from the endothelium this factor is removed and GLUT-4 expression declines. GLUT-3 
expression may then increase with passage to compensate for the loss of GLUT-4 
expression. This is, of course, speculation, and what such a factor may be is unclear.
3.4.2 PDGF-BB-stimulated glucose transport in VSMC
Little is known about glucose transport in VSMC. To date the only work on glucose 
transport in VSMC has looked at the effects of IGF-1, insulin and angiotensin II 
(Sowers, 1996, Fujiwara & Nakai, 1996, Quinn & McCumbee, 1998). There has been 
no work published on the effects of PDGF-BB (one of the growth factors believed to 
play a major role in regulating VSMC proliferation in atherosclerotic plaque 
development (Bobik & Campbell, 1993, Ross, 1993)) in regulating glucose transport in 
VSMCs. We were interested in determining the effects of PDGF-BB on glucose 
transport in VSMC. PDGF-BB stimulated a biphasic increase in glucose transport in 
VSMCs (Figure 3.3), with an acute phase that was maximal within 1 hour of exposure 
of cells to PDGF-BB and independent of new protein synthesis, as determined by use of 
the inhibitor cycloheximide (Figure 3.4). The maximum increase in the acute phase of 
PDGF-BB-stimulated 2-deoxyglucose transport in VSMC was ~ 6-fold. This value for 
PDGF-BB-stimulated acute-phase glucose transport was rather high when compared to 
the increases that this and other mitogens can stimulate in other cell lines, typically two­
fold (Thomson & Gould, 1997). It is unclear why this may be the case. One possible 
explanation is presence of the GLUT isoform, GLUT-3, in this cell line (see section
3.3.1) as well as GLUT-1, This may mean that the cell has a larger pool of glucose 
transporters available for transport. Upon appropriate stimulation, the cell may be able 
to translocate/activate more glucose transporters, and therefore be able to stimulate a 
greater increase in rates of transport than cells which do not contain GLUT-3. However,
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1it should be noted that the rate of PDGF-BB-stimulated glucose transport in the VSMCs 
used could be somewhat variable (typically between 2- and 5-fold). The chronic phase of 
PDGF-BB-stimulated 2-deoxyglucose transport became apparent after about two hours 
(Figure 3.3), with an increase in transport of ~10-fold over basal. The chronic phase of 
PDGF-BB-stimulated 2-deoxyglucose transport plateaued after -  6 hours and was 
dependent on synthesis of new proteins (Figure 3.4). The biphasic pattern of glucose 
transport in VSMCs in response to PDGF-BB is consistent with previous work on 
mitogen-stimulated glucose transport in other cell lines (Thomson & Gould, 1997). Dose- 
response studies suggest that PDGF-BB induces these effects via its cognate receptor.
The 3-O-methyl glucose transport rate reported for PDGF-BB stimulated transport was 
only 1.5 fold that of basal 3-O-methyl glucose transport. This does not correlate well with 
the 6-fold increase in 2-deoxyglucose transport seen with PDGF-BB in VSMCs. As 3-0- 
methyl glucose is not a substrate for hexokinase it is not phosphorylated once it enters the 
cell, unlike 2-deoxyglucose, and so remains a substrate for glucose transporters and is 
transported out of, as well as in to, the cell. Ideally, 3-O-methyl glucose transport would 
be measured over time points as low as 5 seconds when the amount o f glucose in the cells 
is still low and the degree of flux out of the cell is minimal. At early time points the 
difference between basal and stimulated transport rates is greatest (see figure below). 
However, this is practically very difficult to do.
PDGF-BB
3-O-methyl 
glucose transport Basal
Time (seconds)
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The differences between the gradients of the curves are largest at the lowest time points 
(blue lines), and as time progresses the differences in the gradients of the two curves 
becomes less (red lines). As the time points I was able to measure were further along 
the curve, the differences between basal and stimulated rates of transport, k, were 
smaller. Therefore I obtained a low value for PDGF-BB-stimulated 3-O-methyl glucose 
transport, 1.5-fold.
3.4.3 Characterisation of signalling mechanisms involved in mediating PDGF- 
BB-stimulated glucose transport in VSMC
PI3 ' kinase
Wortmannin and LY 294002 effectively inhibited PDGF-BB-stimulated 2- 
deoxyglucose transport. Wortmarmin completely inhibited PDGF-BB-stimulated 
glucose transport at doses o f -100 iiM, with an IC50 o f -20 nM (Figure 3.9). LY 
294002 was also effective at inhibiting PDGF-BB-stimulated glucose transport, with an 
EC50 o f -1.3 pM (Figure 3.9). These figures for IC50 are consistent with those 
previously published for inhibition of glucose transport via specific inhibition of PI3’ 
kinase (Gould et al, 1994, Thomson et al, 1996). Therefore PÏ3’ kinase activity is 
necessary for mediating PDGF-BB-stimulated 2-deoxglucose transport.
Immunoblotting of VSMC whole cell lysates demonstrated that there was p85 but no 
p55 PI3’ kinase regulatory subunit present in VSMCs (Figure 3.8). As only the p85 
regulatory subunit is present in VSMCs, then this isoform of PI3’ kinase must be 
responsible for mediating PDGF-BB-stimulated 2-deoxyglucose transport in VSMC.
MAP kinase
To determine the role that MAP kinases may play in mediating PDGF-BB-stimulated 2- 
deoxyglucose transport in VSMC, it was first determined which of the MAP kinases 
were stimulated by PDGF-BB in VSMCs. Both p38 and p42/44 were strongly 
phosphorylated, therefore activated, by 10 ng/ml PDGF-BB in VSMCs. The stimulation
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was greatest within 5 minutes of stimulation with PDGF-BB. After fifteen minutes the 
phosphorylation of p42/44 and p38 was beginning to decrease, and after 60 minutes the 
levels of phosphorylation had returned to basal levels (Figure 10). JNK was not 
significantly phosphorylated in response to 10 ng/ml PDGF-BB (Figure 10), however 
the anti-phospho JNK antibody cross-reacted with phospho-p42/44, making analysis of 
PDGF-BB-stimulated JNK activation difficult.
This is a very interesting observation, as previous work had indicated that p38 was 
involved in cytokine-stimulated glucose transport, but had no role in tyrosine kinase 
receptor activated transport (Gould et al, 1995). Similarly, it was shown that p42/44 
was involved in mediating glucose transport stimulated by ÎGF-1 (a tyrosine kinase 
receptor agonist), but there was no role for p38 here (Gould et al, 1995). Here, 
however we appear to have a pathway, activated by an agonist acting at a tyrosine 
kinase receptor, that activates both p38 and p42/44, and activation of both these MAP 
kinases is necessary for stimulation of glucose transport.
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To determine the role of p38 and p42/44 activation in PDGF-BB-stimulated 2-deoxy 
glucose transport in VSMCs, the specific inhibitors SB 203580 (p38 inhibitor) and PD 
98059 (p42/44 inhibitor) were used. As can be seen in Figure 3.11, both SB 203580 and 
PD 98059 were effective at inhibiting 2-deoxyglucose transport. SB 203580 was 
capable of inhibiting PDGF-BB-stimulated glucose transport at lower doses than PD 
98059. The approximate IC50 values for SB 203580 and PD 98059 were 10 pM and 
30pM respectively. From this we can see that both p38 and p42/44 are required for 
PDGF-BB-stimulated 2-deoxyglucose transport in VSMC. To ensure that the inhibitors 
were working in a specific manner, and not cross-reacting with other MAP kinases, 
immunoblot analysis was carried out to determine the levels of phosphorylation, and 
activation, of the p38 and p42/44 in the presence of these inhibitors. It was seen that SB 
203580 only inhibited the phosphorylation of p38 and had no effect on the levels of 
phosphoiylation, and therefore activation of p42/44. Conversely, PD 98059 only 
inhibited the phosphorylation and activation of p42/44 and had no effect on p38 
activation.
Both PI3’ kinase and the MAP kinases p38 and p42/44 are involved in mediating the 
acute phase of PDGF-BB-stimulated glucose transport, as determined by the use of 
specific inhibitors of these signalling molecules.
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3.5  Su m m a r y
Cultured rat aortic vasculai' smooth muscle cells express the glucose transporters 
GLUT-1 and GLUT-3, but not the insulin responsive glucose transporter, GLUT-4. 
This is in contrast to fresh rat aortic vascular smooth muscle cells that express GLUT-1 
and GLUT-4, but no GLUT-3. It is cuiTently unclear why the VSMCs down-regulate 
the expression of one glucose transporter and increase the expression of another when 
they are cultured. It is however, clear that culture of VSMC can result in diminished 
expression of several proteins (i.e. PKG down-regulation in cultured VSMC, Cornwell 
et al, 1994). It is possible that the cell up-regulates GLUT-3 expression to compensate 
for the loss of GLUT-4 in these cells.
In rat aortic VSMCs PDGF-BB is capable of stimulating cell growth, as measured by 
increased [^H] thymidine incorporation, and a biphasic increase in glucose transport in 
VSMCs. The acute phase of this transport is maximal within ~1 hour and is 
independent of new protein synthesis. The maximum rate of 2-deoxyglucose transport 
attained in the acute phase is -500 pmol/min/mg protein, and the EC50 is -10 ng/ml. 
The chi'onic phase of PDGF-BB-stimulated transport occurs after -2  hours and is 
maximal after - 6  hours. The clironic phase of PDGF-BB-stimulated 2-deoxyglucose 
transport is dependent on the synthesis of new protein. The increase in acute phase of 
PDGF-BB-stimulated glucose transport in VSMC is not limited by the rate of glucose 
phosphoiylation as determined by measuring the rat of PDGF-BB-stimulated 3-0- 
methyl glucose transport, an analogue of glucose that is not a substrate for 
phosphoiylation. The Km for basal and PDGF-BB stimulated 3-O-methyl glucose 
transport are 0.36 min'^ and 0.55 min'* respectively. Therefore the rate of PDGF-BB- 
stimulated 3-O-methyl glucose transport is -1.6 fold that of basal 3-O-methyl glucose 
transport.
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All further work in this thesis concentrates on the acute phase of glucose transport in 
VSMCs.
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Figure 3.1 Analysis of glucose transporters in cultures VSMCs
Whole cell lysates were prepared from flasks of VSMCs (passage 12) as described in 
section 2.9. 5 and 15 pg of protein were loaded on a 10 % SDS-PAGE gel and subjected 
to electrophoresis and immunoblotting as described in section 2.8. Positive controls were 
samples of rat brain lysate for GLUTs 1 and 3, and a whole cell lysates from 3T3-L1 
adipocytes for GLUT-4. Blots were developed using antibodies to the C-terminal of 
GLUT-1, -3 and -4 respectively (see section 2.1.2).
GLUT-1 and -3 were present in VSMCs, as determined by the presence of an 
immunoreactive band of approximately 49 kDa, however there was no detectable GLUT- 
4. This blot is representative of three such experiments.
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Figure 3.2 Analysis of glucose transporters in fresh aortic VSMCs
Whole cell lysates were prepared from freshly isolated VSMCs as described in section 
2.9. 20 and 40 pg of protein were loaded on a 10 % SDS-PAGE gel and subjected to 
electrophoresis and immunoblotting as described in section 2.8. Positive controls were 
samples of rat brain lysate for GLUTs 1 and 3, and whole cell lysates from 3T3-L1 
adipocytes for GLUT-4. Blots were developed using antibodies to the C-terminal of 
GLUT-1, -3 and -4 respectively (see section 2.1.2).
GLUT-1 and -4 were present in VSMCs, as determined by the presence of an 
immunoreactive band of approximately 49 kDa, however there was no detectable GLUT- 
3. This blot is representative of three such experiments.
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Figure 3.3 Time-course of 2-deoxyglucose transport in VSMCs in 
response to PDGF
2-deoxyglucose transport assay was earned out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with PDGF (10 ng/ml) for the times 
indicated, prior to 2-deoxyglucose transport assay. Data from a representative experiment 
is shown, repeated three times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
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Figure 3.4 2-deoxyglucose transport in VSMCs in response to PDGF in 
the presence or absence of cycloheximide
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with PDGF (10 ng/ml) for the times 
indicated, in the presence or absence of the inhibitor of protein synthesis, cycloheximide 
(50 pM), prior to 2-deoxyglucose transport assay. Data from a representative experiment 
is shown, repeated tlmee times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
* represents P < 0.05 in cells treated with PDGF alone as compared to basal, untreated 
cells as determined by Student’s t-test.
** represents P < 0.05 as compared to cells treated with PDGF alone for the same time 
period as determined by Student’s t-test.
Cycloheximide has no effect on PDGF-stimulated glucose transport up to two hours. 
However in cells treated with PDGF for 3 and 4 hours cycloheximide inhibits glucose 
transport.
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Figure 3.5 Dose-response curve of 2-deoxyglucose transport in VSMCs 
in response to PDGF
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with PDGF for 1 hour at the 
concentrations indicated, prior to 2-deoxyglucose transport assay. Data from a 
representative experiment is shown, repeated three times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
rate of transport in pmoles of 2-deoxyglucose transporte d/minute/mg of protein.
* represents P < 0.05 in cells treated with PDGF as compared to basal, untreated cells, as 
determined by Student’s t-test.
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Figure 3.6 3-O-methyl glucose transport in VSMCs in response to
PDGF
3-O-methyl glucose transport assay was carried out as described in section 2.6.
Cells were quiesced for 36-48 hours, then treated with PDGF (10 ng/ml) for 1 hour and 3- 
0-methyl glucose transport measured for the times indicated. Data from a representative 
experiment is shown, repeated three times with similar results.
A .
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
cpm of 3-O-methyl glucose transported/well.
B,
The mean cpm/well values were converted using the equation:
-ln((Cm-Ct)/Cm)
where Cm was the maximum cpm/well and Ct was the cpm/well at a given time point, t. 
This gives a straight line, where the gradient of each line represents the rate constant, k, 
for 3-O-methyl glucose transport.
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Figure 3.7 [^H] thymidine incorporation in VSMCs in response to
PDGF
[^H] thymidine incorporation was determined as described in section 2.11. Cells were 
quiesced for 12-24 hours, then treated with PDGF at the concentrations indicated for a 
further 24 hours. 0.5 pCi of [^H] thymidine is added per well for the final 6 hours of the 
incubation with PDGF. Data from a representative experiment is shown, repeated three 
times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation over basal (unstimulated) rates of [^H] thymidine incorporation.
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Figure 3.8 Analysis of PI3’ kinase isoforms in VSMCs
Whole cell lysates were prepared from flasks of VSMCs as described in section 2.9. 25 
and 50 pg of protein were loaded in each lane of a 10 % SDS-PAGE gel and subjected to 
electrophoresis and immunoblotting as described in section 2.8. Positive controls were 
samples from the manufacturer of the antibody. Blots were developed using antibodies to 
p85, p55 PI3’ kinase from Upstate Biotechnology
PI3’ kinase p85 was present in VSMCs, as determined by the presence of an 
immunoreactive band of approximately 85 kDa, however there was no detectable p55. 
This blot is representative of two such experiments.
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Figure 3.9 Effect of PI3’ kinase inhibitors on PDGF-stimulated 2-
deoxyglucose transport in VSMCs
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, treated with wortmannin or LY 294002 for 30 
minutes, then with PDGF (10 ng/ml) for a further hour, prior to 2-deoxyglucose transport 
assay. Data from a representative experiment is shown, repeated three times with similar 
results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
Both LY 294002 and wortmannin inhibited PDGF-stimulated 2-deoxyglucose transport.
* represents P < 0.05 when compared to cells treated with PDGF alone as determined by 
Student’s t-test.
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Figure 3.10 Effects of PDGF on the phosphorylation/activation o f MAP 
kinases
VSMCS were grown to confluency in 6 -well plates and quiesced in serum-free DMEM 
for 36-48 hours. Cells were treated with or without PDGF (10 ng/ml) for 5, 15 or 60 
minutes and then whole cell lysates were prepared as described in section 2.9. 50pl of 
each lysate was loaded in each lane of a 10 % SDS-PAGE gel and subjected to 
electrophoresis and immunoblotting as described in section 2.8. Blots were developed 
using phospho-specific antibodies to p38, p42/44 and JNK MAP kinases, respectively, 
which only recognise the phosphorylated, therefore activated, kinase. The positive control 
on the JNK blot is UV treated HEK cell lysates provided from the manufacturers of the 
antibody (New England Biolabs).
PDGF stimulated phosphorylation, and activation, of both p38 and p42/44, but had no 
effect on the phosphoiylation of JNK (although the cross-reactivity of the JNK antibody 
with p42/44 did not allow accurate analysis of this).
These blots are representative of tlnee such experiments.
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Figure 3,11 Effects of inhibitors of MAP kinases, p38 and p42/44, on 
PDGF-stimulated 2-deoxyglucose transport
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, treated with SB 203580 or PD 98059 for 1 hour, 
then with PDGF (10 ng/ml) for a further hour, prior to 2-deoxyglucose transport assay. 
Data from a representative experiment is shown, repeated three times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a percentage of PDGF-stimulated 2-deoxyglucose transport.
* represents P < 0.05 as compared to cells treated with PDGF alone as determined by 
Student’s t-test.
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Figure 3.12 Analysis of the specificity of the MAP kinase inhibitors SB 
203580 and PD 98059
VSMCS were grown to confluency in 6 -well plates and quiesced in serum-free DMEM 
for 36-48 hours. Cells were pre-treated nothing, 25 pM SB 203580 or 50 pM PD98059 
for 1 hour, followed by PDGF (10 ng/ml) for 5, 15 or 60 minutes. Whole cell lysates were 
prepared as described in section 2.9. 50pl of each lysate was loaded in each lane of a 10 
% SDS-PAGE gel and subjected to electrophoresis and immunoblotting as described in 
section 2.8. Blots were developed using phospho-specific antibodies to p38 and p42/44 
MAP kinases, respectively, which only recognise the phosphorylated kinase.
PDGF stimulated phosphorylation, and activation, of both p38 and p42/44. PD 98059 
inhibited the phosphorylation/activation of p42/44 by PDGF but had no effect on p38 
activation by PDGF. Conversely, SB 203580 had no effect on p42/44 activation by 
PDGF. Therefore the inhibitors SB 203580 and PD 98059 do act in a specific manner, 
with regard to MAP kinase activity.
Cells were not pretreated with any MAP kinase inhibitor 
+PD Cells were pretreated with 50 pM PD 98059 
+SB Cells were pretreated with 25 pM SB 203580
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4.1 A im s
The aims of this chapter are:
1. To determine what effect, if any, cAMP has on basal and PDGF-stimulated 
glucose transport in rat aortic vascular smooth muscle cells.
2. To determine what signalling mechanisms are involved in mediating cAMP’s 
effects on glucose transport in rat aortic vascular smooth muscle cells.
3. To determine what mechanisms the cell may use to endogenously increase 
intracellular [cAMP] and increase glucose transport.
4. To determine if cGMP has any effect on basal or PDGF-stimulated glucose 
transport in rat aortic vascular smooth muscle cells.
96
4.2INTRODUCTION
Cyclic nucleotides have been shown to regulate a number of important functions in 
vascular smooth muscle cells. In terms of atherosclerotic plaque development, the 
most important functions that cyclic nucleotides regulate in vascular smooth muscle 
cells are relaxation (Landgraf et al, 1992, Murthy & Mahklouf, 1995, Toyoshima et 
al, 1998) and proliferation (ICronemann et al, 1999, Ciche et al, 1998).
In vascular smooth muscle cells, contraction occurs when phospholipase Cp activity is 
stimulated. This results in the production of inositol triphosphate (IP3) and diacyl 
glycerol (DAG). IP3 then binds to and activates specialised Ca^  ^channels in the 
sarcoplasmic reticulum, a specialised intracellular Ca^^ storage organelle found in 
muscle cells. Upon activation of the IP3 gated channels, Ca^^ floods into the cytosol of 
the cell, increasing the intracellular levels of Ca^^. The calcium associates with 
calmodulin and activates myosin light chain kinase, which then phosphoiylates and 
activates myosin, resulting in contraction of the cell (reviewed in Horowitz et al, 
1996).
Both cAMP and cGMP have been shown to be able to reduce intracellular levels of 
Ca^  ^and cause relaxation of smooth muscle (Landgraf et al, 1992, Murthy & 
Mahldouf, 1995, Toyoshima et al, 1998). cAMP and cGMP can reduce the levels of 
intracellular Ca^’*’ by two main mechanisms. Firstly PKA and PKG can phosphorylate 
and inhibit the activity of PLC p. This inliibits the production of IP3 and ultimately the 
release of calcium from the sarcoplasmic reticulum, via activation of the IPs-gated 
calcium channels (Murthy et ai., 1993). The second mechanism that allows cAMP and 
cGMP to inhibit Ca^^ release and cause smooth muscle relaxation is by direct 
phosphorylation of the IP3-gated Ca^”^ channel itself (Komalavilas & Lincoln, 1994, 
Komalavilas & Lincoln, 1996). It is believed that this phosphorylation may desensitise 
the IP3 receptor to IP3 , therefore greater levels of IP3 are required to open the Ca^ "' 
channel. Through these two mechanisms cAMP and cGMP are capable of reducing 
intracellular [Ca^^], and ultimately cause relaxation of smooth muscle cells. PKA and
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PKG can act alone or in concert to mediate smooth muscle cell relaxation (Murthy & 
Makhlouf, 1995).
cAMP and cGMP can also regulate smooth muscle cell proliferation (Ki'onemami et 
al., 1999, Chiche et al, 1998).These cyclic nucleotides mediate their inhibitory effects 
on proliferation by inhibiting the expression of certain cyclins necessary for cell cycle 
progression (Ki'onemann et al, 1999). cAMP appears to be more potent in inhibiting 
VSMC proliferation, but this could be due to the decrease in PKG expression in 
VSMC which have been passaged in culture. In VSMCs which have had their PKG 
expression augmented by transfection, the antiproliferative effects of NO/cGMP are 
enhanced (Chiche et al, 1998).
It is tempting to speculate that, as cAMP and cGMP are major regulators of 
proliferation and relaxation of vascular smooth muscle cells, perhaps aberrant cAMP 
and cGMP signalling may be important in atherosclerotic plaque development (see 
sections 1 .1 . 1  and 1 .1 .2 ).
Very little is currently known about the role of cyclic nucleotides in regulating glucose 
transport. There are various reports of cAMP and cGMP being stimulatoiy, inhibitoiy 
or without effect on glucose transport depending on what tissue or cell lines are used.
The cAMP analogue 8 -Br cAMP stimulates glucose transport in 3T3-L1 
preadipocytes (Cornelius et al, 1991). In cultured rat thyroid cells glucose transport is 
increased by thyroid stimulating hormone in a cAMP-dependent manner (Hosaka et 
al, 1992). In these cells cAMP analogues stimulated an increase in the levels of 
GLUT-1 mRNA, but caused a decrease in GLUT-4 mRNA. In fat cells cAMP has no 
effect on basal rates of glucose transport, but is inliibitoiy with regard to insulin- 
stimulated glucose transport, mediated via GLLUT-4 (Ldnnroth et al, 1987). These 
results suggest that perhaps cAMP’s effect on glucose transport depends on the GLUT 
isoforms expressed, with cAMP being stimulatory with regard to GLUT-1 mediated 
transport but inhibitory with regard to GLUT-4 mediated glucose transport. In 
pancreatic j3 cells, phosphoiylation of GLUT-2 by PKA results in an inhibition of
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glucose transport in these cells (Thorens et al, 1996). In cardiomyocytes cAMP 
analogues have no effect on glucose transport (Fischer et al, 1996).
Less is known about cGMP’s ability to regulate glucose transport. Early reports 
suggested that cGMP could stimulate glucose transport in cardiomyocytes (Shanahan 
& Edwards, 1989), however more recent studies have reported that cGMP is without 
effect on glucose transport in these cells (Fischer et al, 1996). Other work has shown 
that cGMP is inhibitory with regard to insulin-stimulated glucose transport in rat 
adipocytes. This effect is thought to be mediated via cGMP’s inhibition of PDE 3 in 
these cells (Eriksson et al., 1994). However, to date the role of cGMP in regulating 
glucose transport is veiy poorly understood.
As cAMP and cGMP are important regulators of VSMC proliferation and relaxation, 
and are also known to be able to regulate glucose transport, I was interested in 
determining what role, if any, that cAMP and cGMP played in regulating glucose 
transport in rat aortic vascular smooth muscle cells.
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4.3 R e su l t s
4.3.1 Effects of cAMP analogues on basal and PDGF-stimulated glucose
transport
To determine what effect, if any, cAMP has on the acute phase of basal and PDGF- 
stimulated glucose transport, 2 -deoxyglucose transport assays were carried out in 
VSMCs. Cells were treated with 8 -Br cAMP (0.1 -1 mM) for 1 hour, either in the 
absence or presence of PDGF (10 ng/ml) prior to 2-deoxyglucose transport assay. As 
described in chapter 3, PDGF stimulated an increase in 2-deoxyglucose transport, here 
a 2.08 ±0.17 fold increase (n=3 experiments) (Figure 4.1). cAMP had very little 
effect on PDGF stimulated glucose transport, but did stimulate a 1.98 ± 0.07 fold 
increase in basal glucose transport (n=3 experiments) (Figure 4.1).
To ensure that the increase in 2-deoxyglucose transport was not due to some peculiar 
effect of the analogue, the ability of dibutyryl cAMP, another cAMP analogue, to 
stimulate glucose transport in VSMC was tested. Both cAMP analogues stimulated a 
~2 fold increase in 2-deoxyglucose transport, with dibutyryl cAMP stimulating a 1.96 
±0.18 fold increase and 8 -Br cAMP stimulated a 2.38 ± 0.4 fold increase (n=3 
experiments), both with an EC50 of -0.5 mM (Figure 4.2). A time course of 8 -Br 
cAMP stimulated 2-deoxyglucose transport was carried out using treatments of 0.5 
mM 8 -Br cAMP for 0-2 hours (Figure 4.3). 2-deoxyglucose transport increased within 
30 minutes of exposure to 8 -Br cAMP, and was still increasing up to two hours after 
stimulation. All work carried out in this chapter uses a 1 hour stimulation with 8 -Br 
cAMP.
As with PDGF-stimulated glucose transport, it was necessary to ensure that the 8 -Br 
cAMP stimulated transport was not dependent on the rate of phosphorylation of the 2 - 
deoxyglucose. Cells were treated with or without 0.5 mM 8 -Br cAMP, and 3-0- 
methyl glucose transport was measured over varying time points (as described in 
section 2.6). 8 -Br cAMP stimulated an increase in 3-0-methyl glucose transport 
compared to untreated cells at all time points measured (Figure 4.4). This data can be
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1PKA
The most obvious downstream effector for cAMP is PKA. To determine if PKA plays 
a role in mediating 8-Br cAMP-stimulated glucose transport the PKA inhibitor H-89 
was used. Cells were treated for 15 minutes with H-89 (0-500 nM), then 0.5 mM 8-Br 
cAMP was added and cells incubated for a further 1 hour. H-89 fully inhibited 8-Br
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converted to give a straight line as described in section 3.3.2, which allows calculation 
of the rate constant, k, for transport. The rate constants, k, for basal and 8-Br cAMP 
transport were 0.25 min  ^ and 0.65 min'^ respectively, therefore 8-Br cAMP stimulates 
an -2.5 fold increase in the rate of glucose transport in VSMCs. This is very similar to 
the rate of 2-deoxyglucose transport in response to 8-Br cAMP. PDGF, however, 
appealed to stimulate a smaller increase in 3-(9-methyl glucose transport than 2- 
deoxyglucose transport in VSMCs (see Chapter 3). This is probably just due to 
experimental variability.
As cAMP analogues were stimulatory with regard to glucose transport in VSMCs, we y
were interested in determining if they could act as mitogens in these cells. This was V
3achieved by measuring [ H] thymidine incorporation, 8-Br cAMP was inhibitory with 
regard to [ H] thymidine incorporation (Figure 4.5) and therefore was not acting as a 
mitogen in these cells.
So, analogues of cAMP were stimulatoiy with regards to glucose transport in VSMCs 
but were inhibitory with regards to cell growth. The effect of cAMP analogues on 
glucose transport in VSMCs were not additive to those of PDGF, suggesting that 
PDGF and cAMP utilise some of the same signalling components in mediating 
glucose transport.
4.3.2 Cell signalling mechanisms regulating cAMP-stimulated glucose 
transport in VSMCs
Next it was of interest to determine which cell signalling pathways may be involved in 
mediating cAMP-stimulated transport.
cAMP stimulated glucose transport at doses as low as 50 nM (Figure 4.6). This figure 
is in keeping with the IC50 for H-89 effects on PKA activity (40 nM).
As 8-Br cAMP’s effect on 2-deoxyglucose transport is not additive with PDGF’s 
stimulation of 2-deoxyglucose transport, we were interested in determining if cAMP- 
PKA were components of the signalling pathway mediating PDGF-stimulated glucose 
transport. In certain tissues PDGF can stimulate an increase in intracellular [cAMP]. 
This happens when PDGF stimulates an increase in PKC activity (see section 1.2.3.1) 
that can phosphorylate and activate certain adenylyl cyclase isoforms (AC II) (see 
section 1.3.1, table 1.2). First it was deteimined which adenylyl cyclase isoforms are 
present in VSMCs by reverse transcription PCR, using primers specific for each 
isoform studied. The primers used for the RT- PCR are shown in table 4.1. The 
presence of AC I, II, IV, V, and IX was examined. AC 111 expression was not 
examined, as it is expressed solely in the olfactory tissue (see section 1.3.1, Table 
1.2), and the presence of the isoforms VII and VIII was not determined as the primers 
for RT-PCR were not available. RT-PCR showed that the isoforms 11, VI, and IX are 
expressed in VSMCs (Figure 4.7). The primers for AC IV also gives a band but this is 
also present in the negative control so is most likely a false positive (Figure 4.7).
To deteimine if cAMP/PKA are components of the signalling pathway involved in 
mediating PDGF-stimulated glucose transport the effect of the PKA inhibitor, H-89, 
on PDGF-stimulated glucose transport was tested. Cells were treated for 15 minutes 
with H-89 and then treated with PDGF (10 ng/ml) for a further 1 hour prior to 2- 
deoxy glucose transport assay. H-89 had no effect on PDGF-stimulated 2- 
deoxyglucose transport (Figure 4.8).
As cAMP/PKA are not components of the PDGF-stimulated transport, but cAMP- 
stimulated transport is not additive with PDGF-stimulated glucose transport, it is 
possible that these two stimuli utilise some of the same signalling components. The 
role of PI3’ kinase and MAP kinases in mediating 8-Br cAMP-stimulated glucose 
transport was therefore investigated.
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PIS ’ kinase
To determine the role of PI3’ kinase in mediating 8-Br cAMP, cells were treated with 
100 nM wortmannin, a PI3’ kinase inhibitor, for 30 minutes, then further treated with 
or without 0.5 mM 8-Br cAMP for 1 hour, prior to 2-deoxyglucose uptake assay. 8-Br 
cAMP stimulated ~ 2 fold increase in glucose transport (Figure 4.9). Wortmannin had 
no effect on basal levels of glucose transport, but inhibited the 8-Br cAMP-stimulated 
glucose transport (Figure 4.9).
MAP kinases
Next, we were interested in determining if there is a role for any of the MAP kinase 
family, p42/44, p38 or JNK, in mediating 8-Br cAMP-stimulated glucose transport in 
VSMCs. Firstly the ability of 8-Br cAMP to stimulate the phosphorylation, and 
therefore the activation of p38, p42/44 and JNK was assessed by using phospho- 
specific antibodies for the MAP kinases. 1 mM 8-Br cAMP had no effect on the 
phosphorylation of p42/44 or JNK at all time points looked at, however p38 
phosphorylation was stimulated by 1 mM 8-Br cAMP, as determined by the presence 
of an immunoreactive band of 38 kDa (Figiue 4.10). Stimulation was maximal after 5 
minutes stimulation with 8-Br cAMP, and was beginning to decline by 15 minutes. 
After 60 minutes p38 phosphorylation had returned to basal levels.
To determine if p38 plays a role in mediating 8-Br cAMP-stimulated glucose 
transport, the p38 specific inhibitor SB 203580 was used. SB 203580 completely 
inhibited 8-Br cAMP stimulated glucose transport at a dose of 10 pM (Figure 4.11). 
This figure for inlhbition of glucose transport by inhibition of p38 is consistent with 
previous results (Gould et al, 1995).
To determine if PKA is upstream of 8-Br cAMP mediaited p38 activation, the ability 
of H-89 to inhibit p38 phosphorylation was measured. Cells were treated with or 
without H-89 (50nM) for 15 minutes, then treated with 0.5 mM 8-Br cAMP for 
various times. Whole cell lysates were prepared as described in section 2,9 and 
subjected to immunoblotting (see section 2.8). H-89 had no effect 8-Br cAMP
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stimulated phosphoiylation of p38 (Figure 4.12). Therefore, cAMP activation of PKA 
is not responsible for 8-Br cAMP mediated phosphorylation of p38 in VSMCs.
4.3.3 Endogenous mechanisms of increasing [cAMP] and rates of glucose 
transport in VSMC
Next, we were interested in what possible ways the cell may generate intracellular 
cAMP and increase glucose transport in VSMCs. The most obvious way that muscle 
cell can increase intracellular cAMP levels is via stimulation of p2 adrenoceptors 
(Watson & Arkinstall, 1994). These receptors couple to Gas, which then stimulates 
adenylyl cyclase activity and increases intracellular [cAMP] (see sectionl.3.1). 
Stimulation of VSMCs with the p2 adrenoceptor agonist, isoprenaline, had no effect 
on basal levels of glucose transport but did stimulate large increases in the 
intracellular [cAMP] (Figure 4,13). Other possible endogenous agonists that could 
raise intracellular [cAMP] and therefore increase the rate of glucose transport in 
VSMC are agonists of the PGI receptors (Watson & Arkinstall, 1994). The PGI 
receptor agonist iloprost had little effect on cAMP levels in VSMCs and had no effect 
on 2-deoxyglucose transport in VSMCs (Figure 4.14),
The inability of agonists that stimulate adenylyl cyclase activity, and cAMP synthesis, 
to stimulate glucose transport, raised the interesting possibility that it may be 
necessary to have a very localised increase in [cAMP] to give rise to increased glucose 
transport rates. One mechanism by which cells can give rise to localised increase in 
[cAMP] is by decreasing phosphodiesterase activity at specific intracellular sites (see 
section 1.3.2). In cultured VSMCs the PDFs 1,3, 4, 5 and, to a lesser extent 2, are 
expressed (Polsen & Strada, 1996). PDEs 1 and 2 hydrolyse both cAMP and cGMP, 
PDEs 3 and 4 hydrolyse cAMP specifically and PDE 5 hydrolyses cGMP specifically. 
To determine if a localised increase in [cAMP], caused by decreased PDE activity, 
can stimulate 2-deoxygluocse transport in VSMCs, inhibitors of PDE activity were 
used. Unfortunately there are currently no specific inhibitors of PDE 1 available, 
therefore it was not possible to determine a role for PDE 1 here. As PDE 2 constitutes 
very little of the PDE activity present in VSMCs (Polsen & Strada, 1996), the effect of 
inhibition of PDE 2 activity on 2-deoxyglucose transport was not assessed. Cells were
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treated with specific inhibitors of PDE 3 (milrinone), PDE 4 (rolipram) or PDE 5 
(zaprinast) for 1 horn' prior to 2-deoxyglucose transport assay (see section 2.5). Only 
the inhibitor of PDE 3, milrinone, had any effect on glucose transport, causing an 
approximately 2 fold increase in glucose transport in VSMCs at doses as low as 500 
nM (Figure 4.15). The inhibitors of PDE 4 and 5 were without effect on 2- 
deoxyglucose transport in VSMCs (Figure 4.16).
4.3.4 Effects of cGMP on basal and PDGF-stimulated glucose transport in 
VSMCs
To determine what effect, if any, cGMP has on glucose transport in VSMCs, the 
analogue 8-Br cGMP was used. Cells were treated with 8- Br cGMP (0-1 mM) for 1 
hour, either in the absence or presence of PDGF (10 ng/ml). PDGF-stimulated a 2.5 ± 
0.32 fold increase in 2-deoxyglucose transport and 8-Br cGMP inhibited this transport 
completely at a dose of 1 mM (n=3 experiments) (Figure 4.17). However, 8-Br cGMP 
is without effect on basal rates of 2-deoxyglucose transport (Figure 4.17).
cGMP is generated by guanylyl cyclases (see section 1.4.1). Soluble guanylyl cyclases 
are activated by NO whereas transmembrane guanylyl cyclases are activated upon 
agonist binding (see section 1.4.1). To determine if activation of transmembrane 
guanylyl cyclase or soluble guanylyl cyclase can also inhibit PDGF-stimulated glucose 
transport cells were treated with ANF (atrial natriuretic factor), an agonist of a 
transmembrane guanylyl cyclase expressed in VSMCs (Garbers & Lowe, 1994), or 
with sodium nitroprusside (SNP), a nitric oxide donor. ANF was indeed capable of 
inhibiting PDGF-stimulated glucose transport however SNP had no effect on glucose 
transport (Figure 4.18).
As described in section 3.3.3, both PI3’ kinase and the MAP kinases p38, p42/44 are 
involved in mediating PDGF-stimulated glucose transport in VSMCs. We were 
therefore interested in determining if the inhibitoiy effects of ANF/cGMP on glucose 
transport are via inhibition of stimulation of MAP kinases. Cells were quiesced in 
serum-free DMEM for 36-48 hours then treated with ANF (300 nM) for 30 minutes 
followed by PDGF (10 ng/ml) for various times. Lysates were prepared and subjected
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I
to immunoblotting. To determine the level of phosphorylation, and therefore 
activation, of the proteins, phospho-specific antibodies to both p38 and p42/44 were 
used to develop the immunoblots. ANF was not capable of inhibiting PDGF- 
stimulated phosphorylation and activation of either p38 or p42/44 (Figure 4.19). As 
yet we have been unable to ascertain the effects of cGMP on PI3 ’ kinase activity.
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4 .4  D iscuss io n
Currently cyclic nucleotides have been reported to affect glucose transport in a variety 
of ways depending on the cell type used. For example, in 3T3-L1 preadipocytes the 
cAMP analogue, 8-Br cAMP, is stimulates glucose transport (Cornelius et al, 1991), 
however it is inhibitory with regard to insulin-stimulated glucose transport in fat cells 
(Ldnnroth et al., 1987). In pancreatic p cells, phosphorylation of GLUT-2 by the 
cAMP stimulated protein kinase, PKA, results in a decrease in the rates of glucose 
transport (Thorens et al, 1996), however, in cardiomyocytes agents which alter the 
levels of cAMP had no effect on glucose transport (Fischer et al, 1996). Less is 
known about the effects of cGMP on glucose transport, with early reports suggesting 
that cGMP could stimulate transport in cardiomyocytes (Shanahan & Edwards, 1989), 
however more recent work has shown that cGMP is without effect on glucose 
transport in cardiomyocytes (Fischer et al, 1996).
Cyclic nucleotides play an important role in regulating vascular smooth muscle cell 
function. They are involved in regulating smooth muscle cell relaxation and inhibiting 
proliferation, as described in section 4.2 (Landgraf et al, 1992, Murthy & Mahklouf, 
1995, Toyoshima et al, 1998, Kronemann et al, 1999, Ciche et al, 1998). In the 
work of this chapter we determined what role, if any, cyclic nucleotides play in 
regulating glucose transport in rat aortic vascular smooth muscle cells.
4.4.1 Effects of cAMP on basal and PDGF-stimulated glucose transport
Analoguesof cAMP, 8-Br cAMP and dibutyryl cAMP, both stimulate an 
approximately two-fold increase in 2-deoxyglucose transport in VSMCs (Figure 4.2). 
This stimulation of glucose transport was not additive with PDGF stimulated glucose 
transport (Figure 4.1). This suggests that both PDGF and cAMP use components of 
the same signalling mechanisms to effect increased glucose transport, or that there 
was a limited pool of glucose transporters in these cells available for transport, and 
that this pool is fuly active in the presence of 10 ng/ml PDGF. However, although 
cAMP and PDGF can both stimulate glucose transport in VSMCs, cAMP inhibited
107
cell growth, as determined by [^H] thymidine incorporation (Figure 4.5), unlike PDGF 
which stimulated cell growth (see 3.3.2, Figure 3.7).
As discussed in the introduction (see section 1.2.3.1), increased glucose transport may 
be achieved by translocation of transporters from an intracellular site to the plasma 
membrane, increasing the total number of glucose transporters at the cell surface, by 
an increase in the intrinsic activity of the transporter, or by a combination of the above 
(Gould & Holman, 1993, Czech et al, 1992). cAMP/PKA has been reported to be 
able to affect traffic along the exocytic pathway as well as alter the intrinsic activity of 
glucose transporters. PKA has been shown to play a regulatory role in traffic along the 
exocytic route. By treating NRK cells (normal rat kidney cells) with the PKA inhibitor 
FI89, it was shown that PKA activity was required for transport along the whole 
exocytic pathway (Muniz et al, 1996). By treating these cells with agents that 
increase PKA activity, such as IB MX or forskolin, transport was increased from the 
Golgi to the plasma membrane. In hepatocytes, cAMP has been shown to increase 
translocation of the NaVtaurocholate cotransport polypeptide (Ntcp) to the plasma 
membrane resulting in an increase in the NaVtaurocholate cotransport in these cells 
(Mukhopadhyay et al, 1998). Protein kinase A has also been shown to be involved in 
the regulated exocytosis of the transport protein aquaporin-2 from intracellular 
vesicles to the plasma membrane (Katsura et al, 1997). These examples show that 
cAMP/PKA is capable of eliciting the movement of proteins from intracellular sites to 
the plasma membrane by a mechanism which is similar to that used by insulin to 
increase glucose transport in adipocytes with GLUT-4. Therefore it is possible that 
cAMP/PKA is increasing glucose transport in VSMC by increasing the number of 
functional glucose transporters at the plasma membrane. If there is a limited pool of 
glucose transporters available for translocation to the cell surface, it is possible that 
this pool of transporters is fully translocated to the cell surface in response to PDGF 
(10 ng/ml). Therefore, when cells are treated with 8-Br cAMP in addition to PDGF no 
increase in the rates of glucose transport are seen, as there are no further transporters 
available for translocation.
As well as possibly being able to cause translocation of transporter proteins to the cell 
surface, cAMP/PKA is capable of altering the activity of glucose transporters. In
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pancreatic (3 cells, protein kinase A rapidly phosphorylates GLUT-2 after activation of 
adenylyl cyclase. This results in a decrease in the rate of 3-0-methyl glucose transport 
(Thorens et al, 1996). In brown adipocytes noradrenaline can increase the rate of 
glucose transport in a cAMP dependant manner. This is not due to an increase in the 
total amount of immunoreactive GLUT-1 present in the plasma membrane, however 
there is an increase in photoaffinity labelling with the reagent 2-V-[4-(l- 
azitrifluoroethyl)benzoyl]-[2-^H] 1,3-bis-(D-mannose-4-yloxyl)-2-propylamine (ATB- 
[^H]BMPA) of cell surface GLUT-1 (Shimizu et al, 1998). This indicates that 
noradrenaline’s effects on glucose transport in these cells are through an increase in 
the functional activity of GLUT-1. Therefore we can see that cAMP can alter the 
functional activity of glucose transporters.
These examples demonstrate that cAMP/PKA could increase the rate of glucose 
transport either by an increase in the number of transporters at the cell surface, by 
altering the intrinsic activity of the transporter or by a combination of both of these 
mechanisms.
4.4.2 Cell signalling mechanisms involved in mediating cAMP-stimulated 
glucose transport
PKA
The most obvious downstream effector of cAMP is the cAMP-stimulated protein 
kinase, PKA. By using the PKA inhibitor H89, we showed that cAMP-stimulated 2- 
deoxyglucose transport did indeed require PKA activity (Figure 4.6), As PDGF and 
cAMP stimulation of glucose transport are not additive with each other, we were 
interested in determining if cAMP/PKA were components of the PDGF signalling 
pathway leading to increased glucose transport. In cells expressing adenylyl cyclase II 
(see table 1.2), PDGF can elevate cAMP levels in a PKC dependant manner (Smit et 
ah, 1998). In airway smooth muscle, protein kinase C activity can stimulate adenylyl 
cyclase II activity and results in an increase in [cAMP] (Pyne et al, 1994, Moughal et 
al, 1995). Therefore it was possible that stimulation of VSMCs with PDGF resulted 
in activation of adenylyl cyclase II and an increase in [cAMP],
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We determined by RT-PCR that type II adenylyl cyclase was indeed expressed in 
VSMCs (Figure 4.7). Therefore it was possible that PDGF could be stimulating an 
increase in [cAMP] and that this could be a component of the signalling pathway 
responsible for increased glucose transport in VSMCs. However, when cells are pre­
treated with the PICA inhibitor H89 before treatment with PDGF there was no 
inhibition of glucose transport, indicating that cAMP and PICA are not components of 
the signalling mechanism mediating PDGF-stimulated glucose transport.
PI3 ’ kinase
Wortmannin (100 nM) was capable of fully inhibiting 8-Br cAMP stimulated glucose 
transport in VSMCs (Figure 4.9). 100 nM is the concentration of wortmannin capable 
of eliciting a 100% inhibition of PDGF-stimulated glucose transport, as determined in 
chapter 3 (section 3.3.3). Therefore PI3’ kinase is activity is required to mediate 
cAMP-stimulated glucose transport in VSMCs. The role of PI3’ kinase plays in 
mediating cAMP-stimulated glucose transport is unclear. It is possible that PI3’ kinase 
acts as a signalling molecule downstream of cAMP/PKA. However, PI3’ kinase 
activation is also involved in regulating a variety of vesicular trafficking events 
(Coiwera & Czech, 1998, Wumser, et al, 1999) and may therefore be important in 
recruiting GLUTl to the plasma membrane.
MAP kinases
To determine if there was a role for MAP kinases in cAMP-stimulated glucose 
transport it was first assessed which MAP kinases were stimulated in response to 8-Br 
cAMP in VSMCs. Only p38 MAP kinase is phosphorylated, and activated, in 
response to 8-Br cAMP (Figure 4.10). The specific inhibitor of p38, SB 203580, was 
used to determine if p38 activity was necessary for cAMP-stimulated glucose 
transport. SB 203580 fully inhibited cAMP-stimulated glucose transport at doses as 
low as 10 pM (figure 4.11). This dose is consistent with that from previous work on 
p38’s role in glucose transport (Gould et al, 1995). Therefore p38 activity is required 
to mediate cAMP-stimuIated glucose transport.
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There are several reports of cAMP being able to stimulate the activity of p38. In rat 
epididymal fat cells, isoproterenol and cAMP analogue chlorophenylthio-cAMP will 
stimulate a rapid and sustained increase in p38 activity (Moule & Denton, 1998), and 
in T-cells PKA can mediate the release of MAP kinases from proteins which inhibit 
their activity (Saxena et ah, 1999). These reports state that cAMP’s effects on p38 
activity are mediated via activation of PKA. However, we have showed that 
stimulation of p38 phosphorylation and activation in response to 8-Br cAMP is not 
dependent on PKA activity (by the use of the PKA inhibitor H89) in VSMCs (Figure 
4.12). It is unclear how cAMP could be stimulating p38 activity independent of PKA 
activity. Recent work has shown that cAMP can directly bind and activate certain 
guanine nucleotide exchange factors (GEFS) (de Rooij etal., 1998). It is therefore 
possible that cAMP could activate small G-proteins, by activation of GEFS, which are 
upstream from p38 activation. However, this is as yet speculation.
So, overall, cAMP requires protein kinase A, PI3’ kinase and p38 MAP kinase 
activity to stimulate glucose transport in VSMCs.
4.4.3 Endogenous mechanisms for generating cAMP and stimulating glucose 
transport
From section 4.3.1 it was shown that cAMP analogues could stimulate an increase in 
glucose transport in VSMCs (Figure 4.2). We were therefore interested in determining 
what endogenous ligands could stimulate an increase in intracellular [cAMP] and 
glucose transport. Two obvious candidates were agonists of the |32 adrenoceptor and 
of the PGI receptor. Both of these receptors are expressed in vascular smooth muscle 
tissue and couple predominantly to Gas to stimulate the production of cAMP (Watson 
& Arkinstall, 1994). However agonists of both receptors failed to stimulate any 
increase in glucose transport in VSMCs, at doses which did stimulate an increase in 
cAMP production in the cells (Figures 4.13 and 4.14). Therefore stimulation of cAMP 
production by activation of adenylyl cyclase is not sufficient to stimulate glucose 
transport in VSMCs.
I l l
This raised the possibility that it was a very localised increase in [cAMP] that may be 
necessary to stimulate glucose transport. There are several reports on the importance 
of the spatial distribution of cAMP in eliciting specific cellular effects (Hempel et al,
1996, Aass et al, 1988, Jureviçius & Fischmeister, 1996). By inhibition of specific 
PDEs at specific subcellular locations a small, very localised increase in cAMP 
concentration can be achieved (see section 1.3.2 for information on PDEs). These 
small increases in local cAMP concentration can then stimulate PKAII isoforms held 
at specific sites by AKAPs (A Kinase Anchoring Proteins) (see section 1.3.3 for 
overview). This tailoring of cAMP signalling is reviewed in Houslay & Milligan,
1997. VSMCs express PDEs 1, 2, 3, 4 & 5 (Polsen & Strada, 1996). We determined 
that by inhibiting PDE 3 activity an increase in glucose transport rates, similar to that 
seen with cAMP analogues, is achieved (Figure 4.15), however no effect is seen on 
glucose transport rates when inhibitors of PDE 4 and 5 are used (Figure 4.16). This 
supports the idea that a localised increase in [cAMP], caused by a decrease in PDE 
activity, could stimulate glucose transport in VSMCs.
4.4.4 Effect of cGMF on basal and PDGF-stimulated glucose transport in 
VSMCs
Very little is known about cGMP’s ability to regulate glucose transport. An early 
report suggested that cGMP could stimulate glucose transport in rat cardiomyocytes 
(Shanahan & Edwards, 1989), however a more recent report has shown that agents 
that increase levels of cGMP have no effect on glucose transport in these cells 
(Fischer et a l, 1996). We used the cGMP analogue, 8-Br cGMP, to determine if 
cGMP could affect glucose transport in VSMCs, 8-Br cGMP had no effect on basal 
rates of glucose transport but was able to inhibit PDGF-stimulated glucose transport 
(Figure 4.17). This was a surprising result, as cAMP and cGMP often work in concert 
to elicit their effects in VSMCs, i.e. their effects on proliferation and relaxation (see 
section 4.2).
cGMP is generated by guanylyl cyclase. There are two types of guanylyl cyclase; 
soluble guanylyl cyclase that is activated by nitric oxide (NO), and transmembrane
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guanylyl cyclase, which is activated upon binding of an appropriate agonist (see 
section 1.4.1). We determined if agents that can raise intracellular cGMP, can also 
inhibit PDGF-stimulated glucose transport in VSMCs. Treatment of cells with ANF, 
an agonist of transmembrane guanylyl cyclase, did inhibit PDGF-stimulated glucose 
transport, whereas sodium nitroprusside (SNP), an NO donor, had no effect on PDGF- 
stimulated glucose transport (Figure 4.18). It is intriguing that both agents should 
result in an increase in intracellular [cGMP], but apparently have different effects on 
glucose transport in VSMCs. It is possible that perhaps the spatial distribution of 
cGMP within the cell could play an important role in determining the effects seen, or 
perhaps soluble guanylyl cyclase isoforms are not expressed in cultured VSMCs.
As was shown in section 3.3.3 the MAP kinases, p42/44 and p38 are involved in 
mediating PDGF-stimulated glucose transport. cGMP has been shown to inhibit 
activation of MAP kinases in BHK cells (baby hamster kidney cells). We were 
therefore interested in determining if the inhibitory effects of cGMP on PDGF- 
stimulated glucose transport were via inhibition of MAP kinase activity. We 
determined, however, that neither 8-Br cGMP nor ANF had any effect on PDGF’s 
ability to stimulate either p42/44 or p38 (Figure 4.19). Therefore cGMP’s inhibitory 
effects on PDGF-stimulated glucose transport are not mediated via inhibition of MAP 
kinases. As yet we have not looked at the effect of cGMP on P13’kinase, but as MAP 
kinases and P13’ kinase are the only two signalling mechanisms known to be involved 
in mediating PDGF-stimulated glucose transport, this is the next most obvious target 
for cGMP’s effects.
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A4 .5 . Su m m a r y
Cyclic nucleotides play an important role in regulating a number of VSMC functions, 
including proliferation and relaxation (Murthy & Makhlouf, 1995, Kronemann et al.,
1999, Chiche et al, 1998). cAMP and cGMP have been shown to be stimulatory, 
inhibitory or without effect on glucose transport depending on what cells are studied.
However, although cyclic nucleotides are important second messengers in VSMCs 
and are known to affect glucose transport, no work has been done on the role of cyclic 
nucleotides in regulating glucose transport in VSMCs.
Here we showed that analogues of cAMP could stimulate an approximately two-fold 
increase in glucose transport in VSMCs. This stimulation of glucose transport by 
cAMP analogues is not additive with PDGF-stimulated glucose transport, indicating
'.bthat both cAMP and PDGF must use some of the same signalling components to
mediate the increase in glucose transport. The stimulation of glucose transport by
cAMP analogues requires PKA, however, cAMP/PKA are not components of the
PDGF-stimulated signalling pathway mediating glucose transport in VSMCs (as the i
PKA inhibitor, H89, has no effect on PDGF-stimulated glucose transport). As well as I
PKA, both p38 and PI3’ kinase are necessary for cAMP-stimulated glucose transport. r
Ligands that stimulated adenylyl cyclase activity and an increase in intracellular
[cAMP] in VSMCs, such as isoprenaline and iloprost, had no effect on glucose !
transport in VSMCs, however by inhibiting PDE 3 activity, to give a small localised ;
increase in [cAMP], an increase in glucose transport similar to that seen with cAMP
analogues was seen (approximately two-fold). This indicates that it is the spatial
distribution of cAMP in the cell rather than the overall amount of cAMP that is
important in the stimulation of glucose transport in VSMCs.
Analogues of cGMP are without effect on basal glucose transport rates in VSMCs but 
are inhibitory with regard to PDGF-stimulated glucose transport. ANF, a ligand of 
transmembrane guanylyl cyclase, is also inlribitory with regard to PDGF-stimulated 
glucose transport, whereas SNP, an NO donor (NO stimulates soluble guanylyl
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cyclase activity), is without effect on glucose transport in VSMCs. The ability of 
cGMP to inhibit PDGF-stimiilated glucose transport is not via an inhibition of MAP 
kinase activity. The effects of cGMP on PI3’ kinase activity have not yet been 
determined.
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Figure 4.1 2-deoxyglucose transport in VSMCs in response to 8-Br
cAMP with and without PDGF
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with 8-Br cAMP for 1 hour at the 
concentrations shown followed by PDGF (10 ng/ml) a further hour, prior to 2- 
deoxyglucose transport assay. Data from a representative experiment is shown, repeated 
three times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
* represents P < 0.05 when compared to untreated cells as determined by Student’s t-test..
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Figure 4.2 Effect of cAMP analogues on 2-deoxyglucose transport in
VSMCs
2-deoxygIucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with 8-Br cAMP or dibutyryl cAMP for 
1 hour at the concentrations shown, prior to 2-deoxyglucose transport assay. Data from a 
representative experiment is shown, repeated tliree times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
* represents P < 0.05 as compared to basal/untreated cells as determined by Student’s t- 
test.
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Figure 4.3 Time-course of 2-deoxyglucose transport in VSMCs in
response to 8-Br cAMP
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with 8-Br cAMP (0.5 mM) for the times 
indicated, prior to 2-deoxyglucose transport assay. Data from a representative experiment 
is shown, repeated tliree times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
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Figure 4.4 3-O-methyl glucose transport in VSMCs in response 8-Br
cAMP
3-O-methyl glucose transport assay was carried out as described in section 2.6.
Cells were quiesced for 36-48 hours, then treated with 8-Br cAMP (0.5 mM) for 1 hour 
ans 3-O-methyl glucose transport measured for the times indicated. Data from a 
representative experiment is shown, repeated thiee times with similar results.
A.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
cpm of 3-O-methyl glucose transported/well.
B.
The mean cpm/well values were converted using the equation:
-ln((Cm-Ct)/Cm)
where Cm was the maximum cpm/well and Ct was the cpm/well at a given time point, t. 
This gives a straight line, where the gradient of each line represents the rate constant, k, 
for 3-O-methyl glucose.
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Figure 4.5
[^H] thymidine incorporation was determined as described in section 2.11. Cells were 
quiesced for 12-24 hours, then treated with 8-Br cAMP at the concentrations indicated for 
a further 24 hours. 0.5 pCi of [^H] thymidine was added per well for the final 6 hours of 
the incubation with PDGF. Data from a representative experiment is shown, repeated 
tlnee times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation over basal (unstimulated) rates of [^H] thymidine incorporation.
* represents P < 0.05 when compared to basal/untreated cells as determined by Student’s 
t-test.
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Figure 4,6 Effect of PKA inhibitor, H 89, on basal and 8-Br cAMP-
stimulated 2-deoxyglucose transport
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with the PKA inhibitor, H-89 for 15 
minutes, followed by 8-Br cAMP (0.5 mM) for a further hour, prior to 2-deoxyglucose 
transport assay. Data from a representative experiment is shown, repeated three times 
with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
* represents P < 0.05 when compared to cells treated with 8-Br cAMP alone as 
determined by Student’s t test.
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Figure 4.7 RT-PCR analysis o f adenylyl cyclase isoforms expressed in
VSMCs
RT-PCR was carried out to determine which adenyl cyclase isoforms were expressed in 
VSMCs.
mRNA was extracted from cultured VSMCs and reverse transcription was carried out 
using the Wizard RT-PCR kit from Promega as described in section 2.17.11. The 
products of reverse transcription were the used in PCR reactions using the primers 
defined in Table 4.1 and PCR conditions are described in section 2.17.11.
AC I adenyl cyclase 1 
AC II adenyl cyclase II 
AC IV adenyl cyclase IV
AC V adenyl cyclase V 
AC VI adenyl cyclase VI 
AC IX adenyl cyclase IX
M 1 kb ladder
+ RT-PCR positive control
RT-PCR negative control 
S RT-PCR of VSMC mRNA
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Figure 4.8 Effect o f H89 on basal and FDGF-stimulated 2-deoxyglucose
transport
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with the PKA inhibitor, H-89 for 15 
minutes, followed by PDGF (10 ng/ml) for a further hour, prior to 2-deoxyglucose 
transport assay. Data from a representative experiment is shown, repeated three times 
with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
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Figure 4.9 Effect of wortmannin on 8-Br cAMP-stimulated 2-
deoxyglucose transport
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with or without wortmannin (100 nM) 
for 30 minutes followed by 8-Br cAMP (0.5 mM) for a further hour, prior to 2- 
deoxyglucose transport assay. Data from a representative experiment is shown, repeated 
three times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
* represents P < 0.05 when compared to basal untreated cells as determined by Student’s 
t test.
** represents P < 0.05 when compared to cells treated with 8-Br cAMP alone as 
determined by Student’s t test.
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Figure 4.10 Effects o f 8-Br cAMP on the activation/phosphorylation of 
MAP kinases
VSMCS were grown to confluency in 6-well plates and quiesced in serum-free DMEM 
for 36-48 hours. Cells were treated with or without 8-Br cAMP (0.5 mM) for 5, 15 or 60 
minutes and then whole eell lysates were prepared as described in section 2.9. 50pl of 
each lysate was loaded in each lane of a 10 % SDS-PAGE gel and subjected to 
electrophoresis and immunoblotting as described in section 2.8. Blots were developed 
using phospho-specific antibodies to p38, p42/44 and JNK MAP kinases, respectively, 
which only recognise the phosphorylated, therefore activated, kinase. The positive control 
on the JNK blot is from the manufacturers of the antibody (New England Biolabs).
8-Br cAMP stimulated phosphorylation, and activation of p38, but had no effect on the 
phosphoiylation of p42/44 or JNK (although the cross-reactivity of the JNK antibody 
with p42/44 did not allow accurate analysis of this).
These blots are representative of three such experiments.
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Figure 4.11 Effects o f SB 203580 on basal and 8-Br cAMP-stimulated
2-deoxyglucose transport
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with or without SB 203580 for 1 hour 
followed by 8-Br cAMP (0.5 mM) for a further hour, prior to 2-deoxyglucose transport 
assay. Data from a representative experiment is shown, repeated three times with similar 
results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
* represents P < 0.05 when compared to cells treated with PDGF alone as determined by 
Student’s t test.
127
Effect o f SB 203580 on basal and 8-Br 
cAMP-stimulated 2-deoxyglucose transport
2.5
2 ~ '§
s .5 “
;  g-a .2
O.SH
TJL
100100
Basal
8-Br cAMP
[SB 203580]pM
Figure 4.12 Effect of H89 on 8-Br cAMP-stimulated p38 
phophorylation/activation
VSMCS were grown to confluency in 6-well plates and quiesced in serum-free DMEM 
for 36-48 hours. Cells were treated with or without H-89 (50 nM) for 15 minutes 
followed by 8-Br cAMP (0.5 mM) for 5, 15 or 60 minutes and then whole cell lysates 
were prepared as described in section 2.9. 50pl of each lysate was loaded in each lane of a 
10 % SDS-PAGE gel and subjected to electrophoresis and immunoblotting as described 
in section 2.8. Blots were developed using phospho-specific antibodies to p38, which 
only recognise the phosphorylated, therefore activated, kinase.
H-89 has no effect on the ability of 8-Br cAMP to phosphorylate, therefore activate p38. 
These blots are representative of three such experiments.
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Figure 4.13 Isoprenaline-stimulated cAMP generation and 2-
deoxyglucose transport in VSMCs
Upper panel
Adenyl cyclase assay was carried out as described in section 2.16.
Cells were quiesced for 36-48 hours, 24 hours prior to assay the cells were labelled with 
[^H] adenine at 1 pCi/ml. Cells were treated with isoprenaline for 30 minutes, prior to 
adenyl cyclase assay. Data from a representative experiment is shown, repeated three 
times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
Lower Panel
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with isoprenaline for 30 minutes prior 
to 2-deoxyglucose transport assay. Data from a representative experiment is shown, 
repeated three times with similar results.
Each point represents the mean of triplicate determinations + S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
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Figure 4.14 Iloprost-stimulated cAMP generation and 2-deoxyglucose
transport in VSMCs
Upper panel
Adenyl cyclase assay was carried out as described in section 2.16.
Cells were quiesced for 36-48 hours, 24 hours prior to assay the cells were labelled with 
[^H] adenine at 1 pCi/ml. Cells were treated with iloprost or PGEl for 30 minutes, prior 
to adenyl cyclase assay. Data from a representative experiment is shown, repeated three 
times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
Lower Panel
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with iloprost for 30 minutes prior to 2- 
deoxyglucose transport assay. Data from a representative experiment is shown, repeated 
three times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
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Figure 4.15 Effect o f PDE 3 inhibitor, milrinone, on 2-deoxyglucose
transport in VSMCs
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with milrinone for 1 hour prior to 2- 
deoxyglucose transport assay. Data from a representative experiment is shown, repeated 
three times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
* represents P < 0.05 when compared to basal/untreated cells as determined by Student’s 
t-test.
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Figure 4.16 Effects of PDE inhibitors, zaprinast and Ro-20-1724, on 2-
deoxyglucose transport in VSMCs
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with Ro-20-1724 (upper panel), or 
zaprinanst (lower panel) for 1 hour prior to 2-deoxyglucose transport assay. Data from a 
representative experiment is shown, repeated three times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
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Figure 4.17 Effect of 8-Br cGMP on basal and PDGF-stimulated 2-
deoxygiucose transport
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with 8-Br cGMP for 1 hour, followed 
by PDGF ( 10 ng/ml) for 1 hour, prior to 2-deoxyglucose transport assay. Data from a 
representative experiment is shown, repeated three times with similar results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
* represents P < 0.05 when compared to cells treated with PDGF alone as determined by 
Student’s t test.
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Effect o f  8-Br cGMP on basal and 
PDGF “Stimulated 2-deoxyglucose transport
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Figure 4.18 Effects o f ANF and SNP on PDGF-stimulated 2-
deoxyglucose transport
2-deoxyglucose transport assay was carried out as described in section 2.5.
Cells were quiesced for 36-48 hours, then treated with ANF (upper panel) or SNP (lower 
panel) for 30 minutes, followed by PDGF for 1 hour, prior to 2-deoxyglucose transport 
assay. Data from a representative experiment is shown, repeated three times with similar 
results.
Each point represents the mean of triplicate determinations ± S.E.M. Data is expressed as 
a fold stimulation of basal (unstimulated) transport rates.
* represents P < 0.05 when compared to cells treated with PDGF alone as determined by 
Student’s t test.
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Figure 4.19 Effect of ANF on PDGF-stimulated MAP kinase, p38 and 
p42/44, phosphorylation/activation
VSMCS were grown to confluency in 6-weIl plates and quiesced in serum-free DMEM 
for 36-48 hours. Cells were treated with or without ANF (300 nM) for 30 minutes 
followed by PDGF (10 ng/ml) for 5, 15 or 60 minutes and then whole cell lysates were 
prepared as described in section 2.9. 50pl of each lysate was loaded in each lane of a 10 
% SDS-PAGE gel and subjected to electrophoresis and immunoblotting as described in 
section 2.8. Blots were developed using phospho-specific antibodies to p38 and p42/44 
which only recognise the phosphorylated, therefore activated, kinase.
ANF had no effect on the ability of PDGF to phosphorylate, therefore activate, p38 or 
p42/44.
These blots are representative of three such experiments.
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5.1 A im s
The aims of this chapter were:
1. To generate GLUT-1/green fluorescent protein (GFP) chimeras.
2. To use the GLUT-1/GFP chimeras to follow the movement of GLUT-1 within 
cells in response to agonists that stimulate an increase in glucose transport.
3. To determine if GLUT-1 and GLUT-3 are phosphorylated in response to either 
PDGF or cAMP analogues.
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GLUT-1 is thought to be the glucose transporter responsible for the increase in 
glucose transport (Thomson & Gould, 1997).
The acute phase of growth factor-stimulated glucose transport occurs within minutes. 
This is thought to occur by a movement of GLUT-1 from the recycling endosomal
thought that alteration of the intrinsic activity of the transporter itself can regulate the 
rate of glucose transport. For example, in pancreatic p cells, phosphorylation of 
GLUT-2 by PKA reduces the rate of glucose transport in these cells (Thorens et al, 
1996), and in CHO cells phosphorylation of GLUT-4 inhibits glucose transport (Piper
It is of interest, therefore, to determine what role each of these two possible 
mechanisms play in mediating mitogen-stimulated glucose transport.
1I
I5.2 In t r o d u c t io n
Exposure of quiescent cells to mitogens results in the stimulation of numerous 
intracellular signalling cascades, culminating in cell growth and division several hours 
later. Due to the increased energy requirements of growing cells, one of the early 
responses of cells common to all mitogens is an increase in the rate of glucose uptake.
I
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system to the plasma membrane, therefore increasing the number of functional 
transporters at the plasma-membrane, and also possibly via an increase in the intrinsic 
activity of the transporters (Gould and Holman, 1993, Czech et al, 1992). However 
the molecular mechanisms underlying these effects are poorly understood.
As yet, it is unclear what contribution increased transporter activity and increased 
translocation of glucose transporters play in increased glucose transport in response to 
mitogens. In adipose tissue, for example, which expresses the glucose transporter 
GLUT-4, the increase in glucose transport in response to insulin is mediated entirely 
by a translocation of GLUT-4 to the cell surface (Holman & Kasuga, 1997). In 
platelets, thrombin has been shown to stimulate the translocation of the glucose 
transporter GLUT-3 from an intracellular location to the cell surface resulting in 
increased glucose transport (Sorbara et al, 1997). In other work, however, it is "I
»
:e ta l, 1993).
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As discussed above it is likely that mitogen-stimulated transport is mediated via the 
glucose transporter GLUT-1. To study the translocation of GLUT-1 within the cell 
green fluorescent protein (GFP) can be utilised. GFP, from the jellyfish Aequora 
victoria, is a protein of 238 amino acids in a single polypeptide chain (reviewed in 
Tsien, 1998). The chromophore, the part of the protein that confers the fluorescent 
properties on the protein, is formed from residues 65-67, which are Ser-Tyr-Gly in the 
native protein. These residues undergo a series of reactions during protein folding to 
form a/7-hydroxybenzylideneimidazolinone, the chromophore. The protein forms a p- 
barrel from eleven p-strands through which an a-helix is threaded bearing the 
chromophore. GFP fluoresces when the chromophore is hit by photons of the 
appropriate wavelength (in this case 395-397 nm), this causes excitation of electrons 
within the chromophore. When these electrons return to their basal, non-excited state, 
they emit light, the green fluorescence, of wavelength 504 nm (reviewed in Tsien,
:1998). GFP retains its fluorescent properties when recombinantly expressed in both 
prokaryotic and eukaryotic living cells and is therefore a powerful tool for following 
the movement of recombinant proteins within a cell, for example along the secretory 
pathway and membrane traffic pathways (Kaether & Gerdes, 1995, Girotti &
Banting, 1996, Niwaer^/., 1996, Rizzuto 1995).
In this chapter, chimeras of GFP and GLUT-1 were constructed to be used to follow 
the movement of the glucose transporter in live cells in response to mitogens. As well 
as this, the phosphorylation state of both GLUT-1 and GLUT-3 in cultured vascular 
smooth muscle cells in response to 8-Br cAMP and PDGF (see chapters 3 and 4) was 
determined.
I
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5.3 R esu l t s
5.3.1 Generation of GLUT-l/GFP chimeras
To help study the movement of GLUT-1 in response to mitogens within living cells
designed to incorporate restriction sites to allow subcloning of products into the vector 
pcDNA 3 (Figure 5.1). The PCR reactions, restrictions, gel extractions of DNA and 
ligations were carried out as described in section 2.17. Restriction analysis and DNA
than those transfected with the calcium phosphate kit, with the cells showing less 
stress fibres. All further transient transfections were earned out using the QIAGEN 
“Superfect transfection kit” with an incubation period of 3 hours.
I
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GLUT-l/GFP chimeras were made. Both N- and C-terminal tagged GLUT-l/GFP 
were made. Chimeras were made using a PCR-based technique. PCR primers were !
sequencing (as described in section 2.17) confirmed the structure of the chimeras.
To determine which transient transfection method would be most effective in the 
expression of the chimeras different techniques were used, 3T3-L1 fibroblasts were 
grown to the appropriate confluency on coverslips and transiently transfected with the 
N-terminal tagged GLUT-l/GFP using Qiagen’s “Superfect transfection reagent” and 
with Invitrogen’s “Calcium Phosphate transfection kit” according to manufacturer’s
- V:
i
directions. The cells were incubated with the DNA/transfection reagent mix for 
varying times to optimise the transfections. Cells were examined using confocal 
microscopy as described in section 2.18 (Figure 5.2). Transfection using Qiagen’s 
“Superfect transfection reagent” with an incubation of 3 hours, and Invitrogen’s 
“Calcium phosphate transfection kit” with an incubation of 20 hours were the most 
effective methods for transient expression of GLUT-l/GFP chimeras, with each 
technique giving a higher number of cells expressing the chimera (Figure 5.2 A & D). 
Cells transfected with QIAGEN’s “Superfect reagent” appeared slightly less stressed
Next the expression of the N- and C-terminal chimeras was compared. 3T3-L1 
fibroblasts were transiently transfected using Qiagen’s “Superfect transfection 
reagent” with both the N- and C-terminal GLUT-l/GFP chimeras. Cells were
.|;i
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5.3.2 Stimulation of movement of GLUT-l/GFP with PDGF in 3T3-L1 
fibroblasts
3T3-L1 fibroblasts were transiently transfected with N-terminal GLUT-1 GFP, using 
Qiagen’s “Superfect transfection reagent”, as described above. Cells were then
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examined using confocal microscopy, and the distribution of the N- and C-terminal 
chimeras compared (Figure 5.3). The N-terminal chimera shows an even intracellular 
distribution, with a degree of plasma membrane association. The amount of N- 
terminal GLUT-l/GFP seen at the cell surface appeared to vary depending on the level 
of expression of the chimera i.e. high expression levels give rise to an increase in the 
amount of chimera at the cell surface (Figure 5.3 A & B). In contrast the C-terminal 
GLUT-l/GFP chimera showed a veiy punctate distribution within the cell (Figure 5.3 
C & D). The chimera formed small rings clumped together at intracellular sites, and 
no C-terminal GLUT-l/GFP could be seen at the cell surface.
As the C-terminal GLUT-l/GFP chimera showed a punctate intracellular distribution, 
it was possible that the addition of GFP at the C-terminal resulted in mis-targetting of 
the chimera. To determine if the C-terminal GLUT-l/GFP chimera was indeed 
trapped in the recycling endosomes, colocalisation of the chimera with transferrin 
(labelled with Texas-Red). Cells were transiently transfected with C-terminal GLUT- 
l/GFP and 1 hour prior to visualisation of cells, transferrin Texas-Red (20 pg/ml) is 
added to the cells. The transferrin receptor is a well-established prototypic marker for 
the endosomal recycling system, therefore colocalisation of the C-terminal GLUT- 
l/GFP chimera with transferrin Texas-Red would indicate that the chimera is indeed 
trapped in the endosomal network. The C-terminal GLUT-l/GFP chimera was 
completely co-localised with the transfenin Texas-Red (Figure 5.4), indicating that 
the C-terminal chimera was indeed trapped in the recycling endosomes. It is possible 
that as well as being trapped in the endosomal system the chimera disrupts the 
recycling endosomal system as a whole.
All further work using the GLUT-l/GFP chimeras used only the N-terminally tagged 
chimera.
quiesced for ~2-3 hours, then treated with PDGF (10 ng/ml) for a further 1 hour. Cells 
were visualised both before and after treatment with PDGF (Figure 5.5).
Prior to treatment with PDGF the N-terminal GLUT-1 GFP chimera was 
predominantly localised intracellularly, with a small degree of plasma membrane 
association (Figure 5.5 A & B). After treatment with PDGF the degree of plasma 
membrane association appeared to have increased. However, after treatment with 
PDGF, the celPs over all morphology appeared to change, with the cells becoming 
longer and thinner (Figure 5.5 C & D), therefore it was difficult to conclusively 
interpret any changes in the cellular distribution of GLUT-l/GFP in these cells.
Other reagents, such as LPA, insulin and IGF-1, were used to try and stimulate the 
movement of GLUT-l/GFP in these cells, and although they did appear to stimulate a 
degree of translocation of the chimera within the cell the results were variable (results 
not shown). As discussed above, the degree of association of the chimera with the 
plasma membrane is rather variable, depending on the level of expression. This meant 
that in cells expressing a high level of chimera, there was already a high degree of 
plasma membrane association even in quiescent cells, therefore upon treatment with 
PDGF it was difficult to see any increase in plasma membrane association.
5.3.3 Analysis of phosphoiylation state of GLUT-1 and GLUT-3 in VSMCs
Firstly I wished to deteiinine if GLUTs 1 and 3 were substrates for PKA, as PKA is 
required for mediating 8-Br cAMP’s stimulation of glucose transport (see section 
4.3.2). Both GLUT-1 and GLUT-3 contain consensus motifs for PKA phosphoiylation 
(phosphorylation on serine/thi'eonine residues presented in the sequences RRXS/T or 
RXS/T or KRXXS/T (reviewed by Kemp & Pearson, 1990)). GLUTs 1 and 3 were 
immunoprecipitated (IP) from VSMC lysates using anti-GLUT-1, anti-GLUT-3 and 
random IgG as a control, as described in section 2.12. Half of the immunoprecipitates 
were analysed by immunoblotting, as described in section 2.8, to determine that IP 
had been successful (blots developed using protein A-HRP instead of secondaiy 
antibody, to stop cross reactivity of secondary antibodies with denatured GLUT-1 and 
GLUT-3 antibodies in IP samples. Protein A will only recognise antibodies in native
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structure) (Figure 5.6). The other half of the IP was the subjected to in vitro 
phosphorylation using PKA, as described in section 2.13. Samples were then run on 
SDS-PAGE (section 2.7) and the gels were fixed in 14% acetic acid, 7% methanol, 
dried and exposed to X-ray film to identify proteins that had been phosphorylated 
(Figure 5.7). Although the bands from the IPs using GLUT-1 and GLUT-3 were more 
intense than IPs earned out using random IgG, there were no bands phosphoiylated in 
the GLUT-1 and GLUT-3 IPs of the appropriate molecular weight (47-50 IcDa) that 
could represent phosphoiylated GLUT-1 and GLUT-3.
Next, it was considered that perhaps the GLUTs in these cells already had a basal 
level of phosphorylation, as the cells from which the lysates were prepared were not 
quiesced, meaning that no increase in phosphoiylation could be seen. To overcome 
this potential problem, immunoprecipitated GLUTs were first dephosphorylated (see 
section 2.13), then subjected to in vitro phosphoiylation, as above (Figure 5.8). Again 
the intensity of the bands in the lanes from the GLUT-1 and GLUT-3 
immunoprecipitates was far greater than in the lanes from immunoprecipitates carried 
out using random IgG. However, like the previous experiment, there were no bands 
present of the appropriate molecular weight (48-50 kDa) to represent specific 
phosphorylation of GLUT-1 or GLUT-3.
Next, the effects of treating the VSMCs with PDGF and 8-Br cAMP (two reagents 
that can stimulate glucose transport in VSMCs, see chapters 3 and 4) on 
phosphorylation of GLUT-1 and -3 was investigated. In vivo phosphorylation was 
carried out as described in section 2.14. Cells were grown to confluency in 6 well 
plates and quiesced for 36-48 hours, cells labelled with 0.2 mCi/ml [^ ^P] 
oithophosphoric acid for 90 minutes at 37°C to allow the intracellular pool of ATP to 
become ^^ P labelled. After the 90-minute labelling the cells were treated with or 
without PDGF (10 ng/ml) or 8-Br cAMP (1 mM) for 1 hour. Two wells from each 6- 
well plate were used for each condition. After this time immunoprécipitation of 
GLUT-1 and GLUT-3 was carried out as described in section 2.12, and the 
phosphorylation of each GLUT analysed (Figure 5.9). No specific phosphorylation of 
either GLUT-1 or GLUT-3 was observed in response to either PDGF or 8-Br cAMP.
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As very little is understood about the mechanisms mediating increased glucose 
transport in response to mitogens, two strategies were adopted to address this 
question. Firstly, green fluorescent protein (GFP) was used to tag the glucose 
transporter GLUT-1 to allow visualisation of its movement through the cell, and to 
determine what role, if any, translocation of GLUT-1 plays in mediating mitogen- 
stimulated increases in glucose transport. And secondly, as phosphorylation has been 
shown to be able to alter the intrinsic activity of glucose transporters (Thorens et al, 
1996, Piper et al, 1993), the degree of phosphoiylation of the glucose transporters 
GLUT-1 and GLUT-3 was assessed under various conditions.
5.4.1 Generation of GLUT-l/GFP chimeras
Both N and C terminally tagged GLUT-l/GFP chimeras were made. However it was 
found that the C-terminal tagged chimera was mis-targetted within the cell and 
appearred to be trapped in the recycling endosomes (Figure 5.4). There is evidence 
that the C-terminal tail of glucose transporters is very important with regard to correct 
targetting of the transporter to the plasma membrane (Verhey et al, 1993). It is
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5.4  D isc u ssio n
Currently, the mechanism(s) responsible for increased glucose transport in response to 
mitogens is poorly understood. It is believed that an increase in the intrinsic activity of 
the glucose transporters and/or an increase in the number of functional glucose 
transporters at the cell surface are responsible for increased glucose transport 
(Thomson & Gould, 1997).
In some cell systems it is clear that only increased translocation of glucose 
transporters to the cell surface is responsible for increased glucose transport (i.e.
GLUT-4 translocation in response to insulin in adipocytes (Holman & Kasuga,
1997)). In other systems, however, it appears that only altered activity of the
-Itransporter is responsible for changes in the rate of glucose transport (i.e. PKA 
phosphorylation of GLUT-2 in pancreatic (3-cells, Thorens et al, 1996).
1possible therefore that due to the presence of the GFP moiety on the C-terminal tail 
that the GLUT-l/GFP chimera is being mistargetted within the cell, and is unable to 
exit the recycling endosomes to reach the plasma membrane. Another possibile 
explanation for the punctate distribution of the C-terminal GLUT-l/GFP chimera, is 
that the chimera is misfolding and forming an aggresome strucure (Johnston et al,
1998, Garcia-Mata et al, 1999). Aggresomes are a novel structure, that have been 
proposed to represent a general cellular response to misfolded proteins (Jolmston et 
al, 1998), therefore this chimera was not pursued.
The N-terminal chimera showed a much more even intracellular distribution in 
membranes association (Figure 5.3). The degree of chimera associated with the 
plasma membrane appeared to vary depending on the levels of GLUT-l/GFP 
expressed. In cells expressing a high level of chimera there was a greater level of i
membrane association (Figure 5.3 B), whereas in cells with a low level of chimera 
expression (Figure 5.3 A). This is the kind of expression pattern expected if the GFP 
was not altering the pattern of GLUT-1 expression and targetting.
5.4,2 Stimulation of movement of GLUT-l/GFP with PDGF in 3T3-L1 
fibroblasts
The movement of the N-terminally tagged GLUT-l/GFP was studied in response to 
PDGF and various other agonists Itnown to stimualte glucose transport in 3T3-L1 
fibroblasts. Treatment of quiesced cells for 1 hour with PDGF resulted in a 
redistribution of the chimera, from diffuse intracellular expression to a more 
membrane associated pattern. However, during incubation of cells with PDGF, the 
cells appeared to undergo a morphology change. When cells were first visualised they 
had an even rounded shape, however after a period of time they became elongated and 
occasionally extended stress fibres. (Figure 5.5). The change in cell morphology 
made analysis of GLUT-l/GFP translocation very difficult, and it was difficult to 
determine if it was the change in morphology or the agonist that was causing 
redistribution of the chimera to the cell surface (stress will also stimulate an increase 
in glucose transport).
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In addition to the reshaping of the cells, further problems were encountered in that the 
level of plasma membrane association of the chimera varied greatly depending on the 
levels of expression of the chimera (Figure 5.3 A & B). Even in cells that had not been |
treated with agonist there could be a high degree of chimera at the cell surface if there 
was a high level of expression of the chimera (Figure 5.3 B). This meant that in these 
cells it was difficult to see any increase in the amount of chimera at the cell surface in 
the presence of agonist.
A number of other agonists known to stimulate glucose transport in 3T3-L1 
fibroblasts, such as LPA and IGF-1, were also used, and although they did appear to 
stimulate a degree of translocation of the chimera within the cell the results were 
variable (results not shown). Similar problems were encountered using these agonists 
as were encountered with PDGF.
5.4.3 Analysis of phosphorylation state of GLUT-1 and GLUT-3 in VSMCs
cAMP analogues were able to stimulate an increase in 2-deoxyglucose transport in a 
PKA dependant manner (see section 4.3). It was interest therefore to determine if 
either GLUT-1 or GLUT-3 are substrates for PKA, as this is a potential mechanism 
for mediating the increase in glucose transport. Both GLUT-1 and -3 contain a 
number of potential PKA phosphorylation sites (serine/threonine residues presented in 
the sequences RRXS/T or RXS/T or KRXXS/T, reviewed by Kemp & Pearson,
1990). However neither immunoprecipitated GLUT-1 nor GLUT-3 were 
phosphorylated in vitro by PKA (Figure 5.6). To ensure that the GLUTs 1 and 3 were 
not phosphorylated prior to in vitro phosphorylation the immunoprecipitated GLUTs 
were dephosphoiylated before in vitro phosphorylation. Dephosphorylation of the 
immunoprecipitated GLUTs had no effect on PKA’s ability to phosphorylate GLUT-1 
or GLUT-3 (Figure 5.7). Therefore it is veiy unlikely that the ability of cAMP 
analogues to stimulate glucose transport in VSMCs is mediated by direct 
phosphorylation of glucose transporters by PKA.
Next, it was determined if GLUT-1 and GLUT-3 were phosphorylated in vivo in 
response to either PDGF or 8-Br cAMP (both agents which have been shown to
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stimulate increased glucose transport in VSMCs, see Chapters 3 and 4). As with the in 
vitro phosphorylation there were no specific bands present in cells treated with PDGF 
or 8-Br cAMP as compared to control cells (Figure 5.8). It is unlikely therefore that 
either PDGF or 8-Br cAMP mediates increased 2-deoxyglucose transport via 
phosphorylation of GLUT-1 or GLUT-3 resulting in altered glucose transporter 
activity.
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5.5  Su m m a r y
GLUT-l/GFP chimeric proteins were utilized to analyse the movement of GLUT-1 in 
response to mitogens. The C-terminally tagged GLUT-l/GFP showed a punctate 
intracellular distribution that colocalised with transferrin-Texas-Red. This indicated 
that the C-terminal GLUT-l/GFP was trapped in the recycling endosomal system. 
There is evidence that the C-terminal tail of GLUT-1 contains motifs that are very 
important for its correct targetting to the plasma membrane (Verhey et al, 1993). It is 
likely therefore that the C-terminally tagged GLUT-l/GFP is trapped in the recycling 
endosomes because of the presence of the GFP moiety on the C-terminal tail of the 
transporter interfering with the targetting signals.
The N-terminal GLUT-l/GFP chimera showed a much more even intracellular 
distribution with a degree of membrane association. Treatment of cells expressing the 
N-terminal GLUT-l/GFP chimera resulted in movement of the chimera from this 
intracellular location to the plasma membrane. However the degree GLUT-l/GFP 
associated with the plasma membrane in untreated cells was very variable making 
analysis of any movement of GLUT-l/GFP difficult.
The phosphorylation state of the glucose transporters GLUT-1 and GLUT-3 was 
investigated. Neither GLUT-1 nor GLUT-3 was a substrate for PKA in vitro. There 
was no increase in the phosphoiylation of GLUT-1 and GLUT-3 in vivo in response to 
either PDGF or 8-Br cAMP. Therefore it seems unlikely that increased glucose 
transport in VSMCs in response to mitogens is mediated by altered activity of glucose 
transporters via phosphorylation of GLUTs.
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Figure 5.1 PCR based method used to synthesize G LUT-l/G FP  
chimeras
PCR reactions were carried out as described in section 2.17.1. PCR primers were 
designed to incorporate restriction sites that would allow subcloning of products into 
pcDNA 3, and to remove stop and start codons that would occur in the middle of the 
chimera. Once PCR products were generated they were restricted (see section 2.17.7) and 
cloned into the appropriate restriction sites of the expression vector pcDNA3 (ligations 
described in section 2.17.8). Restriction analysis and DNA sequencing (section 2.17.7 
and 2.17.11) confirmed the structure of the chimeras.
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N-term inally tagged GLUT-1
Kpnl START
1. TTTTGGTACÇGACGAGATGAGTAAAGGAGAAGAA
KOZAK
EcoRI
3. TTTTGAATTCGAGCCCAGCAGCAAGAAGGTC
GLUT-1GFP
4.CCCGACTGAGGGTTCACACTGAGCTCTTTTI2. CTACTTGATATGTTTCTTAAGTTTT
STOP XholEcoRI
C-term inally tagged GLUT-1
BgIR START
5, TTTTGAAGATCTGACGAGATGGAGCCCAGCAGC
EcoRI
KOZAK
7. TTTTGAATTCAGTAAAGGAGAAGAACTX
GFPGLUT-1
6. CCCCCGACTGAGGGTTCAÇCTTAAGTTTT
EcoRI
. CTACTTGATATGTTT. AGCTCTTTT
STOP Xhol
Figure 5.2 Optimising transient transfection method for expression of 
G LUT-l/G FP chimeras
3T3-L1 fibroblasts were transiently transfected with the N-terminal GLUT-l/GFP 
chimera using a variety of methods to determine the most effective technique for transient 
transfection, and visualised using confocal microscopy as described in section 2.18.
A & B Cells transfected using QIAGEN’s “Superfect transfection reagents” with 
incubations of 3 and 6 hours respectively.
C & D Cells transfected using Invitrogen’s “Calcium phosphate transfection kit” with 
incubations of 6 and 20 hours respectively.
Shown are images representative of three such experiments with similar results.
Transfection using Qiagen’s “Superfect transfection reagent” with an incubation of 3 
hours, and with Invitrogen’s “Calcium phosphate transfection kit” both gave the highest 
rate of transfection (A & D). Cells transfected with Qiagen’s “Superfect reagent” looked 
less stressed than those transfected with the calcium phosphate reagent, therefore all 
further transfections were carried using Qiagen’s “Superfect transfection reagent” with an 
incubation of 3 hours.
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Figure 5.3 Comparison of distribution of N-terminal and C-terminal 
tagged G LUT-l/G FP chimeras
3T3-L1 fibroblasts were transiently transfected with both the N- and C-terminal GLUT- 
l/GFP chimera using Qiagen’s “Superfect transfection reagent” with an incubation of 3 
hours. Cells were visualised using confocal microscopy as described in section 2.18.
A «& B 3T3-L1 fibroblasts expressing the N-terminal GLUT-l/GFP chimera.
C & D 3T3-L1 fibroblasts expressing the C-terminal GLUT-l/GFP chimera.
Shown are images representative of three such experiments.
The N-terminal chimera shows an even intracellular distribution with a degree of 
membrane association. The degree of plasma membrane association appears to increase 
as the level of expression of the chimera increases.
The C-terminal chimera shows a punctate intracellular distribution with no membrane 
association at all.
1 5 1

Figure 5.4 Colocalisation of C-terminal GLUT-l/G FP with transferrin- 
texas red
3T3-L1 fibroblasts were transiently transfected with the c-terminal GLUT-/GFP using the 
QIAGEN’S “Superfect transfection reagent”. 1 hour prior to visualisation cells were 
treated with transferrin Texas-Red (20 pg/ml). Cells were visualised using confocal 
microscopy and images were merged using Metamorph software as described in section 
2.18.
A GLUT-l/GFP localisation within cells.
B Transfemn Texas-Red localisation within 3T3-L1 fibroblasts.
C Colocalisation of GLUT-l/GFP and transferrin texas red.
Shown are images representative of three such experiments.
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Figure 5.5 Translocation of N-terminal G LUT-l/G FP in response to
PDGF
3T3-L1 fibroblasts were transiently transfected using QIAGEN’s “superfect transfection 
reagent”. Cells were quiesced for 2-3 hours, then treated with PDGF (10 ng/ml). Cells 
were visualised using confocal microscopy as described in section 2.18, before and after 
treatment with PDGF.
A & B 3T3-L1 fibroblasts expressing the N-terminal GLUT-l/GFP chimera which have 
been quiesced for 2 hours.
C  & D  3T3-L1 fibroblasts expressing the N-terminal GLUT-l/GFP chimera which have 
been quiesced for 2 hours and treated with PDGF for a further 1 hour.
Shown are images representative of thi'ee such experiments.
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Figure 5.6 Immunoprécipitation o f GLUTs 1 and 3 from VSMCs
Whole cell lysates were prepared form VSMCs as described in section 2.9 and GLUTs 1 
and 3 were immunoprecipitated from the lysates (as described in section 2.12). As a 
control the immunoprécipitations were carried out using random IgG as well as 
antibodies to GLUT-1 and GLUT-3.
Samples from the immunoprécipitations, using either the GLUT-1 or GLUT-3 antibodies 
as indicated, were run on a SDS-PAGE and subjected to immunoblotting. Immunoblots 
were developed using protein A-HRP instead of a secondary antibody, as secondary 
antibodies would cross react with denatured GLUT-1 and GLUT-3 antibodies within the 
immunoprecipitated samples, whereas protein A only recognises antibodies in their native 
structure.
The position of molecular weight markers are illustrated on the left side of the figure in 
kilo Daltons (kDa).
+ve control Sample of rat brain whole cell lysate
SN Supernatant left after immunoprécipitation of GLUTs
aG l, G3 Immunoprecipitated GLUT-1 and GLUT-3 respectively
IgG Immunoprecipitates carried out using random IgG
Shown is a representative blot. There is very little GLUT-1 or GLUT-3 left in the 
supernatant from the immunoprecipitates and virtually all the GLUT-1 and GLUT-3 has 
been successftilly immunoprecipitated. Random IgG did not immunoprecipitate any 
significant amount of GLUT-1 or GLUT-3.
All immunoprécipitations were checked in this manner before being used for in vitro 
phosphorylations.
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Figure 5.7 In vitro phosphorylation of GLUTs 1 and 3 with PKA
GLUTs 1 and 3 were immunoprecipitated from VSMCs (section 2.12) and subjected to in 
vitro phosphoiylation with PKA (see section 2.13). As a control samples were 
immunoprecipitated with random IgG and subjected to phosphorylation with PKA. 
Samples were analysed by running on SDS-PAGE, gels were dried and exposed to X-ray 
film to identify phosphoiylated proteins.
The position of moleculai' weight markers are illustrated on the left side of the figure in 
kilo Daltons (kDa).
IgG proteins immunoprecipitated using random IgG
aG l, G3 proteins immunoprecipitated using antibodies to GLUT-1 and GLUT-3
respectively
Shown is a representative figure of tlu*ee such experiments.
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Figure 5.8 In vitro phosphorylation of GLUTs 1 and 3 with PKA after
déphosphorylation with PP2A
GLUTs 1 and 3 were immunoprecipitated from VSMCs (as described in section 2.12). 
Immunoprecipitates were dephosphorylated with (protein phosphatase 2A) PP2A then 
subjected to in vitro phosphorylation with PKA (see section 2.13). As a control samples 
were immunoprecipitated with random IgG , dephosphorylated and subjected to in vitro 
phosphoiylation with PKA. Samples were analysed by running on SDS-PAGE, gels were 
dried and exposed to X-ray film to identify phosphorylated proteins.
The position of molecular weight markers are illustrated on the left hand side of the figure 
in kilo Daltons (kDa).
IgG proteins immunoprecipitated using random IgG
aGl/G3 proteins immunoprecipitated using antibodies to GLUT-1 and GLUT-3
respectively
Shown is a representative figure of three such experiments.
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Figure 5.9 In vivo phosphorylation of GLUTs 1 and 3 in VSMCs
treated with PDGF and 8-Br cAMP
Cells were grown to confluency in 6 well plates and quiesced for 36-48 hours, labelled 
with [^^P], then treated with or without PDGF (10 ng/ml) or 8-Br cAMP (1 mM) for 1 
hour, and in vivo phosphorylation carried out as described in section 2.14. Two wells 
from each 6-well plate were used for each condition. After this time immunoprécipitation 
of GLUT-1 and GLUT-3 was carried out as described in section 2.12, and the 
phosphorylation of each GLUT analysed.
The position of molecular weight markers are illustrated on the left hand side of the figure 
in kilo Daltons (kDa).
Shown is a representative figure of tiu'ee such experiments.
No bands were present at the appropriate size (47-50 kDa) to represent specific 
phosphoiylation of either GLUT-1 or GLUT-3 in response to either PDGF or 8-Br cAMP.
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Atherosclerosis is an inflammatory disease of the vasculature, and is a major contributor 
to the progression of coronaiy heart disease. Fundamental to plaque development is 
increased proliferation and migration of vascular smooth muscle cells (VSMCs) within 
the plaque (Ross, 1993). The aberrant proliferation and migration of VSMCs within the 
plaque is stimulated by the secretion of a number of growth factors and cytokines by 
endothelial cells, macrophages, lymphocytes and VSMCs themselves within the plaque 
(Bobik & Campbell, 1993). PDGF is believed to be one of the most important growth 
factors involved in mediating increased VSMC proliferation in plaque development 
(Ross, 1993).
Increased glucose transport is an early cellular response common to all mitogens 
(Thomson & Gould 1997). As increased proliferation of VSMCs is an important factor in 
atherosclerotic plaque development it is reasonable to assume that this is accompanied by 
increased glucose transport in VSMCs. However, to date, very little is known about 
regulation of glucose transport in VSMCs. The work in this thesis investigated the 
regulation of glucose transport in VSMCs.
It was shown that vascular smooth muscle cells freshly isolated from aorta expressed both 
GLUT-4 and GLUT-1 glucose transporters. However as the cells were isolated and 
cultured, GLUT-4 was lost from the cells and the levels of the glucose transporter GLUT- 
3 increased. The levels of GLUT-1 were unchanged in freshly isolated VSMCs as 
compared to cells that had been passaged in cell culture.
PDGF (a growth factor believed to be important in regulating VSMC growth in plaque 
development, Bobik & Campbell, 1993) was able to stimulate a two- to five-fold increase 
in 2-deoxyglucose transport in VSMCs and this increase in glucose transport was 
dependent on the activity of both PI3’ kinase and the MAP kinases p38 and p42/44.
Cyclic nucleotides are important regulators of smooth muscle cell function, regulating 
such things as proliferation and relaxation (Landgraf et al, 1992, Murthy & Makhlouf,
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1995,Toyoshima et al, 1998, Ki'onemann et al, 1999, Chiche et al, 1998), and as such 
their role in regulating glucose transport in VSMCs was studied. Like PDGF, analogues 
of cAMP were able to stimulate a two-fold increase in 2-deoxyglucose transport in 
VSMCs. This cAMP-stimulated increase in glucose transport was not additive with 
PDGF-stimulated glucose transport, cAMP-stimulated glucose transport, like PDGF- 
stimulated glucose transport, was dependent on the activity of PI3’kinase and the MAP 
kinase p38, however MAP kinase p42/44 was not activated in response to cAMP 
analogues. As well as p38 and PI3’ kinase, cAMP-stimulated 2-deoxyglucose transport 
was dependent on protein kinase A (PKA) activity. Although cAMP analogues can 
stimulate an increase in 2-deoxyglucose transport, agonists that stimulate a large increase 
in intracellular [cAMP] are unable to stimulate an increase in 2-deoxyglucose transport in 
VSMCs. However, by using inliibitors of PDE 3, which would result in a small but very 
localised increase in [cAMP], a two-fold increase in 2-deoxyglucose transport can be 
achieved. This suggests that the subcellular localisation of any increase in [cAMP] is vital 
to increase glucose transport rates, rather than the overall concentration of intracellular 
cAMP.
Analogues of cGMP had no effect on basal glucose transport rates, but was inhibitory 
with regard to PDGF-stimulated 2-deoxyglucose transport in VSMCs. This was an 
unexpected result as cAMP and cGMP often work in concert to mediate their effects in 
VSMCs. Treating the cells with ANF, which will stimulate transmembrane guanylyl 
cyclase activity, and increase intracellular [cGMP], could mimic the effect of cGMP 
analogues on PDGF-stimulated 2-deoxyglucose transport, but SNP, which will stimulate 
soluble guanylyl cyclase activity and increase intracellular [cGMP] was without effect on 
PDGF-stimulated glucose transport rates.
Attempts were made to understand the mechanisms responsible for increased glucose 
transport, in terms of translocation and altered activity of glucose transporters. Work 
using chimeric proteins of GLUT-1 and GFP were of limited use. The degree of plasma 
membrane association of the chimera was very variable making it difficult to interpret any
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movement of the chimera from intracellular sites to the plasma membrane. Work 
analysing the phosphorylation states of the glucose transporters in VSMCs indicated that 
neither GLUT-1 nor GLUT-3 were phosphorylated in response to either PDGF or cAMP 
analogues. It is therefore unlikely that phosphorylation of glucose transporters is 
responsible for altered rates of glucose transport in VSMCs in response to PDGF or 
cAMP analogues.
The work carried out in thesis has touched on several interesting areas that could be 
further investigated in the future. For example, the possibility that a small localised 
increase in [cAMP] is required to increase 2-deoxyglucose transport in VSMCs, rather 
than a large increase in the overall [cAMP]. Recent work on the translocation of the 
transporter protein, aquaporin, has illustrated that it is indeed the subcellular localisation 
of cAMP, and the PKAs that can be activated at this location, that are important for 
increased translocation of aquaporin to the cell surface (Klussmann et al, 1999). By 
treating cells with a peptide which prevents the binding of regulatory subunits of PKA 
and AKAPs (proteins to which PKA regulatoiy subunits bind, conferring a specific 
subcellular localisation upon the PKA) the ability of agents which increase intracellular 
[cAMP] to cause translocation of aquaporin to the cell surface was lost. If possible, it 
would be valuable to carry out similar work in VSMCs, to determine if the increase in 
glucose transport seen in response to the PDE 3 inhibitor, milrinone, was lost if the 
subcellular localisation of the appropriate PKAs was disrupted. This would allow us to 
determine if it is indeed a small localised increase in [cAMP] that is required to increase 
glucose transport in VSMCs.
Other work of interest to pursue is to investigate the mechanisms by which cGMP inliibit 
PDGF-stimulated glucose transport. It is laiown that VSMCs in culture do not express 
PKG, the cGMP activated kinase (Cornwell et al, 1994). Therefore the effects of cGMP 
on PDGF-stimulated glucose transport must be mediated via some other mechanism, 
perhaps by direct inhibition of some of the signalling proteins required for PDGF- 
stimulated glucose transport. In this thesis, it has been shown that ANF (which will
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generate cGMP, and is capable of inhibiting PDGF-stimulated glucose transport) does not 
affect PDGF’s ability to stimulate p38 or p42/44 activity, therefore cGMP is not 
inhibiting PDGF-stimulated glucose transport at this level. The only other signalling 
molecule that has been shown to be involved in PDGF-stimulated glucose transport is 
PI3’ kinase. The effects of cGMP on PI3’ kinase activity in VSMCs have not yet been 
studied, and this would be a logical protein to investigate.
Although several difficulties were encountered in using the GLUT-l/GFP chimeras, with 
more time better use could have been made of these. For example, one of the biggest 
problems in using the N-terminal GLUT-l/GFP was that the degree of chimera associated 
with the plasma membrane was very variable. If the cells were expressing high levels of 
chimera there tended to be a higher degree of plasma membrane association. One way in 
which this problem may be overcome is if cells were stably transfected to express the 
chimera. This way cells could be selected that express a more moderate level of chimera 
and show an even intracellular distribution of chimera in basal/untreated cells, and the 
movement of the chimera would be more easy to follow and quantify.
162
R e f e r e n c e s
Aass H., Skomedal T. & Osnes J. Molecular and Cellular Cardiology 20, 847-860 
(1988).
Backer J.M., Myers M.G., Sun X. et al. Journal o f Biological Chemistry 268, 8204- 
8212 (1993).
Baldwin J.M., Baldwin J.M. & Leinhard G.E. Biochemistry 21, 3837-3842 (1982).
Barrett M.P., Walmlsey A.R. & Gould G.W. Current Opinion in Cell Biology 11, 
496-502 (1999).
Banos L.F., Marchant R.B. & Baldwin S.A. Biochemical Journal 309, 731-736 
(1995).
Battegay E.J., Raines E.W., Seifert R.A., Bowen-Pope D.F. & Ross R. Cell 63, 515- 
524(1990^
Benzakour O., Kanthou C., Kanse S.M., Scully M.F., Kaldcar V. V., & Cooper D.N. 
Thrombosis and Haemostasis 75, 854-858 (1996).
Bobik A. & Campbell J.H. Pharmacological Reviews 45, 1-42 (1993).
Bolger G.B. Cellular Signalling 851-859 (1994).
Bolger G.B., McPhee I. & Houslay M.D. Journal o f Biological Chemistry 271, 1065- 
1071 (1996).
Bos J.L. Trends in Biochemical Science 20, 441-442 (1995).
163
Brant A.M., McCoid S.C., Thomas H.M., Davies A., Baldwin S.A., Parker J.C., 
Gibbs E.M. & Gould G.W. Cellular Signalling 4, 641-650 (1992).
Brüggermann A., Prado L.A., Stiilimer W. & Pongs O. Nature 365, 445-448 (1993).
Burant C.F., Takeda J., Brot-Laroche E., Bell G.I. & Davidson G.Q. Journal o f 
Biological Chemistry 267^14523-14526 (1992).
Campbell G.R. & Campbell J.H. Experimental Molecular Pathology 42, 139-162 
(1985^
Canos E. & Mahadevan L.C. r/55'20, 117-122 (1995).
Carpenter C.L., Auger K.R., Chanudhuri M. et al. Journal o f Biological Chemistry
268, 9478-9483 (1993).
Chamley-Campbell J.H., Campbell G.R. &Ross R. Physiol.RevieM>s 59, 1-61 (1979).
Chiche J., Schlutsmeyer S.M., Bloch D.B., de la Monte S.M., Robetrs Jr. J.D., 
Filippov G., Janssens S.P., Rosenzweig A. & Bloch K.D. The Journal o f Biological 
273, 34263-34271 (1998).
Chinkers M., & Wilson E.M. Journal o f  Biological Chemistry 267, 18589-18597
(1992).
Chuang L.M., Hausdorff S.F., Myers M. Jr. et al. Journal o f  Biological Chemistry
269, 27645-27649 (1994).
Clarke J.F., Young P.W., Yonezawa K. et al. Biochemical Journal 300, 631-635
(1994).
Coffer P.J., Jing J., Woodgett J.R. Biochemical Journal 335, 1-13 (1998).
164
Colledge M. & Scott J.D. Trends in Cell Biology 9, 216-221 (1999).
Cornelius P., Marlowe M., Call K. & Pekala P.H. Journal o f Cellular Physiology 146, 
298-308 (1991).
Cornwell T.L., Soft G.A., Traynor A.E. & Lincoln T.M. The Journal o f Vascular 
Research 31, 330-337 (1994).
Corvera S.,& Czech M.P. Trends in Cell Biology 8, 442-427 (1998).
Cushman S.W. & Wardzala L.J. Journal o f Biological Chemistry 255, 4758-4762 
(1980).
Czech M.P., Clancy B.M., Pessino et al. Biochemical Science 17, 197-201 (1992).
Davidson N.O., Hausman A.M.L., Iflcovits C.A., Buse J.B., Gould G.W., Burant C.F. 
& Bell G.L JowrW  q/'P/zyjm/ogy 262, C795-C800 (1992).
Davis R.J. Trends in Biologicl Science 19, 470-473 (1994).
de Jonge FI.R. Advances in Cyclic Nucleotide Research 14, 315-333 (1981).
De Rooij J., Zwartlcruis F.J.T., Verheijen M.FÏ.G., Cool R.H., Nijman S.M.B., 
Wittinghofer A. & Bos J.L. Nature 396, 474-477 (1998).
DelFAcqua M.L. & Scott J.D. The Journal o f Biological Chemistry 272, 12881-12884
(1997).
DiFrancesco D. & Tortora P. Nature 351, 145-147 (1991).
Edelmann A.M., Blumenthal D.K. & Ki'ebs E.G. Annual Review o f Biochemistry 56, 
567-613 (1987).
165
Egan S.E., Giddings B.W., Brooks M.W., et a l Nature 363, 45-51 (1993).
Evans J.L., Honer C.M., Wolmelsdorf B.E. et al. Cellular Signalling 0007, 365-376 
(1995).
Fanti W.J., Johnson D.E. & Williams L.T. Annual Review o f Biochemistry 62, 453- 
481 (1993).
Farese R.V., Rosie N., Standaert M. et al. Diabetes 35, 951-957 (1986).
Faux M.C. & Scott J.D. Cell 85, 9-12 (1996).
Fischer Y., Kamp J., Thomas J., Popping S., Rose H., Caipéné C. & Kammermeier H. 
American Journal o f Physiologyf 270, C1211-1220 (1996).
Fisher D.A., Smith J.F., Pillar J.S., St. Denis S.FI. & Cheng J.B. The Journal o f 
Biological Chemistry 273, 15559-15564 (1998).
Flier J.S., Muecklar M., McCall A. & Lodish El.F., Journal o f Clinical Investigation 
79,657-661 (1987).
Francis S.H. & Corbin ]ID. Advances in Pharmacology 26, 115-170 (1994).
Frost S.C. & Lane M.D. Journal o f Biological Chemistry 260, 2646-2652 (1985), 
Fujiwara R. &Nakai T. Atherosclerosis 127, 49-57 (1996).
Fukomoto FT, Seino S., Imura H., Seino Y. & Bell G.L, Diabetes 37, 647-661 (1988).
Fukomoto H., Seino S., Imura H., Seino Y., Eddy R.L., Fukushima Y., Byers M.G., 
Shows T.B. & Bell G.I. Proceedings o f the National Academy o f Science U.S.A. 85, 
5434-5438 (1988).
166
Gamm D.M., Francis S.H., Angelotti T.P., Corbin J.D. & Uhler M.D. The Journal o f  
Biological Chemistry 270, 27380-27388 (1995).
Garbers D.L. & Lowe D.G. The Journal o f  Biological Chemistry 269, 30741-30744
(1994).
Garcia-Mata R., Bebok Z., Sorscher E.J. & Sztul E.S. Journal o f Cell Biology 146, 
1239-1254 (1999).
Gibbs A.F., Chapman D. &, Baldwin S.A. Biochemical Journal 256, 421-427 (1988).
Gibbs E.M., Lienhard G.E. & Gould G.W. Biochemistry 27, 6681-6685 (1988).
Girotti M. & Banting G. Journal o f Cell Science 109, 2915-2926 (1996).
Gonzales-Crussi F. American Journal o f Anatomy 130, 441-460 (1971).
Gould G.W., Brant A.M., Kahn B.B., Shepherd P R., McCoid S.C. & Gibbs E.M.
35, 304-309 (1992).
Gould G.W. & Holman G.D. Biochemical Journal 295, 329-341 (1993).
Gould G.W., Jess T.J., Andrews G.C., Herbst J.J., Plevin R.J. & Gibbs E.M. Journal 
o f Biological Chemistry 269, 26622-26625 (1994).
Gould G.W., Cuenda A., Thomson F.J., Cohen P. Biochemical Journal 311, 735-738
(1995).
Gould G.W. In: Facultative Glucose Transporters, Molecular Biology Intelligence 
Unit. ppl0-12 (1997).
167
Heil W.G., Landgraf W. & Hofmann F. European Journal o f Biochemistry 168, 117- 
121 (1987).
Hempel C.M., Vincent P., Adams S.R., Tsien R.Y. & Selverston A.I. Nature 384, 
166-169 (1996).
Hiraki Y., Rosen O.M. & Birnbaum M.J. Journal o f Biological Chemistry 263, 
13655-13662 (1988).
Hobbs A.J. Trends in Pharmacological Science 18, 484-491 (1997).
Holman G.D. & Kasuga M. Diabetologia 40, 2990-1003(1997)
Horowitz A., Menice C.B., Laporte R. & Morgan K.G. Physiological Reviews 76, 
967-1003 (1996).
Hosaka Y., Tawata M., Kurihara A., Ohtaka M., Endo T. & Onaya T. Endocrinology 
131, 159-165 (1992).
Houslay M.D. and Milligan G. Trends in Biological Sciences 22, 217-224 (1997). 
Hurley J.H. Current Opinion in Structural Biology 8, 770-777 (1998).
Iyengar R. PHS'PP JbwfW  7, 768-775 (1993).
Jarchau T., Hausler C., Markert T., Pohler D., Vandekercldiove J., de Jonge H.R., 
Lohmann S.M. & Walter U. Proceedings o f the National Academy o f Sciences U.S.A. 
91,9426-9430(1994).
Jolmson R.A., Alvarez R. & Salomon Y. Methods in Enzymology 238, 31-56 (1994).
Johnston J.A., Ward G.L. & Kopito R.R. Journal o f Cell Biology 143, 1883-1898 
(1998).
168
Jung C.Y. Journal o f  Membrane Biology 5, 200-214 (1971).
Jureviçius J. & Fiscluneister R. Proceedings o f the National Academy o f Science 
US-.X. 93,295-299(1996).
Kaether C. & Gerdes FI. FEBS Letters 369, 267-271 (1995).
Katsura T., Gustafson G.E., Ausiello D.A. & Brown D, American Journal o f  
Physiology 272, F816-F822 (1997).
Kayano T., Burant G.F., Fukomoto H., Gould G.W., Fan Y.S., Eddy R.L., Byers 
M.G., Shows T.B., Seino S. & Bell G.I. Journal o f Biological Chemistry 265, 13276- 
13282(1990).
Kemp B.E. & Pearson R.B. Trends in Biological Science 15, 342-347 (1990).
Kihara S., Ouchi N., Funahashi T., Shinohara E., Tamura R., Yamashita S. & 
Matsuzawa Y. Atherosclerosis 136, 163-168 (1998).
Kitagawa K., Nishino H. & Iwashima A. Biochim. Biophys. Acta. 887, 100-104
(1986).
Kitagawa T., Tanaka M. & Akamatsu Y. Biophys. Acta. 980, 100-108 (1989).
Klussmann E., Marie K., Wiesner B., Beyermann M. & Rosenthal W. The Journal o f 
Biological Chemistry 274, 4934-4938 (1999).
Kohn A.D., Summers S.A., Birnbaum M.J. & Roth A. Journal o f Biological 
2 7 1 , 31372-31378 (1996).
Komalavilas P. & Lincoln T.M. The Journal o f Biological Chemistry 269, 8701-8707
(1994).
169
Komalavilas P. & Lincoln T.M. The Journal o f  Biological Chemistry 271, 21933- 
21938(1996).
ICronemann N., Nocldier W.A., Busse R. & Schini-Kerth V.B. British Journal o f 
Pharmacology 126, 349-357 (1999).
Kuhne M.R., Pawson T., Leinhard G.E. et al., Journal o f Biological Chemistry 268, 
21478-21481 (1993).
Kumar R., Caitledge W.A., Lincoln T.M. & Pandey K.N. Hypertension 29, 414-421
(1997).
Landgraf W., Ruth P., Keilbach A., May B., Welling A. & Hofmann F. Journal o f  
Cardiovascular Pharmacology 20, S18-S22 (1992).
Lazar D.F., Wiese R.J., Brady M.J. et al. Journal o f Biological Chemistry 270, 20801- 
20807 (1995).
Ledoux S., Dussaule J., Chatziantoniou C., Ardaillou N., Vandermeersch S. & 
Ardaillou R. American Journal o f Physiology 272, C82-C89 (1997).
Leevers S.J., Vanhaesabroeck B. & Waterfield M.D. Current Opinion in Cell Biology 
11,219-225 (1999).
Lemmon M.A., Falasca M., Ferguson K.M. & Schlessinger J. Trends in Cell Biology 
7,237-242(1997).
Libby P., Warner S.J.C., Salomon R.N. & Birinyi L.K. New England Journal o f 
318, 1493-1498 (1988).
Lin M.C., Almus-Jacobs F., Chen H.H. et al. Journal o f Clinical Investigation 99, 
737-744 (1997).
170
Lônnroth P., Davies J.L, Lomii'oth I. & Smith U. Biochemical Journal 243, 789-795
(1987).
MacEwan D.J., Kim G.D. & Milligan G. Molecular Pharmacology 48, 316-325 
(1995).
MacEwan D.J. & Milligan G. Molecular Pharmacology 50, 1479-1486 (1996).
Magiin R., Biirgering B.M., Coffer P.J., Pardasani D., Lin Y., Charbot J. & Sorisky A. 
Endocrinology 137, 3590-3593 (1996).
Manganiello V.C., Murata T., Taira M., Belfrage P. & Degerman E. Archives o f  
Biochemistry and Biophysics 322, 1-13 (1995).
McPhee L, Pooley L., Lobban M., Bolger G. & Houslay M.D. Biochemical Journal 
310, 965-974 (1995).
Merrall N., Wakelam M.J.O., Plevin et al. Biochim. Biophys. Acta. 1117, 191-198
(1993).
Merrall N.W., Plevin R.J., Stokoe D. et al. Biochemical Journal 295, 351-355 (1993). 
Milligan G. TIPS 14, 239-243 (1993).
Mosse P.R.L., Campbell G.R., Wang Z.L. & Campbell J.H Laboratory Investigation 
53, 556-562 (1985).
Moughal N., Stevens P.A., Kong D., Pyne S. & Pyne N.J. Biochemical Journal 306, 
723-726 (1995).
Moule S.K. & Denton R.M. FEBS Letters 439, 287-290 (1998).
171
Muldiopadhyay S., Webster C.R.L., Anwer M.S. The Journal o f biological Chemistry 
273,30039-30045 (1998).
Muekler M., Caruso C., Baldwin S.A. et al.Science 229, 941-945 (1985).
Muniz M., Alonso M., Hidalgo J. & Velasco A. The Journal o f Biological Chemistry 
271,30935-30941 (1996).
Murray K.J. Pharmacol. Ther. 47, 329-345 (1990).
Murthy K.S., Severi C., Griders J.R. & Maldilouf G.M. American Journal o f 
264, G967-G974 (1993).
Murthy K.S.& Makhlouf G.M. American Journal o f Physiology 286, Cl 71-180
(1995).
Myers M.J., Backer J., Sun X. et al. Proceedings o f the National Academy o f Science 
U.S.A. 89, 10350-10354 (1992).
Myers M,Jr., Wang L.M., Sun X.J. et al. Cellular Biology 14, 3577-3587 (1994).
Nagamatsu S., Kornhauser J.M., Burant C.F., et al. Journal o f Biological Chemistry 
267,467-472(1992).
Nakashiraa Y., Raines E.W., Plump A.S., Breslow J.L., Ross R. Arterioscler Thromb 
F a jcP W  18, 842-851 (1998).
Napoli C., D’Armiento F.P., Maiicini F.P., et al. Journal o f Clinical Investigation 100, 
2680-2690 (1997).
Nave B.T., Flaigh R.J., Flayward A.C., Siddle K. & Shepherd P.R. Biochemical Jornal 
318,55-60(1996).
172
Niwa H., Inouye S., Hirano T., Matsuno T., Kojima S., Kubota M., Ohashi M. & Tsui 
F.I. Proceedings o f the National Academy o f Science U.S.A. 93, 13617-13622 (1996).
O’Connell J.C., McCallum J.F., McPhee I., Wakefield J.M., Houslay E.S., Wishart 
W., Bolger G., Frame M. & Houslay M.D. Biochemical Journal 318, 255-262 (1996).
Patki V., Lawe D.C., Corvera S., Virbasius J.V. & Chawla A. Nature 394, 433-434
(1998).
Pawson T. & Gish G.D Cell 71, 359-362 (1992).
Piper R.C., James D.E., Slot J.W., Puri C. & Lawrence Jr. J.C. The Journal o f 
Biological Chemistry 26H, 16557-16563 (1993).
Poison J.B. & Strada S.J. Annual Review o f Pharmacology and Toxicology 36, 403-27
(1996).
Pyne N. J., Moughal N., Stevens P.A., Tolan D. & Pyne S. Biochemical Journal 304, 
611-616 (1994).
Pyne N.J. & Pyne S. Cell Signalling 10, 363-369 (1998).
Quinn L.A. & McCumbee W.D. Journal o f  Cellular Physiology 177, 94-102 (1998).
Quinn M.T., Parthasarathy S., Fong L.G. & Steinberg D., Proceedings o f the National 
Academy o f Science U.S.A 84, 2995-2998 (1987).
Resnick N., Collins T., Atkinson W., Bonthron D.T., Dewey C.F. Jr., Gimbrone M.A. 
Jr. Proceedings o f the National Academy o f Science USA 90, 4591-4595 (1993).
Rizzuto R., Brini M., Pizzo P., Murgia M. & Pozzan T. Current Biology 5, 635-642
(1995).
173
Rollins B.J., Morrison E.D., Usher P., et al Journal o f Biological Chemistry 263, 
16523-16526 (1988).
Ronnstrand L., Mori S., Arridsson A-K., et al. EMBO 11, 3911-3919 (1992).
Ross R. & Glomset J.A. Science 180, 1332-1339 (1973).
Ross R. & Glomset J.A. New England Journal o f Medicine 296, 369-377 and 420-425 
(1976).
Ross R. Nature 362, 801-809 (1993).
Ross R. New England Journal o f  Medicine 340, 115-126 (1999).
Rubin C.S., Biochimica et Biophysica Acta 1224, 467-479 (1994).
Sakaue M., Bowtell D. & Kasuga M. Molecular and Cellular Biology 15, 379-388
(1995).
Saxena M., Williams S., Tasken K. & Mustelin T. Nature Cell Biology: 1, 305-311
(1999).
Schmidt W., Poll-Jordon G. & Loffler G. The Journal o f Biological Chemistry 265, 
15489-15495 (1990).
Schwartz S.M., Heimark R.L. & Majesky M.W. Physiology Review 70, 1177-1209 
(1990).
Shanahan M.F. & Edwards B.M. Endocrinology 125, 1074-1081 (1989).
Shepherd P.R., Gibbs E.M., Waslau C. et al. Diabetes 41, 1360-1365 (1992).
Shimizu Y., Satoh S., Yano H., Minokoshi Y., Cushman S.W. & Shimazu T. 
Biochemical Journal 330, 397-403 (1998).
174
Sjôlund M., Fledin U., Sejersen T., Heldin C-H. & Thyberg J. Journal o f Cellular 
Biology 106, 403-413 (1988).
Skolnik E.Y., Batzer A., Li N. et al Science 260, 1953-1955 (1993).
S mit M.J. & Iyengar R. Advances in Second Messenger and Phosphoprotein Research 
32, 1-21 (1998).
Smit M.J., Verzijl D. & Iyengar R. Proceedings o f the National Academy o f Science 
U.S.A. 95, 15084-15089(1998).
Soderling S.H., Bayuga S.J. & Beavo J.A. Proceedings o f the National Academy o f  
aS-.X 95, 8991-8996 (1998).
Soderling S.H., Bayuga S.J. & Beavo J.A. The Journal o f Biological Chemistry 273, 
15553-15558 (1998).
Soderling S.H., Bayuga S.J. & Beavo J.A. Proceedings o f the National Academy o f  
Sciences U.S.A. 96, 7071-7076 (1999).
Sorbara L.R., Davies-EIill T.M., Koehler-Stec E.M., Vannucci S.J., Horne M.K. & 
Simpson I.A. Biochemical Journal 328, 511-516 (1997).
Sowers J.R. Diabetes 45, supp.3, S47-S51 (1996).
Stanley P.R., Ram J.L. & Sowers J.R. Endocrinology 133, 1693-1699 (1993).
Stary H.C., Chandler A.B., Glagov S., et al. Circulation 89, 2462-2478 (1994).
Stenmark H. Aasland R., Toh B.H. & D’Arrigo A. Journal o f Biological Chemistry 
271,24048-24054(1996).
175
Sternweis P.C. Current Opinion in Cell Biology 6, 198-203 (1994).
Suhasini M., Li H., Lohmann S.M., Boss G.R., Pilz R.B. Molecular and Cellular 
Biology 18, 6983-6994 (1998).
Sun X.J., Rothenberg P., Kalin C.R., et al, Nature 352, 73-77 (1991).
Sun X.J., Wang L-M., Zhang Y. et al Nature 377, 173-177 (1995).
Suzuki K. & Kono T. Proceedings o f  the National Academy o f Science U.S.A. 77, 
2542-2545(1980).
Taylor S. S., Buechler J.A. & Yonemoto W. Annual Review o f Biochemistry 59, 971- 
1005 (1990).
Tesmer J.J.G. & Sprang S.R. Current Opinion in Structural Biology 8,713-719
(1998).
Thomson F.J., Moyes C., Scott P.H., Plevin R. & Gould G.W. Biochemical Journal 
316, 161-166 (1996).
Thomson F. & Gould G.W. In: Facilitative Glucose Transporters, Molecular Biology 
Intelligence Unit. Pp 197-217 (1997).
Thorens B., Sarker H.K., Kaback H.R. et al.Cell 55,281-290 (1988).
Thorens B., Deriaz N., Bosco D., DeVos A., Pipeleers D., Schuit F., Meda P. & Porret 
A. The Journal o f Biological Chemistry 271, 8075-8081 (1996).
Toyoshima H., Nasa Y., Hashizume Y., Koseki Y., Isayama Y., Kohsaka Y., Yamada 
T. & Takeo S. Journal o f Cardiovascular Pharmacology 32, 543-551 (1998).
176
Tsien R.Y. Annual Review o f Biochemistry 67, 509-544 (1998).
Verhey K.J., Hausdorf S.F. & Birnbaum M.J. Journal o f Biological Chemistry 123, 
137-147 (1993).
Waddell I.D., Zomerschoe A.G., Voice M.W. & Burchell A. Biochemical Journal 
286, 173-177 (1992).
Walmsley A.R., Barrett M.P., Bringaud F. & Gould G.W. Trends in Biological 
Sciences 23, 476-480 (1998).
Walter U. Rev. Physiol. Biochem. Pharmacol. 113, 42-85 (1989).
Watson S. & Arkinstall S. In: The G-protein Linked Receptor, Academic Press Ltd.
(1994).
Wiese R.J., Mastick C.C., Lazar D.F. et al. Journal o f Biological Chemistry 270, 
3442-3446(1995).
Witters L.A., Vater C.A. & Leinhard G.E. Nature 315, 777-778 (1985).
Wolfe L., Corbin J.D. & Francis S.Fl. Journal o f Biological Chemistry 264, 7734- 
7741 (1989).
Wong Y.El. Methods in Enzymology 238, 81-94 (1994).
Wusmer A.E., Gary J.D. & Emr S.D. The Journal o f Biological Chemistry 274, 9129- 
9132(1999).
Yao FI., York R.D., Misra-Press A., Carr D.W. & Stork P.J.S. The Journal o f 
Biological Chemistry 213, 8240-8247 (1998).
177
Yarwood S.J., Anderson N.G. & Kilgour E. Biochemical Society Transactions 23, 
S175 (1995).
■■Y
I-:;
Ml
Yarwood S.J., Kilgour E. & Anderson N.G. Biochemical and Biophysical Research 
Communications 224, 734-739 (1996).
fI
I
II
M.1:■I
iM
"7I!
